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1 
Introduetion 
1.1 Cervical cancer mortality in the Netherlands 
In recent years in thè Netherlands, around 235 wo men have died ánnually from 
cervical cancer. This is 0.35% of total female mortality 1381. Cervical eaueer 
. mortality stabilised between 1950 and 1965. Between 1965 and 197Ö mortality 
started to dccrease. This deercase occurred befare an effect from screening 
could be expected (see Figure 1.1}. The decrease continued after the start of 
screening, and currently the mortality ra te is less than 40%. of thc level in the 
period 1950-1959. A decreasing mortality befm·e the introduetion of screening 
can be seen in othcr countries as well [82, 126, 96, r6J, Since randomizcd cen•ical 
eaueer screening trials have never taken p1ace, it is not possible to estimate to 
what extent, if any, the decniase tn mortality is due to screening. 
1.2 Cervical cancer worldwide 
The incidence and mortality of cervical eaueer varies between regions in the 
world P6s, tnJ. In developed countries, the incidence and mortality rates are 
lower (2.5 times for mortality) than in developing countrie;;. A lower mortality 
is partly due toa better survival in developed countries (around 60% 5-year 
survival for Europe i''l) than indeveloping countries (e.g. a 38% 5-year survival 
in Bangalore, India [t02J). The Netherlands is amongJ?t the countries with low 
incidence with 9 new cases per 100000 women annually (1993) !>"1. Mortality 
rates ildhe EU-countries are low in the Netherlands (2.4 per 100 000 wo men, 
world standard ra te (wsR) !>"!) and highest in Denmark (5.0 per 100 000 
women, WSR rtJ). 
1.3 The pap smear 
Cen•ical eaueer can be detected at an early stage by screening women who 
have not yet develoj:Jed signs or symptoms. The screening test that has been 
1 
' 2 Cllapter 1. Int-roduetion 
--
Figtire 1.1 1\iortaliti from ccn'ical cancer by calendar year in tlw Nether-
lands fJSl(moving 5-yearly a\'erage per 100000 wamen aged 20 years and over), age 
adjusted to tlw Duteli pop1~lation in 1995, and annuaJ 1mmbers of smears by true 
calendar year and shifted 5 years later, after nrhicl1 time interval a notabie effect 
from screening on mortality is expected to start 
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used up to now is known as the PAP smear. · The technique of this cytological 
test is as folloW?: cells are scraped frÜm the cervix uteri e.g: by the general . 
practitioner, and evaluated microscopically by cytotechnicians and patholo-
gists. If tlie test is positive (abnormalities are observed) a follow-up takes 
place. This can result in the detection of cervical cancer or its precursors 
at a stage in which symptoms are absent i.e. pre-clinical. In over 90% of 
cases, the detected neoplasia is intraepethelial (without invasion of underly-
ing tissues), e.g. dysplasia and carcinmpa in situ, but early invasive cancers 
are also detected by screening. When left untreated, 'cervical intraepithelial 
neoplasia (CIN) will, at least in· some wamen, develop into invasive cervical 
cancer. After treatment, prognosis is.CxcellEmt for CIN, with wellover a 99% 
cure !114, ns, 12, 1o6, 6?, t9sJ. Prognosis is a lso quite good for early invasiv"e cervical 
cancer, with a 97% 5-year survival in FIGO stage IA and around 80% in sta_ge 
. IB 1so, 2o, 54J, A new test that might be useful for the early detection of cecvical 
eaueer is the test for human papilloma-virus (HPV) on acervical scrape. The 
HPV-test is curreritly being investigated for its f:>OSsible use in combination 
with or, as an alternative to, cytological evaluation. 
1.4. TJ1e effectiwness of screening 3 
1.4 The effectiveness of screening 
Because of the good prognosis of screen-detected and treated cases, PAP smear 
testing is expected to reduce the mortality from cervical cancer. Mortality 
reduction, the main goal of cancer screening·, is ideally estimated from ran-
domized controlled trials, but such trials have never been cm-ried out for eer-
vical cancer screening .. The reaso'n is that cervical cancer screening started, 
in parts of the US and Canada, arour1d 1950 in an era in which the idea of 
evidence-based medicine was not yet established I147J. In fact there was such a 
conviction that screening would he effective, a randomized trial seemed uneth-
ical. Evidence for mortality reduction from cervical eaueer screening and the 
assessment of its magnitude consequently had to cmanate from less powerful 
methods, e.g. by camparing regions or periods or individuals with different 
screening intensities in non-randomized cohort studies 1126Jand in case-control 
studies !43, 100, stJ. 
1.5 Balancing benefits, negative side-effects and casts 
The main benefit of effective screening apart from the reduction of mortality 
is the prevention of invasive. cancers. But scr~ening will incvitably a lso have 
negative side-effects for some wamen. Currently, more than 10% ohvomen 
screened will have positive test-results lt4J 1 a large majority of whom will have 
nobenefit at all froin screening. The financial casts of screening arealso high 
and depend largely on the number of PAP smears can:ied out. 
In cervical cancer screening, the balance between benefits, harms and casts is 
vulnerable. The background cumulative risk forcervical eaueer in the Nether-
lands is only around 1.5% (Chapter 6), which means that the incidence and 
mortality reduction wil! affect at most 1.5% of the population, whereas the 
negative side-effects may apply to a much higher proportion of the screened 
won\en (for example 10% per round), and the casts are dominatcd by thc casts 
of the PAP smears and therefore apply to the total sereerred population. The 
quality of screening, in terms of this balance, depends highly on the screening 
strategy followed. Impórtantcomponents of this strategy are the age range 
and interval between subsequent PAP smears, and the follow-up strategy in 
cases of abnormal smear test results. 
1.6 Age range and interval 
Nowadays, in 'Vest-European and North-American countries, many wamen 
have at least one PAP smear during their life. fi•Iost of these wamen have sev~ral 
and some have many smears. Screening was introduced generally in the sixties, 
4 C!Japter 1. Introduetion 
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Table 1.1 Number of smears and screening intenraJ used in couiJtries w.ïth 
eerdeal cancer screeniiJg programme_s or recommCJJ(]ed in IJatioiJal guidelines 
Country Number of smears Screening interval 
per woman in years 
The Netherlands until 1996 7 3 
The Netherlands from 1996 onwards 7 5 
Denmark [2oo] 13 3 
Sweden [135J 12 3 
leeland [195] 17 . 2-3 
Finland (96] 7 5 
United Kingdom (158] 10-16 3-5 
USA (guidelines). (203] ±17 <3 
Australia (61) 27 2 
as opportunistic (non-invitationál) screening by gynaecologists and general 
practitioners and partly also by implcmenting invitational programmes. 
Screening strategies in developed countries differ. In Europe, wamen are 
invited 7 to 16 times during a life-timc, with an interval of2 to 5 years {see 
Table 1.1). In Nartbern America, ammal screening was recommended in the 
sixties and early seventies 11201, Guidelines proposed tostart screening at age 
20, implying that up to 40 sniears would be taken per woman during her 
lifctime I>O<I, Later, guidelines tcnded to.advise intervals of threc years, still 
implying at least 17 smears per woman because of the ad vice to s.tart screening 
at a young agc i'"i. In Australia, programme screening has started targeting 
wamen between the ages of 18 and 70 every two years, thus inviting wamen 
27 times during their life· l6tJ. The ditierences in the number of_smears per 
wonmn between countries are aften nat a reflection of differences in the risk 
of mortalityfrom cervical cancer. Thcy are probably caused by differences in 
the processof decision making, e.g. differences in the criteria, in the methods 
used, and in the in~uence of interest groups. 
Apart from programme screening (i.e. with a personal invit~tion to have a 
PAP smear at set ages), there is also a large.amount of opportunistic screen-
ing taking place. This occurs ·when ·the opportunity for taking a PAP smear 
is at liand, or when the woman and/or her physician think it is time to take 
a smear. In general, opportunistic screening tends to start em·lier in life, to 
concentrate more in yo~ng age, and to be ·applied more frequently than pro-
gramme screening [10o, 164, asJ. The proportion of wamen screened (covçrage), 
a crudal parameter for the public health impact of screening, is lower in a sit-
uatian where only nppartunlstic screening exists 111, sJ. In situations where an 
invitational programme is in operation, oPportunistic screening usually runs in 
parallel. Opportunistic screening reaches thosé wmllen missed by progt:amme 
1. 7. Tlw follow-up of abtwrmal pap sm:cec::arccs ___ _ 5 
screening, but especially adds to screening outside (particularly under) the 
target age-range and increases the frequency of screening within the target 
age-range .. Opportunistic screening has aften been criticised for its lack of 
efficienéy and the amount of unfavourable effects that it generales. But some 
investigators have been more supportive. rs5, 221. 
1.7 The follow-up of abnormal pap smeárs 
As far as follo~v-up is concerned 1 a PAP smcar has three possible outcomes: 
negative (i.e., no particular follow-up is advised and the normal screening 
schedule is to be followed), borderline (i.e., repeat smears are advised) and 
positive (i.e. referral to the gynaecologist-colposcopist is required). How to 
define normal, borderline and positive abnormalities has always been and still 
is highly debated. Between the sixties and nineties, there has been an ongoing 
shift towat·ds more intensive follow up (see Table 10.3). This trend has led to 
the present practice ofvery intensive follow-up. The ten si on between the stress 
on physicians ( sametimes manifested inthefarm oflawsuits) to do 'everything 
possible' to prevent a potentially life threatening disease, and the des i re for 
a medical intervention with as little unnccessary harm as possible 1 is very 
prominent in c~rvical cancer screéning. In follow-up too the balance between 
benefits 1 harms and casts should bc of major concern. 
'1.8 Screening in the Netherlands: a historica! overview 
The work presented in this thesis has been performed as part of the evalua-
tion of programme screening in the eighties and nineties in the Netherlands. 
Cervical cancer screening was introduced in the late sixties in the Nether-
lands. Aftersome small scale feasibility projectsin the early seventies, a pilot 
project for programme screening was started in 1976. It was centrally orga-
.nized and financed by the Government 1 and took place in tl~ree pilot regions: 
Nijmegen, Rotterdam and Utrecht, covering 24% of the Dutch female popula-
tion. Wamen from age 35 to 53 were ÏilVited every 3 years to attend screening. 
The PAP srnears were taken by specially trained wamen at local public health 
care units. This programme was meant to serve as a regional trial and was 
planned to campare mortality trends in the screening regions with trends in 
the other partsOf the country. Under politica} pressure however 1 the screening 
plogramme was soon extended to other regions, reaching almast nationwide 
covcragc around 1980. :rvieanwhile1 gynaccologists and general practitioners 
increasingly took smears 1 particularly in wamen who were too young for pro-
gramme screening. The total number of smears increased from an estimated 
6 Chapter i. Introduetion 
----
'rable 1.2 Important factors influencing tlu~ effects and casts of cërdcal cancer 
- lucidenee of discase by age_and year of birth 
- Regression rate of pre-invasive discase by age 
- Duration and its variability of preclinical discase 
- Test characteristics (sensitivity and specificitY) 
- Prognosis for the situation without screening and the impravement in prognosis result-
ing from-early detection 
- Attendance pattem and relationship between altendance and risk 
- Demography, deaths from causes otlwr than cervical cancer, hysterectomies for reaspns 
other than cerviêal cancer 
100 000 in 1970 to 500 000 in 1975 and 1 million in 1982 t'l. In 1982, the Gov-
ernm~nt policy changed and programme screening directly financed by the 
government was stopped. By 1985, organized screening had ended in most 
partsof the country, and the number of smears also dropped. 
During the late eighties programme screening was started again, covet:ing 85% 
of the municipalities in 1990 tmt. The number of smears was 750 000 in 1987 
and 940000 in 1990 after which it remained at. about the samelevel t><J. Pro-
gramme screening during this period was strongly decentralized, the munici-
palities were responsible for inviting wamen and for monitoring a~d evaluating 
the programme. Wamen were invited to make an appointment with their gen-
eral practitioner to have a smear. The casts for the mmiicipalities had to be 
covered by general preventive funds (Wet Collectieve Voorzieningen). The · 
screening age range and intervals remained unchanged. This decentral way of 
conductinga cervical eaueer screening programme was strongly crificized. Of 
particular concern was the quality of the smears belng taken by the general 
practitioners, the covera.ge of the programme and the amount of inefficient 
screening (e.g. in toa young wamen and toa frequently). 
In 1990, the lviinistry of Public Health instructed that a study be undertaken 
tolook at where the 'bottlenecks' ofthe ( decentrally organized) cervical cancer 
screening programme were occurring. An ·important condusion of this study 
was that due to a Jack of directive powers and earmarked financing, effect-
evaluation, and ·hence the opportunity for adjustments, was insuftkient [1231. 
The Government decided that programme screening should be continued, but 
only if it could be better organized tmJ. The Dutch Health Insurance Council 
was requested to advise the Gaverument on an improved way of erganizing 
and financing the programme. A totalreconsidoration followed, including the 
screening age range ·and interval. It resulted in a newly organized sèreening 
pro~ramme, which was implemented nationwide in 1996. The age-range was 
extended from 35-53 to 30-60 years, and the interval from 3 to 5 years, lcaving 
the number of seven invitations a !i fe-time unchanged. The chciice of age-range 
1.9. New dewlopments 7 
and interval was amongst othei's based on the work presented and discussed 
in this thesis, in partienlar on the results presenled in Chapter 7. According 
to the new recommendations, the follow-up for borderline abnonnalities was 
intensified, so that more wamen will be referred for colposcipical/histological 
evaluation. This decision to intensify fellow-up was nat evidence-based (see 
chapter 10). On theether hand, it was decided that the percentage of border-
line smear ('Pap 2') should decrease. The organization ofthis new programme 
remains largely decentralized. However, the Gaverument has taken (financial) 
responsibility for quality control and for evaluation of effects and casts of the 
pro gramme. Regional organizations are responsible for reporting the data that 
are necessary for quality control and evaluation. These data are arranged in a 
set of evaluation tables which are compatible with those issued by the Europe 
Against Cancer Programme for quality assurance in cervical cancer screening 
f45J, One of the objectives of this reorganisation and of the evaluation system 
is that the casts of improving the screening programme should be campen-
saled by the deercase in opportunistic PAP smears outside the age-range and 
frequency guidelines. 
1.9 New developments 
New developments in screening Îleed thorough evaluation befare implementa-
tion in a rnass-screening can be considered. The first important new develop-
ment explored in this thesis is computer aided cyto-morphologic evaluation of 
PAP smears, as a possible methad of improving sensitivity andfor specificity 
{1221. Computer aided screeing is expected to affect the casts of the Iabaratory 
evaluittion, a substantial part of the total casts of cervical cancer screening 
. [mJ, The second development that will be addressed is the increasing knowl-
edge of the relationship between HPV (human papillamavirus) infections and 
the development of cervical cancer. HPv' is found in more than 90% of invasive 
cervical cancers f26J, \vhile the observed prevalenee of oncogene HPV types in the 
general female population over age 30 years, at least in developed countries, 
is a_round 3-6% [t5. 149, 53, 1soJ. The first longitudinal studies seem to confirm 
that HPV infections are astrong risk factor for the future development of eer-
vical eaueer. Hence, HPV detection possibly could be useful in cervical eaueer 
screening. And if eventually an effective preventive vaccine against HPV infec-
tions is developed 1201, 73J, primary prevention of cervic.al cancer could be an 
elileient alternative, gradually substituting cervical eaueer screening. 
8 Cllapter 1. lnt;oduction 
1.10 The objective of this thesis 
The objectivo ofthis thesis is to evaluate cen•ical cancer screening byassessing 
its.various effects and casts. Questions to be addressed are: 
1. Is cervical eaueer screening effecth•e in reducing mortality? And if So, how 
large are the beneficia! effects (reduction in incidence and mortality)? 
2. How large are the unfavourable health effects of cervical cancer screening? 
Are they outweighed by the beneficia! health effects? 
3. Under what 'condition is cervical cancer·screening cöst-effecti\•e? 
4. What screening age range and intervals should be ebasen from the viewpoint 
of cost-effectiveness? 
5. What follow-up strategy after non-negative smears should be chosen from 
the viewpoint of cost-effectiveness? 
6. Should cervical cancer screening be continued? And what changes should 
be recommended in order to improv~ its efficiency? 
7. Should new techniques, like automated cytological evaluation of cervical 
smears or HPV-detection in cervical scrapes, be added to or replace conw!n-
tional PAP smear screening? 
In Chapter 2-10 the findings regarding these questions wil! be reported and 
discussed. The coilclusions for each of the seven questions wil! be presented 
in Chapter 11. 
1.11 The use of a model 
Prediction of the effects and casts of cervical cancer screening for differ-
ent screening strategies is a complex matter that involves many factors (see · 
Table 1.2). Therefore, a computerized simulation model is indispensable. The 
work presented in this thesis is based on the use of a cervical cancer screen-
ing version of MI SCAN, a micro-simulation programme that was designed for 
the evaluation of eaueer screening [s1, usJ. This model has also been used for 
evaluation of breast eaueer screening i"'l. In the model, all the factors listed 
in .Table 1.2 are described and quantified (see Chapter 6). Table 1.3 gives an 
overview of the data used for quantification and validation. After this quan-
tification and validation (i'"· 16o, 16>J and Chapter 6) the model has been used 
to predict health effects and casts of cervical cancer screening policies. 
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Table 1.3 Oven'iew of tbe data used in estimating model parameter values. 
For details and references see also clJapters 6 imd .7 
Screening data (detection and incidence rates by age, rank and interval) from British 
Columbia, Dutch pilot regions, and the IARC study 
Cervical·cancer incidence, mortality and survival data 
Data on the screening pattem in the Dutch female population 
Cast data (concerning screening, diagnosis and treatmCnt) 
Hystercctomy data 
Dutch national demograpbic data 
1.12 Reading guidance 
Evaluation is a cyclic process of analyzing new data, evaluation of casts _and 
effects of screening, explörative analysis of new options, etc. This means that 
the more or less chronological order of the manuscripts included in this thesis 
does not always represent a logica! ordering of steps in the evaluation of a 
screening programme. 
A logica! ordering of the chapters of this thesis is: 
0. Analyses of the data for model quantification regarding the effects of screen-
ing 
~ see the thesis of Gerrit van Oortmarssen Jt62J 
1. Testing the model predictions against observed data 
- Chapter 6 
2. Performing cast-analyses to assess the casts of screening and link the effects 
to casts and savings 
- Chapters 4 and 5 · 
3. Predicting the benefits, the negative side-effects and the casts of different 
screenillg strategies 
Chapters 2 ( camparing elileient policies with different numbers of smears 
per woman), 3 ( camparing opportunistic with efficient screening) and 7 
(optimizing screeningage-ranges and intervals) 
4. Investigating the potential value of two new developments 
- Chapters 8 (computer-assisted PAP smearevaluation) and 9 (HP V-screening) 
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Diagnostic and treatment procedures 
induced by cervical cancer screening 
This chapter is based on M. van Baliegooijen et al 
Eur J Cancer, Vol.26, no.9, pp.941-945. 1990 
Abstract· 
2 
The amount of diagnostic and treatment procedures induced by cen•ical eaueer 
screening has been assessed prospectively and related to mortality reduction. As-
sumptions are based on data froni Dutch screening programmes and on a scenario 
for future developments. \Vith 5 invitations for screening, between ages 37-70 
cvery eight years, 13 dcatbs are avoided per million women per screening year. 
Each death avoided is balanced by 2800 preventive smears, 9 woroen referred to a 
gyneaCology department and 4 minor treatment procedures ( conserving treat~ent 
or exconisation). 25 invitations in a life-time avoids 27 deaths per million women 
per screening year. but with per death avoided 7300 preventive smears, 22 refer~ 
rals and 8 small treatment procedures. Thus intensifying screening will not only 
result in diminishing returns of extra screening cfforts, but also in incrcasing risk 
for women to undergo unnecessary (no invasive discase or death avoided) diagnost.ic 
and treatment procedures. The balance between beneficialand ad verse effects dete-
riorates strongly when hysterectomies play an important part in the management 
of cervical intraepithelial neoplasia. 
Acknowledgement ThiS study was financed by the Prevention Fund. 
2.1 Introduetion 
The appropriateness of screening forcervical eaueer s~wuld be balanced between 
beneficia! health effects and adverse effects and costs. As the avoidanee of 
' death is thc principal aim, most evaluations have concentrated on the relation 
between life-years saved and costs, which shows a diminishing return for the 
extra effmts involved in screening women more frequently [64, 13 2 , 167). Although 
11 
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Table 2.1 Primary treatment procedures found (a) in eiglit DutclJlwspitals*, 
in 1982-1986, and (b) in the pilot region of Nijmegen in 1981-1984 
<CIN !lij CIN lil IA 
Treatment {a) {b) (a) (b) {a) {b) 
None ND 61% 
Conserving trea~rrient ND 10% 25% 28% 
Exconisation ND 6% 64% 15% 3il% 0% 
Exconisation + hysterectomy ND 4% 46% 50% 
Hysterectomy ND 23% 7% 48% 16% 50% 
Unknown ND 9% 
Total {n) 100% 66 663 46 24 2 
* Academisch Medisch Centrum (Amsterdam), Medisch Centrum Alkmaar (Alkmaar), 
Sint· Franciscos Gasthuis Rotterdam (Rotterd~m), Ziekenhuis Leyenburg (Den Haag), 
Ikazia Ziekenhuis Rotterdam (Rotterdam), RI< Ziekenhuis Groningen (Groningen), 
Catherina Ziekenhuis Eindhoven (EindhoVen), Westein·de Zieketth_uis Den Haag (Den 
Haag). Annual reports 1982-1986 
t Womcn referred to a gynaccology department for cervical cancer assessment, in whom 
no CIN or only CIN I/11 is found 
ND No data 
unnecessary referrals and diag~ostic and loc al therapeutic procedures are often 
discussed as the majo:r adverse effect of cervical cancer screening, reports on 
this effect are scarce. Treatments of advanced eaueer will be reduced by early 
detection. But due to the follow-up of fa! se positive smears and of lesions that 
would have regressed -spontaneously, there will be a considerable increase in 
the number of diagnostic and minor therapeutic procedures. We have assessed 
this increase and related it to the number of life-years gained. 
2.2 Methods 
2.2.1 Yield of early detection 
The effects of cervical eaueer screening have been predicted by a mathematica! 
modelroo. 88, '"i. The model has been validated by analysing cervical eaueer 
. screening data from the British Columbia Cohort Study '"' and from pilot 
cervical cancer screening projects {1976-1985) in the Netherlands r.oJ. Both 
analyses led to similar conclusions f88J, Model-based analysis of the Dutch data 
led to the following estimates: (a) mean duration of the pre-clinical stages, 17 
years and shortest at old ages; (b) regression rate of pre-invasive disease, 60% 
on average and highest at young ages; and (c) sensitivity of cervical cytology, 
70% for cervical intraepithelial neoplastic ( CIN 111). With other assumptions 
(e.g. shmter duration, less regression or higher sensitivity) the observed Dutch 
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screening results and incidence and mortality data couldnot bepxplained. The 
false positive rate, defined as the percentage of wamen in whom 'no CIN 111 or 
invasive eaueer was found after.an abnormal (at least moderate.dysplasia) 
eervical smear, was 0.4%. This number bas been used in our ealeulations. 
The validated model was used to simulate different screening p'olicies in Dutch 
wamen during the period 1988~2015. Effects of screening occurring after 2015 
have been taken into account. The population dynamics including deaths 
by eauses other than eervical eaueer have been ineorporated into the .model. 
The impact of cervical cancer screening befare 1988 and of hysterectomies 
performed for reasans otl1er than ecrvical eaueer have also been taken into 
account. The population attendance rate has been assumed to be 65% on 
average, as obscrved in the Duteh pilot regions. Attcndance deercases gradu-
ally for wamen over 50, to 55% for wamen aged 70. 
The model prediets the yearly number of smears, th.e yearly number of wamen 
diagnosed with CIN III, micro-invasive or eervical ca'ncer by stage, the yearly 
number of wo men d~tected .in whom no CIN 111 or worse is found during follow 
up and the yearly number of wamen dying from cervical cancer. 
Effects \~ere calculated compared with no early detection, which was also 
simulated and in which wamen are only detected .by symptoms. In our model 
detection by symptoms oecurs in stage IB at tbc earliest. 
2.2.2 Diagnosis and treatment 
Assessment of the number of wamen referrcd to a gyneacological department 
beeause of an abnormal eervical smear is of major importanee when estimating 
the extent of diagnosis induced by screening. Referred wamen are supposed 
to undergo colposcopy at least once; most will have ectocervical biopsy and 
in some endocervical curettage will be done. We calculated the number of 
referred wamen from the predicted numbers of detected wamen. We assumed 
that all wamen with a histologically confirmed ciN m+ and 65% of the wo men 
followed up without a confirmed CIN m+ havebeen referred to agynaecologist. 
The other 35% of the latter group is assumed to have had only repeat smears 
done by the general practitioner, as the data from the pilot regions indicate. 
In the pilot regions, a PAP smear with moderate dysplasia was followed by a 
repeat smear within a few weeks. A smear with severe dysplasia or more led 
to immediate referral to a gynaecologist. 
To calculate the nu mb ers ofprimary treatment procedures a schedule has been 
devised a realistic frequency of treatments by stage of disease. This schedule 
was applied on the predicted numbers of detected wamen by stage. 
The possible treatment procedures in CIN and microinvasive cervical eaneer 
are summarised in Tab/e 2.1. Conserving treatments ( cryocoagulation, elec-
trocoagulation, laser-evaporation and d,iathcrmie ablation) and exeonisations 
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Table 2.2 Assumptions used fn the ptospecti\'e calculation of numbers of pri-
mary treatment procedures: pprcentages of primaty t.reatment pmcedures by eer-
vical cancer stage 
Detected by 
Screening · Symptoms 
Treatment <CIN 111* CIN 111 IA IB 11+ 11+ 
None (absence of CIN III) 81% 
Conserving 12% 24% 
Conserving + exconisationf 1% 1% 
Exconisation 6% 64% 38% 
Econisation + hysterectomy 3% 62% 
Hysterectomy 8% 0% 90% 40% 16% 
Prirhary radiation 10% 60% 79% 
No primary treatment 5% 
(advanced disease) 
* \Vamen referred to a gynaecology department for cervical caoeer asscsshlent, in whom 
no CIN or only CIN rjn is found 
Because of exconisations as a retreatment procedure assumed in 5% of the wamen who 
had conserving treatment 
are considered as minor treatrrient procedures., Tab/e 2.1 also shows the treat-
ment procedures used in eight Dutch hospitals of different size and in different 
regions during 1982-1986 and in the screening programme in the pilot region of 
Nijmegen during 1981-1984 (office of Evaluatio11 and Registration of Cervical 
Cancer). 
The differerice between the two data sets stresses the variability in medica! 
practice. Hysterectomies were more frequent in Nijmegen. The reasans for 
this were not investigated. Current developments towards less aggressive treat-
ments are the further introduetion of colposcopy in the assessment of suspected 
cervical abnormalities and the decreasing rates for·hysterectomies in general 
(there has been a more than 3.0% fall in the age group 35-50 in the Nether-
lands since the late 1970s) 1"~1. Hospita! departments that reported data on 
their treatment procedures are probably departments that follow these devel-
opments more closely than average. The percentage for less aggressive pro-
Gedm·es in tht!se. hospitals, however, may 'he a good approximation for future 
practice. So we used the hospita! data for the assumptions on the average 
stage-specific treatment (sec Table 2.2). 
As no detailed data were available on treatment procedures in wo men with less 
than CIN 111 we based our assumptions for this group on reported information 
on interviews with expert gynaecologists. Of the wonien foliowed up in whom 
no CIN 111 or invasive disease is fo~nd 70% are wo_men without any neoplasia 
and 30% are with CIN I/1! (Office of Evaluation and Registration of Cervical 
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Cancer and {125J). 'Ve assumcd no treatmcnt in the first group. The percentages 
for conserving treatment and exconisations in thc group with GIN I or GIN 11 
arebasedon the assumption that about 60% of these won\en are treated and 
40% are strictly foliowed up by cytolog)'· F):om the treated group 30% must 
(at least) have exconisation because in a bout 30% of the women with GIN the 
transformation zone and/ or the lesion cannot entirely beseen with colposcopy. 
So the percentage of conserving trcatmcnts in the women referred with less 
than GIN III is assumed to be 13% (30% x 60% x 70%) and the percentage of 
exconisations to be 6% (30% x 60% x 30% [rounded]). Moreover, 5% of the 
wamen who had conserving treatment are assumcd to have exconisation as a 
re-treatment. 
In the management of wamen with cervi~al cancer stage IA, ~t least an exçon-
isation is assumed. In the Netherlands there is consensus to avoid diagnosing 
s~age IA without doing exconisation first. The two possible primary treatment 
procedüres in invasive cen•ical cancer stages m or higher are radical surgery 
(with or without additional radiotherapy) and radiotherapy (alone). Data 
were stuclied from the eight hospitals, the Nijmegen region and from several 
other Dutch studies !t07, 2021, All results were similar, and since no changes are 
expected in the neat: future, they were adopted. The difference in Table 2.2 
in the assumptions between stage IJ+ detected by early deleetion and stage 
IJ+ detected by symptoms is based on the more favourable distri bution over 
the stages IIA, IIB, 111 and IV in wamen detected by screening compared with 
these detected by symptoms {69{, 
2.2.3 Screening polides 
'Ve will discuss the results for three·.screening policics, with an increasing 
number of illVitations for screening during a life-time: 5, 10 and 25. l'vlore 
invitations lmplies a shorter interval between successive invitations. These 
intervals are 8, 5 and 2 years. The age-ranges are, respectively, 37-70, 27-72 
and 26-74 years. This is a broad age range that does not correspond with most 
current practice. All three are so-callcd cfficient screening policies. Polides 
are efficient when their distribution of screenings over the ages leads to thc 
largest number of life-years gainedat a certain level of casts, or conversely to 
the least costs fora certain number oflife-years gained. Our study on the costs 
of cervical eaueer screen~ng is preserited elsewhere I118J, 
2.3 Results 
The s·tage distribution 1 number of snlears, number of wamen foliowed up and 
m~rtality from cen•ical cancer are shown in Table 2.3 for the three detection 
strategies. All results are preSenteel per screening year, which means that 
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Figure 2.1 Rela~ioiJship between various beneficia] and ad\'erse effects of 
screening and intensity of screening, as representcd by efflcient cervical screen-
ing polides nrith 5, 10 and 25 invitaUons. Le\'el of effects at 5 invitations is set to 
100 (alllines go througl1 origin) 
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invitations per life·time 
the total outcomes and effect·s of screening performed in 1988-2015 have been 
divided by the number of screening years: 27 (i.e. 'by year'). 
\Vith more intensive screening a shift o~curs i~1 the detected preeancers and 
cancers towards earlier stages. The total number of women foliowed-tip increases 
significantly: from 349 (5 invitations) to 1044 (25 invitations) per million 
womeri peP year, mainly due to the increase in follow-up ofwomen, withno his-
tological abnormalities or only CIN 1 or QIN 11. With intensification of screening 
from 5 to 10 invitations, 184 additionallife-years are gained, while a further 
increase from 10 to 25 ilwitations adds only 134 life-years more per million 
wamen per year. 
Intensifying the policy from 5 to 25 ilwitations per life-time causes a five-
fold increase in the number of women referred (see Table 2.4). This i;,duces 
additional diagnostic and treatment procedures. ~viore specifically, an increase 
from 5 to 25 .invitations makes the number of conserving treatments rise from 
25 to.106 and exconisations rise from 47 to 157 per million women per year. 
The effect on the number of hysterectomies (total plus radical) of intensifying 
early detection efforts is modest. The reason is that the rise in the number of 
tot al hysterectomies caused by the increase in the number of women detected 
with CIN lil {see Table2.3) is neutralised by a decreasein radical hysterec-
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Table 2.3 Out"comcs of tlu·Cc eflicicnt cen'ical cancer early detection strate-
gies. Prospective calculations. Numbers are per year per miJlion wamen (all ages). 
Resolts without early detection are gîven in camparisou 
Number of invi"tations* No early 
5 10 25 detection 
< CIN IIIt 140 299 745 0 
CIN III 53 113 174 0 
IA 5 6 5 0 
IB 49 42 36 57 
II+scr I 1 I 0 
II+syn'lpt 101 92 82 124 
Tot al 349 554 1044 182 
Number of smears 36800 78700 196100 0 
Deaths from cervical cancer 67 60 54 80 
( difference)) {-13) {-20) ( -27) 
Lifeyears lost 1172 989 854 1434 
( difference)) {-262) (-446) {-580) 
* Per woman during her lifetime 
t Wamen with abnormal smears in whom no CIN or only CIN 1/11 is found 
i Difference with the situation with no early detectie~ 
tornies caused by the fall in the number of wamen diagnosed with cervical 
eaueer stage IB or higher. The number of primary radiotherapies falls as a 
result of the decreasein the number of diagnosed stages IB and higher. 
Tables 2.3 and 2.4 can be used to calculate the balance between the efforts and 
risks neerled to pi"event more deaths from cervical cancers by m_ore intensive 
screening. With 5 invitations, for every death avoided, 2800 preventive PAP 
smears, 9 referrals and 4 minor treatment procedures are needed. With 25 
invitations, the corresponding figures are 7300, 22 and 8. 
One reason for the deteriorating balance between beneficia! and ad verse effects 
is the strongly increased detection of wamen wi~h no abnormalitie·s or with 
lesions which are less ad vaneed than CIN III {see Tab/e 2.3}. The second reason 
is the increased detection of wamen with ClN III that would have regressed 
spontaneously. According to our predictions, this nurnber would go from 32 
to 77 to 121 per million women per year when intensifying the policy from 5 
to 10 to 25 invitations, respectively. The resulting additional treatments, a 
negative side-effect inherent to early detection of cervical cancer, do not reslllt 
in avoided invasive disease or life-years gained. Adverse effects all increase at 
last two to three times as fast as the beneficia! effects when intensifying the 
early detection policy (see Figurc 2.1). 
Ovei·all the diagnostic and treatment procedures induced by cervical ~ancer 
screening preeede the mortality rcduction by many years. Discounting of 
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Table 2.4 Effect on diagnostic and primary treatment procedures of tiJree 
efficient ccn'ical cancer carly detection strategies (prospective calculatiC!ns). Per 
year per million·women (all ages), differet1ce compared· witlJ n~ screening 
Number of invitations• No early 
5 10 25 detection 
Vlomen referred +117 +266 +598 182 
Conserving treatments +25 +53 +106 0 
Exconisations +47 +96 +157 0 
Hysterectomies -2 -2 -3 72 
PrimarY radiotherapies -19 -26 -35 104 
Total treatments +52 +121 +226 175 
• Per woman during her lifetime 
effects (when not consiclering the casts) is disputable. Nevertheless, when all 
effects are discounted with a rate of 5%, the ratios between unfavourable and 
favourableeffects rise between 160% and 2.00%. There is not only a diminishing 
return for the extra effmts involved in screening wamen more frequently, but 
there is also an increasing risk for wamen to be referred and treated without 
havi~g the bell~fit of invasive disease being presented. 
2.3.1 More aggressive early treatment 
The results presented are very sensitive to the Ï.reatment procedures assumed 
in pre-invasive ai1d micro-invasive stages, because of the large number of 
wamen concerned. Therefore we also made calculations for a more aggres-
sive schedule1 with a shift from minor treatment procedures to hysterectomies 
and less untreated wamen (see Table 2.5). The results {see Table 2.6) should 
be compared with those of Table 2.4, There is a sharp increase in the num-
ber of hysterectomies: fora limited early detection policy (5 invitations), a 
net deercase of 2 hysterectomies has now turned into a net inCrease of 48. 
For more intensive screening policies, this number increases nearly linearly, 
contrary to the number of deaths avoided. This is an important finding, as 
intensive polides are aften ·advocated, for instanee by the -.National Cancer 
Institute {t52J, 
The beneficia! effects of screening are unaffected by the new assumptions, as 
survival is reported to remain excellent when more local treatment procedures 
are used in CIN and cervical eaueer stage IA, provided the rightSelectimi criteria 
are used 112, toa, t75J. 
The numbers and types oftreatments without early detection remain unchanged, 
as no wamen with pre-invasive or micro-invasive discase are detected by symp-
toms in our calculations. 
2.4. Discussion 
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Table 2.5 AJore aggressive treatment schedule in CIN and micro-imrasive eer-
vical cancer (percentages of primary treatment procedures by stage) 
Treatment < CIN 111* CIN 111 IA 
None (absence of GIN 111) 55% 
Conserving treatment 10% 20% 
Exconisation JO% 20% 5% 
Exconisation + hysterectomy 45% 
Hysterectomy 25% 60% 50% 
\Vamen referred to a gynaecology department for. cerviçal ca neer assessment, in whom 
no CIN or only CIN-I/II is found 
2.4 Discussion 
Complete data on treatmcnts used in women with CIN I and CIN II are Scarce. 
A bout 10% of wamen with CIN 111 in ilritish clinics I"· no, "'I have total hys-
terectomies, and 60-70% have conserving treatment and 20-30% have exconi-
sations. Th is is the opposite of what is indicated by Dutch data. The possibil-
ity of a quality-bias in the British data, cannot be ruled out. ilut if the average 
treatment schedule was as suggested by the ilritish data, the numbers of con-
serving treatments and exconisations in Table 2.4 should be interchanged. The 
totallevel of ad verse effects would be lower, but the pattern of increasing risks 
for wamen with increasingly intensive policies would remain unchanged: 
Results have been calculated for an average duration of preclinical disease of 17 
years, a regression ra te of 60% and a sensitivity ·af 70%. The calculations have 
been repeated for other valnes for duration, regression and sensitivity, which 
could still explain the results cif screening in Canada and the Netherlands. The 
results were not affected substantially. In a sensitivity an~lysis we also stuclied 
the infiuence of possible changes in incidence and natural history on our results. 
In case of a higher cervical eaueer incidence (in the absence of screening) in thc 
future, all beneficia! effects and some ad verse effects increase proportionally. A 
smaller ( or larger) number of spontaneously regressing lesions makes ad verse 
effects decrease (or increase), lèaving the number of deaths avoided unaltered. 
In efficient poli ei es screening starts at a bout age· 30. It is aften advocated to 
start screening much younger, .perhaps around age 20 {stJI 16 2 J. Indeed, present 
screening by general practitioners and gynaecologists concentrates between the 
ages 20 and 35. Our calculations indicate that such early deleetion polides 
lead to many more diagnostic and treatment procedures per death avoided. 
For instanee a screening policy that invites wamen every year between the 
age of 20 and 35, and every 5 years between 35 and 60 1"1 has the following 
effects. Per death avoided, 11800 srnears, 37 referrals and 16 minor treatment 
procedures are needed. The numbei· of deaths avoided, however, is only 17 per 
million wamen per screening year. We found that the ratio between beneficia! 
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Table .2.6- ProspcctÎ\'e calculatfons with a more aggressh'C treat.ment sclledule: 
effects ori tlw quant.ity of diagnosiS and primmy treat.ment resulting Erom three 
elficient early detection polides (diffcrcnces witl1 tlw situation witll no screening), 
and from tlw situation without screening (absolute numbers), per million womcn, 
per screening year 
NUmber of invitatio'ns• 
5 10 25 
Wamen referred +117 +266 +598 
Conserving treatments +20 .+42 +83 
Exconis_ations_ +20 +45 +86 
Hysterectomies +48 +103 +204 
Primary radiotherapies -19 -26 -35 
1.àtal treatments +71 +164 +338 
Per woman during her Iife-time 
No early 
detection 
182 
72 
104 
175 
' . 
and adverse effects is dramatically unfavourable compared with those from 
efficient policies. Th is· is mainly caused by the regression ra te of CIN mlesions 
being especially high in young wamen and if screening starts from age 30 ar 
35, most of the wamen with progressive CIN lll at early age are still detected 
in this pre-invasive stage, the mean duration ofprogressive CIN III being about 
15 years. · 
Our predictions were made for the situation in which follow-up is advised only 
after a smear with at least a cytologically moderate dysplasia. Colpostopy 
after smears with mild dysplasia (ar even less severe abnormalities) is also 
advocated .. For quantification of the effects of such a strategy, toa little is 
known about the incidence, regression ra te and duration of CIN I ~nd CIN 11, an~ 
a bout the sensitivity of the PAP smear for these abnormalities. Furthermore 
it is uncertain which protoeals for treatment will be used in the future, and 
how medica! practice will be. But the number of referrals and diagnostic 
and conserving treatment proèedur.es per radical treatinent ör death avóided 
will undoubtedly increase. The reasans fm: this are a relative increase in tl~e 
number of false positive results (the predictive value will be lower) and the 
larger nuinber of treaied wamen with regressive lesions, makir1g the plausible · 
3ssumption that regression is also possible from CIN I and CIN 11. 
Because we deal with symptom-free women, there is a close relation between 
balancing risks and. benefits in individual wo men, and dedsion making in 
health care. What counts in bath views is an acceptable ratio betwe~n bene-
ficia! and adverse effects of early detection ofcervical cancer. The question is 
how maliy referrals for diagnosis, conserving treatment procedures, exconisa-. 
tions and total hysterectomies are acceptable per iadical heatment or death 
avoided. Oilr aim was not to provide an absolute answer to this questiàn, but" 
to Provide the material required to cc;>mpare different polides on these criteria. 
Preventive pap-smears: 
balancing costs, risks and benefits 
This chapter is based on M. van Baliegooijen et al 
Br J Cancer (1992), 65, 930-933 
Abstract 
3 
The_ pattefn of spontaueaus screening för cervical eaueer by general practitioners 
and gynaecologists in the Netherlands is conipared with au efficient screening pol~ 
icy resulting from a cost-effecti~e study. Spontaueaus screening tencis to start and 
stOp too earlyin a woman's life, and leaves too many wamen overscreened or unpro-
tected. The combination in young age of a low incidence of invasive eaueer and a 
high incidence of regressive lesions explains relative. ineffectiveness and harmfulness 
of present screening practice. \Vhen screening would ~ake place between ages 30 
and·at least 60, with intervals of about 5 years, as many lives could be saved for half 
·the costs and with.only 60% of the unnecessary referrals and treatments. Much 
attention should be paid to the coverage of the target population. Therapeutic 
fellow-up polides for dysj>lastic lesions should be restrained. 
3.1 Introduetion 
. ~creening has contributed to the deercase in cerVical eaueer mortality inscveral 
countries {s8, 92, 126, 56, 81J, Therc is stil~ debateon the age tostart screening and 
on the intervaL So'me screening recommendations call for intensive screening 
at a young age ''· "' but studies which analyse the health effects of screening 
conclude that screening cfforts should be directcd to middle aged and older 
wamen [1~6, 112, t43, 57, 167J, The advocated interval has been lengthening the last 
few years but in practicc the interval tends to bc still short. 
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Figure 3.1 Age-specific pre\'alence of CIN 111 (!Jistologically confirmcd_ S(WCrc 
dysplasia or carcinoma in sit~) in tlw unscreened population. Es~hnates w!Jicll are 
based· on obsenred data Erom eerdeal eaueer screening programmes in tlw. Nether-
lands (see text). Speculative under age 30 (few data available) 
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The pros and cons of screening polides critically depend on the duration and 
detectability of the preclinical stages of the disease. Knowledge of these impor-
tant parameters can be derived from the results of existing screening pro-
grammes. Therefore, a detailed analysis was made of data from the early 
detection programmes in British Columbia and in the Netherlands. Both 
analyses led to very · simHar conclusions i"l. The first one has been published 
recently in this journall•ó9l, 
In tb is artiele we study the consequences of the results on duration and regres-
si on for balanced PAP smear taking. \Ve campare spontaneous screening with 
optimised screening, studying the costs, risks and benefits. 
3.3 Methods and materials 
3.3.1 The natura! history 
For the Netherlands, the following estimates were derived: 
a smear wil! detect 70% of the cases of CIN IJl ( cervical intraepithelial neo-
plasia) (sensitivity, that pertains to the situation in which women with at 
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Table 3.1 Results: tmmber of smears and tlie major effects of tnro different · 
approaches to cer\'Îcal cancer saeening. All _numbers are per miJlion wamen. per 
year 
Screening Smearsc Life-years Deaths Wamen Unnecessarily 
patterns gained avoided referred treated \Vomend 
Spontaneous0 120000 400 14 . 370 135 
Efficientb 65000 400 18 210 80 
a Spontaneous screening patteen by general practitioners and gyna:écologists 
b Efficient pattern, age 33 to 68, every 5 years, attendance 65% 
c See Fi9ure 3.2 for the age distri bution _of the smears 
d At least loca"l treatment (e.g. cryocoagulation or la;>e~-evaporation). 
least (cytologically) moderate dysplasia twice or severe dysplasia once are 
referred for colposcopy) 
0.4% of the smears wil! be false-positive {no GIN, or at the most GIN II wil! be 
found histologically) 
the mean duration of GIN lil is 15 ycars 
on average 60% of the cases of CIN lil wil! regress spontaneously, this per-
centage is highest at younger age (see Figure 3.1) 
a higher incidence of cervical cancer in non-attenders to screening than in 
at tenders 
3.3.2 Predictive calculations 
The assumptions on natural history have been implemented in à computerised 
epidemiametrie model, which uses also assumptions on demography, age- spe-
cific incidence and stage-specific survival ·(see Habbema· et al t"t, for a full 
description of the model). Screening policies were assumed to be operational 
in the Netherlands in the period 1988-20.15: Health effects and changes in 
number of wo men referred and treated after the terminatien of the programme 
have also been taken into account. 
Outcomes are effectiveness {number of life years gained), casts {number of 
screenings) 'and risks ( the number of wamen unnecessarily referred and treated 
because of falsc positive test results ar regressive lesions). All these resultshave 
been calculated as differcnces with the {hypothetical) situation in which therc 
is no early detection of cervical cancer. As we emphasise the ratio between 
positive and negative effects, for which discounting is disputable, undiscounted 
results are presented. The camparisen between different policies.is only very 
little affected by discounting. 
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Figul'e 3.2 Two screening patterns: annually percentage of tlw female popu-
lation screened by age. I. Spo11taneous screeiJing patter11 by general practitioners 
and gyna~cologists (see text). II. Elfleient screeniiJg pattern (sec text): age 33 to 
68 every 5 years, attendance 65% 
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Spontaueaus screening bas been defincd as screening in the situation without 
any invitational programme, _resulting from the exiSting diversity ofinitiatives 
among the wamen and the doctors involved. We stuclied data on screening 
by general practitioners and gynaecologists in the Netherlands during the 
period 1985-1988, during which there were almast na invitational screening 
programmes ruiming. We found {see Figure 3.2) that it starts at very young 
ages, declines in intensity after age 35 and stops nearly entirely at age 55-60. 
Population coverage is rather poor at older ages. This pattern corresponds 
with reports-of other European and-North American countries [llo, 94, 41, 3, t65J, 
Detailed data on individual screening patterns in spontaneous screening were_ 
not available. We assumed that 50% of the screened women have a smear 
every 2 years, the others being screened less aften. The spontaueauS screening · 
pattern was intorporatcd in our model and the costs, risks and benefits were 
calculated. 
3.3.4 Efficient and spontaueaus screening çompared 
We identified the elileient ( with the lowest costs) screening policy with 65% 
attendance that results in the same number of life-years gained as the spon-
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taneous screening pattem described. We assumed a 65% attendance level 
{percentage of the women screened) because this was reached in centrally 
organised screening with a population based invitation system in Dutch pilot 
regions [7tJ. The efficient policy differS from spontanemis screening in four ways 
(see Figure 3.2}: 
there is no screening ïn very young W!)men: startingage is 33 years; 
wamen are sereerred untillater in life: ending age is 68 yearS; 
the interval is Jonger: 5 years; 
coverage is higher, especially in older wamen. 
Costs, risks and benefits of both screening patterns arè presented in Table 3.1. 
The eflident policy req.uires half the number of smears to reach the same 
number of life-years gained as spontaueaus screening, and the adverse effects 
wil! be cut down by more than 40%. In order to explore the reasous for these 
large differences in risks and benefits, we wil! now have a detailed look at the 
four charaderistics of efficient screening mentioned. 
3.3.5 Screening at a young age 
The isolated effect of screening at young- age vs screening ,later in life is dmllon-
strated for the case.of a single screening (see Tab/c 3.2). With a single invita-
tion at age 40, the number o~women unnecessarily referred for CIN 111 or lesser 
abnormalities and unnecesSarily treated for each death avoided are seven and 
five times lower than with a single screening invitation at age 20-. The chance 
that a first screened woman has a CIN m is highest at young age ( continuons 
line in Figure 3.1). As women with diagnosed CIN mare nearly always treated, 
regression (discontinuous line in Figure3.1) can nat be observed. 
The long duration ofprogressive CIN ll! (about 15 years on average) results in 
timely detection in the large majority of the cases when screening starts at age 
30. Thus, oilly a few deaths wil! be a~oided by additional screening under 30 
years, at the expense of a very large number of screenings and a considerable 
risk of treatment of regressive lesions. 
We basically assumed a stabie inddence of cm·vical eaueer for the bhth cohorts 
· from 1948 onwards. Even when we assumed an inCrease in the incidence for 
wamen born after 1960 with 50%, the startingage of the eflident polides still 
did not fall much under 30. 
3.3.6 Screening in old age 
To study the difference in results withand without screening wamen between · 
50 and 70, we compared two screening polides that both start at age 33, the 
one (already presented in Tab/e 3.1) ending at age 68, the other at age 51 (see 
Tab/e 3.2). The latter polièy is certainly not eflident: 15% more life-years can 
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Table 3.2 Results: number of smears and the major effects of differeiJt cervical 
cancer ·screening patterns. All.numbers are per million wamen per ycar 
Screening Smears Life-years Deaths Women Unnecessarily 
patterns gained avoided referred treated women" 
Young agesa 
1 smear at 20 9000 20 0.4 30 10 
1 smear at 40 10500 110 4 4Q 20 
Old agesb 
until age 68 65000 400 18 210 80 
until age 51 67 500 340 12 220 90 
Intervalse 
every 8 years 37000 260 13 120 45 
every 2 years 196 000 580 27 600 210 
Attendanced . 
100%, 5x 51000 450 23 170 65 
50%, 25x 129 000 440 20 400 140 
a Single screening at age 20, attendance 75% respectively single screening at age 40, 
attendance 75% 
b Efficient pattern, age 33 to 68, every 5 years, attendance 65% respectively screening 
from age 33 to 51, every 3 years, altendance 65% 
c Efficient pattern, age 39 to 71, every 8 years, attendance 65% respectively efficient 
pattern, age 26 to 74, every 2 years, altendance 65% 
d Efficient pattern, age 39 to 71, every 8 years, altendance 100% respectively efficient 
pattern, age 26 to 74,- every .years, attendance 50% 
e At least local treatment (e.g. cryocoagulation or Iaser-evaporation) 
be gained with even less (5%) screenings when the policy is extended to the 
age-group 51-68 by increasing the interval from 3 to 5 years. 
Is the chance that a women wil! develop cervical eaueer later negllgible when 
she rcached the age of 50 without developing a precursor of cervical cancer? 
When this would be true, the high death ra te in old age could only be caused by 
poor screening under 50 years. Available epidemiologie data suggest otherwise. 
The detection ra te for preinvasivc Plus invasive ca neer in wamen who were first· 
screened between 50 and 55 years in Nijmegen and Utrecht {46{ was 4.1-7.6 per 
1000. This is clearly Iess than the cumulative incidence of invasive cancer 
of 11.8 per 1000 wamen of age 55-84 in 1975, i.e. befare screening became 
widespread [t97J, The gap between detection rate and cumul.ative incidence 
can only partly be explained by a sensitivity of the PAP smear of e.g. 70%. 
The püor screening history in women over age 50 is in itself reason enough to 
screen until at least ag<i 65 during the fortbeaming decade {n. '"i. Meanwhile, 
new evidence could be collectedon incide.!lce in older women·and on the need 
for further screening in women who received adequate screening until age 
50-55. 
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3.3.7 The interval between successive screenings 
The effect of screening·frequency is quantified by comparing intervals of 2 and 
8 years (see Ta bie 3.2). With an interval of 8 years 2800 smears are needed per 
death avoided. With an interval of 2 years this number rises to 7300 smears. 
The reasou is that the chance of getting invasive eaueer decreases s·ubstantially 
by a screening in the previous 2-3 years (see Figure 3.3}. As p.ointed out in 
the report 'of the !ARC working group i"l, this decrease can · be se~n in data 
from screening programs even 10 years aftera negative screening. This is not 
surprisinjs with a .mean duration of CIN 111 of 15 years .. 
The balance between risks and benefits also gets worse. With an interval of 8 
· years, nine wo men at~e referred and three wamen are treated per death avoided. 
'Vith-an interval of 2 years, these numbers increase to 22 women rcferred and 
eight women treated. 
3.3.8 The coverage of the target population 
As shown in Table 3.2, cervical eaueer mortality would be lower when all 
wamen would have a PAP smear five tirhes in their life, than whcn 50% of 
the women would be screened 25 times. 
Most cases of invasive ccrvical ca neer nowadays occtir in unscreened or poorly 
screened wamen f12BI, lucidenee in non-attenders appears to be higher than 
in the total population. This condusion of our analysis of the Canadian and 
Dutch screening data is supported by data from Denmark and Norway i"· "'1. 
A further reduction in mortality can primarily be achieved by screening the as 
yet unscreened wamen. The use of a sl10rter screening interval would ·mainly 
result in a more frequent screening of those whoare already being screened. 
3.4 Discussion 
A comparable study has been performed by Eddy ieoJ. Altlwugh his outcomes 
show a very small difference in effectivèness when lengthening the interval 
from 1 to 4 years, he surprisingly reeommenciS screening at least every 3 years. 
Eddy recommends tostart screening in the early 20s, without studying ad verse 
effects and -assuming an age-independent ~·egression rate. · Iri our view high 
regression·rates at young age cause extra risks of screening for young women. 
3.4.1 Follow-up and treatment 
Cervical eaueer screening will always induce unnecessary treatment, because 
of the partly regressive nature of CIN. The seriousness of this ad\rerSe effect 
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Figure 3.3 Relathrc risk of inmSÏ\'C cen'ical cancer in screened wamen with a 
most recent screening 2_-3 years ago comparcd to unscreened wamen. Calculated 
from Day !<>SJ 
. " 
' 
Number of previous screenings 
depends on the treatment applied. We found that in some Dutch gynaeco-
logical centers 'nearly 50% of the wamen with CIN III were treated with hys-
terectomy and in other centers 10% 1'1. From the USA, hysterectomy rates 
in wamen with cervical carcinoma in situ are reported to be 50% [79J. In a 
screening programme with excellent gynaecological follow-up, the number of 
hysterectomies forcervical cancer in the population should fall because of the 
decreasing number of invasive cancers. But with an excessively aggressive 
treatment of Preinvasivè lesions, the number of hysterectûmies can increase 
3-fold when an intensive screening programme is carried out. 
3.5 Conclusions 
Our analysis clearly shows the consequences of screening elfarts still start-
ing and stopping too early in life, and being perfonned too frequently. The 
importance of a high coverage cannot be overemphasised .. 
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The management of cervical intraepithelial 
neoplasia: extensiveness and costs 
in the Netherlands 
This chápter is based on M. van Baliegooijen et al 
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Abstract 
In order to provide greater insight into both the extensiveness and the medica! costs 
of the diagnosis and treatment of screen-detected -cervical intraepithelial neoplasia 
(c!N) in general medical practice in the Netherlands, data from national registries 
and gynaecology departments were retrieved, and experts ·were interviewed. Of the 
5060 women diagnosed with Cl~ in 1988, more than 50% were treated in hospi.tal 
.with conisatiûn or hysterectomy, which on average took 5.5 days stay per admission. 
J'he asscssed average duration of the tot al pre- and posttreatment. period is 4.6 
years. The average total medica! costs in women with detected CIN liJ are Dfl 3700 
per woman. The diagnosis of CIN 1 and 11 involves more medical procedures and time 
than CIN m, but fewer wamen have conisation or hystereetomy, resulting in lower 
total medical casts (Dfl 2572}: The overall extent and casts of the management of 
CIN should be· accounted for when balancillg the benefits, unfavourable effects and 
cost.s of cervical eaueer screening. 
Acknowledgement This study was supported by the :rviinistry of \Velfare, Pubtic 
Health-and Cultural :A-ffafrs of the Net.herlands, and by the Dutch Health Insurance 
Council. 
4.1 Introduetion. 
The aim of this study was to provide ·greater insight into the extent and 
the medica! costs of the diagnosis and treatment of screen-detected cervical 
intra- epithelial neoplasia ( CIN) in general medica! practice. Such. knowledge 
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is most important for assessing the balance ~et,.veen casts and favourable and 
unfavollrable effects of screening for cen•ical cancer. Part of t.he unfavourablc 
effects is caused by detection of non-progressivc lcsions. The number ofwomen 
involved is increasiitg because thc _cut-off point in eytology for colposeopic 
follow-up has been shifting to Jower grade abnonnalities. It is often stressed 
that tlie management of CIN Is quick, safe and eheap. Even if this were true 
in an ideal situation, such a statement should be vcrified for general medic3.l 
praetice. Available literature refers to data from one or two selected trcatment 
eentres per study [105, 78, 193J. \Vè stuclied the number of the various diagnostic 
and trea,tment procedures from national data, and when this was nat possible, 
from a immber of gynaecological departments covering 25% of the population. 
Data from the Dutch nationa] hospita] ad mission registration ( coverage over 
99%) were combined with centrally collected data from at least 85% of th~ 
cytopathology laboratmies (PALGA, Dutch Network and National Database 
for Pathology). Currently the Netherlands is one of the few countries for 
which these data are available on a national scale. 
4.2 Methods and materials 
The study concerns wamen with histologically confirmed CIN: the episode 
stuclied starts with the first visit to the gynaecology department for follow-up 
after an abnormal PAP smear and ends after the woman is referred back to 
normal screening practice. The situation for wamen having invasive cervical 
eaueer has been considered elsewhere {9oJ. Tllis study concentrates on pre-
invasive disease, cervical intra-epithelial neoplasia: CIN I/II and 111. 
The annual numb.er of wamen in whom CIN 1, 11 and JIJ has·been diagnosed 
in the Netherlands was retrieved from PALGA, which is connected to the 
cytopathology Jaboratories. All women with histologically confirmed CIN in 
the period 1987-1990 were selected l"'l. For each of these women, the max-
imal diagnosis within this period was established. The populatiOIJ coverage 
rate of PALGA was 70%, 85%, 98% and 99.6% in 1987, 1988, 1989 and 1990 
respectively. The annual total numbers (corrected for incomplete coyerage) of 
women detected with CIN I/II and CIN III for 1988 are 2590 artd 2570, respec-
tively, and for 1990 3410 and 3420, respectively. 
The annual number of conisations (2180), hysterectomies (425) and days of 
hospitalization (15780) associated with thediagnosis and treatment of CIN (sec 
Table4.1}, were retrieved from national data on hospita] admissions, selecting 
admissions with dysplasiaor carcinóma in situ ofthe cervix uteri (ICD-9 codes 
622.1 and 233.1 respectively) as themaindiagnosis [mJ. Same ofthe cases with 
hysterectomy also had a secondary diagnosis, but thée were a lso hysterectomy 
_cases \vith dysplasia or carcinoma in situ in the secondary diagnoses, which 
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werè not included in our figures. Tagether with tbc retrieved annual number of 
\vomeh with CIN, the hospital data enabled us to compute an average numher 
of medica! procedures per woman with CIN (see Table4.1}. 
In the scarch for CIN grade-specific data and data on out-patient procedures 
(particularly.conserving treatments), all gynaecology departments in the Nether-
lands were sent a request for annual figures on diagnostic and treatment pro-
cedures in the management of CIN. Gynaecologists from 10% of the hospitals 
responded with relevant data, mostly by sending annual reports, data on treat-
ment of wamen with CIN lil ( therc are hardly any data on CIN I and n), annual 
number of conisations, conserving treatments and colposcopies, covering the 
period 1984-1989. These hospitals cover 25% i""i of the Dutch population. In 
these data, 33% of the wamen with CIN lil had conservativc tt:eatri1ent (cry-
ocoagulation, laser evaporation and hot loop diathermy are widely used in 
the Netherlands), 56% had conlsation and 11% hysterectomy. These fractions 
were accepted as our estimates. In the 50% responding hospitals with the high-
·est frequency of conservative treatment, these percentages summated to 58%, 
. 35% and 7%, respectively. In addition, we ass.umed that 15% of all wamen 
treated.will need retreatnl.ent at least once [2111, 75% ofwhom wiH receive con-
servative treatment and 25% of whom will receive conisation, amounting to 
0.44 (0.33 + 0.75 x 0.15) conservative treatments.and 0.60 (0.56 + 0.25 x 0.15) 
conisations. 
In the next step, the fraction for conisations was multiplied by the total num: 
her of wamen diagnosed with CIN 111, resulting in the number of conisations 
which should be attributed to wamen with CIN lil (0.60 x 2570 = 1542) .. The 
number of conisations which should be attributed to wamen with CIN I or II 
was calculated by subtraction (2180- 1542 = 638), and the fraction of wo men 
with CIN I or II having conisation was determined (638/2590 = 0.25). The 
same procedure was foliowed to calculate the number of hysterectomies and 
conservative treatments in wamen with CIN I/II. The total annual number of 
conservative treatments \Vas calculated from the ratio between conservative 
treatments and coilisations in the reporting gynaecology departments and the 
total annual number of conisations (1.273 x 2180 = 2775). The fraction- for 
which no data were available -of wamen with CIN I/11 without a conserva- · 
tive treatment, conisation, Or hysterectomy was. calculated as t~1e residue after 
subtracting the tot al fraction of treatment procedures from 1 plus the fraction 
of retreatments (1.15- 0.63-0.25-0.05, see Table 4.1). The annual number 
of colposcopies reported from the gynaecology departments was extrapolated 
to the nationallevel (15466 colposcopies). 
To. collect information on äspects for which no detailed large se ale data were 
available- nu mb er of consultiltions at the gyllaecology department, Pap smears, 
colposcopies and ( ecto- or endocervical) biopsies, and the duration of the 
total pcriod stuclied - four gynaecologist-colposcopisis from different hos-
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Table · 4.1 Estimatcd at'erage numbcr of diagnostic and treatment procedures, 
and days in hospita/ in womcn with screerJ detccted CIN. Tl1e Netlwl'lands, wamen 
diagnosed in 1988 
CIN 1/11 CIN 111 All CIN 
nl.!mber per number per annual 
woman Woman number 
a b c 
Treatment procedures 
No treatment 0.21 0.00 544 
Conserving treatment 0.63 0.44 2775 
Conisation 0.25 0.60 2180 
Hysterectomy 0.05 0.11 425 
Hospita! days~ 
Conisation 1.1 2.7 9810 
Hysterectomy 0.7 1.3 5100 
Other 0.1 0.2 870 
Tota.l 1.9 4.3 1578 
f:lospital admissions 
Coniaation 0.25 0.60 2180 
Hysteredomy 0.05 0.11 425 
Other 0.03 0.08 285 
Tot al 0.33 0.79 2890 
Assessment pro_cedures 
Pap smears . 8.7 7.3 . 41383 
Colposcopy 6.0 4.6 27200 
Biopsy 2.4 1.8 10799 
Number of consultations and duration of total period stuclied 
Consultations 9.0 7.6 42680 
Years 4.9 4:3 23851 
c = a ?< 2590 + b x 2570, in which 2590 and 2570 are the annual number of women with 
CIN rjn and CJN lil_ respectively 
Example: · 1.1 days for conisations per wamen with CIN 1/II = 0.25 conisations x 4.5 
days (see Table4.2} 
pitals (three university hospitals and one regional hospita!) were intervimved 
in a standardised way. From these intervie,Vs, we could assess which aspects 
show variation in practice, and consequently, since large scale data are missing, 
remain uncertain. The possible influences of these uncertainties were stuclied 
in a sensitivity analysis. 
A cost-effectiveness analysis was the goal of the cost part of this study and 
the casts were assessed from the viewpoint of society. An analysis of the true 
resource casts of all relevant procedures was, however, beyond the scope of this 
study. Apart from the cast per colposcopy and per hospita! day, which reileet 
an assessment of the true resource costs! the casts of diagnosis and treat-
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Table 4.2 Casts (in Dfl) per medica/ procedüre in tl1e management of CIN 
Cost per procedure Days in hospita! Total"costs .. 
Visit 67 0 67 
Pap~smear 52 0 52 . 
· .Prim. colposcopy 145 0 145 
Sec. colposcopy 106 0 106 
Biopsy 87 0 87 
Cryocoagulation etc. 123 0 123 
Conisation 401j 4.5 2622 
Hysterectomy 2536j 12 8458 
* Cost per procedure plus Dfl 494 per day in hospital 
Including Dfl 165 for pre~surgery Iabaratory procedures and chest X-ray 
ment have been approximated by tariffs charged (1993) in the Netherlands 
{see Tablé4.!2). The cost per colposcopy was assessed by interviewing colpo-
scopists for time investment, by r~vie,Ving financial accounts öf gynaecology 
. departments, and by cost analysis ofthe equipment. The cost per hospita! day 
is an estimate of the average cost per day (weighted average for the generaland 
teaching hospitals, and of generaland intensive care), induding "hoteP' casts, 
nursing and medical stáff, standard medical equipment, medication and.over-
head costs. We performed a sensitivity analysis on a lower cast per hospita! 
day (see Discussimi). 
The costs are prescnted in Dutch guildcrs (Dfl) in Table4.3. In 1993, thc 
exchange rates for the British pound was Dfl 2.8 and for the U.S. dollar 
Dfl 1.85. 
4.3 Results 
The resulting numbers of treatments and days of hospitalisation are sum-
mariscd in Table4.1. As expccted, the fraction of women treated with hys-
terectomy or .conisiition was much lower in CIN I/II 'than in CIN III. Important 
· differenc~s in practice occurred in the management of low g_rade lesions. The 
gynaecologists intervicwcd confirmed that in some of the gynaccology depart-
meuts in the Nethcrlands, wamen with CIN I and, toa lesser extent, CIN i I were 
treáted only if there was persistenee or progression in the first 2 years after 
diagnosis. In our calculation, the fraction of women with diagnosed C1N I/11 
whohave no trcatment was 21%. Assuming that halfthe women with CIN r/11 
show regression within 2 years, this would mean that approximately 40% ofthe 
women diagnosed with this condition were initially foliowed-up with cytology 
. and colposcopy. In a sensitivity analysis, we examined the effect of all women 
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with CIN I/rr being treated .immcdiately after diagnosis, other than by conisa-
tion or hysterectomy. 'Ve also examined thc effect of all these womcn being 
. initially foliowed up with cytology and colposcopy (see TableJ,.J,). 
The requircd numbers of PAP smears, colposcopics, and biopsies per wo:nen 
reported by the colposcopists intervicwed showed little variatien with. pri-. 
mary diagnosis. 'Ve aSsumed 1 PAP smear, 1.2 colposcopies and 1.4 biopsies 
per women.during 1.2 consultations over a perioei of 0.3 years. In women ini-
tially foliowed up with cytology and colposcopy only, but treated eventually 
(in our calculations 21% of the women with CIN I/ll), these numbers were do u-
bied becàuse a second diagnosis is required. In treated. women, the numbers 
were increased by 30% for (suspected) recurrence. During follow up without 
treatment, one colposcopy ·and PAP smear per 6 months was added. 
Finally, for all wamen with CIN, we accounted for consultations, PAP smears 
and colposcopies during the follow~up after primary management. This follow 
up ends· when a \voman is refe~Tcd for routine screening. The different kinds 
of schedules used in this period are: 
Procedure at consultations 
5 years of follow-up. with both cytology and colposcopy 
5 years of .follow up with only cytology 
3 years of colposcopy foliowed by 2 years of cytology 
1 yeár with one .colposcopic and two cytologie evaluations 
Number of 
consuftations 
8 
8 
8 
2 
We basically assllmed an intermediate schedule with six consultations, six PAP 
smears, three colposcopies and a duration of 4 years. In a sensitivity armlysis 
we account for more and less intensive schedules (see Table 4.4). The resulting 
numbers of diagnostic procedures during the tata! period stuclied are shown 
in Tab/e4.1. 
Table 4.2 presmits the cost per procedure. In Table4.3, the estimated casts 
for diagnosis and treatment of C!N are presented. The casts of the medica! 
procedures were approximately Dfl1600 for all grades of CIN. The total costs 
in CIN lll were 45% higher than in CIN I/ll, due to the larger number oflwspital 
days. The casts of hospitalisation accounted for more than half of the total 
casts óf Dfl 3727 of the diagnosis, treatment and after treatment follow-up per 
wom8.n with.CIN 111. 
4.4 Discussion 
Multiplication of the estimated numbers of colposcopies per wamen with the 
estimated annual number of cases results in the total number of colposcopies 
(27200) (see Table4.1} which seems to be (80%) toa high compared with 
4.4. Discussion 35 
Table 4.3 Estimated average medica] costs (in Dil) per nroman wlth screen 
detected CIN 
CIN 1/11 CIN 111 
Consultation* 201 7.8% 201 5.4% 
··Pap ·smear 454 17.7% 380 10.2% 
Colposcopyf 673 26.2% 522 14.0% 
Biopsy 206 8.0% 158 4.2% 
Conserving treatmerlt 78 3.0% 54 1.4%. 
Conisation 646 25.1% 1573 42.1% 
Hysterectomy 465 18.1% 930 24.9% 
Other days in hospital 51 2.0% 109 3.1% 
Total costs 2572 100.0% 3727 100.0% 
Ofwhich: 
Costs for Procedures 1649 64.1% 1634 43.8% 
Costs of hospitalizat'ionf 923 35.9% 2093 56.2% 
* Only consultaUons withqut colposcopy are charged 
t One 'Primary colposcopy', all others 'Secondary colposcopy' (see Tabfe4.2} 
f Dfl 494 per day in hospital 
the annual number of 15 466 estimated from the data from the gynaecology 
department. This could partly be due to the eet-vical cancer screehing pro-
gramme reintroduced in the Netherlands since 1987. The total number of 
smears in 1988 was.20% higher than in 1987 1"'1. A substantial number of the 
colposcopies induced by screening in 1988 will only be incorporated in later 
years and are not present in the reports of 1988. Moi"eover, the gynaecolo-
gists intel'\•iewed suggested that there had been substantial underregistration 
of colposcopies in their departments. 
As can beseen from Table4.4, the lengtlt of the follow-up period after treat-
ment is important bath for the extent of the management for the wamen 
involved and for the costs. It also affects the number of colposcopiès, which 
is important in terms of the capacity of the gynaecology departments. The 
considerable variety in practice shows the need for more evidence on how long 
a woman treated for GIN should be foliowed-up colposcopically. How much 
information colposcopy after treatme11t adds to cytology is questionable 1"01. 
\Vhen only cytology is reQuired, the wamen can be re(erred to the general 
practitioner. 
Other importànt cast factors are the number of wamen with CIN having con-
isation and hysterectomy respectively. For th~ Dutch situation, we found 
that the Immbcr of hystcrectomies in ·wamen with CIN rrr differs considerably 
(from 10% to almast 50%) between hospitals 1'1. The use of hysterectomy for 
the treatment of CIN has been decreasing over recent decades. In a litera-
ture search for data from 1980 onwards, we found tlu'ee studies from British 
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'Table 4.4 Scmsitil'ity analysis on a\'ei·age medica] practice. Pereental changes 
in armual total rwmber of colposcopies, c(m~ult<ttions, length of follow-up period 
and casts (in Dfl of tlw management of screendeteeteel CIN in the Netherlands, 
calculations for 1990 
Assumptions Colposcopies 
Baseline assumptions 35977 
Initia! management of wamen with CIN I and CIN 11 
Immediate·treatment in all cases -14% 
Cyto-Jcolposcopic follbw-up +19% 
initially in all cases* 
Follow-up schedule after treatment 
One year, colposcopy 
5 Years, colposcopy during 
the whole period 
-38% 
+95% 
Consu/tations Number of 
.._..,omen in 
follow up 
56467 31559 
-9% 
+12% 
-7% 
+9% 
-65% 
+22% 
Total costs 
(MLN) 
21.5 
-4.2% 
+5.6% 
-13% 
. +20% 
* Where we àssume that 50% of the foliowed up wamen are treated ·after all, because 
regression is not noticed within two years 
liospitals, in which 15-40% of the wamen with CIN had conisation and 1-7% 
hysterectomJr [105, 78, t93J, This compcires favourably with the 41% and 8%, 
respectively, (retreatments included) reearcled in this study. Each of these 
studies, however, came from one treatment centre, and quality bias (towards 
more conservative treatrfl.ent) cannot be ruled out in data from publishing 
( = selected) een tres. Our esti!nates on the use of conisation and hysterec-
tomy are based on nationál data. Furthermore, ilr two of the studies from 
the United Kingdom 11os, 781 conservative treatment was performed as an in-
hospita! treátment and under general anaesthesia. Conservative treatri1ent in 
the Netherlands is performed as an out-patient treatment, under local (if any) 
anaesthesia. 
CmTmü Dutch data, only the distribution of the conisations (and hysterec-
tomies) over the different grades of CIN was based on less complete data 
(although coverage was much higher than in one-centre studies). The respond-
ing 10% of the gynaecology departments represent the larger hospitals, possi-
bly ·causing an overestimation of the use of conservative treatment in CIN 111. 
Correction of such an ovéreStimation in our assesstilent would shift part of the 
conisations and hysterectomies from women with CIN I of 11 to women. with 
GIN m, without affecting the tot al number of these treatment rnadalities used. 
Data from Loizzi and associates f129J, also obtained from one treatment centre, 
show 73% cönisat~ons in women with CIN. Goodwin and colleagues f79J 1 who 
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performeel a population based study on all women from NcwMexico with diag-
nosed carcinoina in situ of the cervix in 1982-1985, found 44% hysterectomics. 
(In the Netherlands, 40%of the CIN n(diagnosis concerns carcinoma in situ). 
These figures reileet more aggrcssive treatment strategies and probably large 
differences in gynaecological practice between regions or countries. 
In the Netherlands, a conisation on average takes 4.5 days in hospita!. If 
we hypothetically assume only one hospita! day per conisation, this would 
reduce the total number of hospita! days by 29%; and the total costs for the 
management of screendeteeteel CIN by 14% (calculations for 1990). As far as 
the cast per hospital day is conccrned, wamen hospitalised for the treatment 
of CIN are probably more healthy than the average hospita! population, and 
consequently, even having generàl anaesthesia, they might need less general 
care. If we arbitrarily deercase the cost per hospita! day from Dfl 494 to 
Dfl 400, the total costs of the management of CIN would deCI·ease by 9%. 
The evidence as to whether women with CIN I and 11 should be followed up 
initially, to give regression a chahce, or should be treated im.mediately, is 
inconclusive. Imnlediate treatmcnt is less costly t.han the "wait and see" man-
agement, but the difference is rather smal! {see Table4.4). Treatment without 
delay saves 2 years of follow-up maximum, at the expense of treating ~ore 
wömetL The difference· in the psychological burden to the wamen .involved 
might be important, but this has hardly been quantified: on the one hand, 
an'xiety may occur as long as no treatr_nent has been given, on the other hand 
wamen in whom CIN regresses have the psychological advantage of not needing 
treatment for a condition associated with cancer. The gynaecologist 's coun-
selling strategy and attitude probably plays a major role in these psychological 
effects. 
Total costs for the management ofwoman with detected CIN amounted to 21.5 
· million guilders in the Netherlands in 1990 (see Table 4.4). This is almost as 
much as the sum of the assessed costs for the diagnosis and primary treatment 
· of wamen with invasive· cervical cancer (757 woman in 1990 (1541) of 14 million, 
and for ad vaneed disease (288 women died from cervical eaueer iii 1990 1"1) of 
~ million [111. 
In Conclusion, the extent of the overall management of CIN is greater 'and the 
c.osts higher than might be expected. Although there has been a trend towards 
more conservative treatment, in the Netherlands half of the cases are treated 
with conisation or hysterectomy. The costs are substantial and the effect on 
the wel! being of the women may be considerable. It is this overall practice 
that should be accounted for when balancing the benefits, unfavourable effects 
and casts of cervical ca neer screening. A fmther trend towards lcss aggressive 
treatment in the near future fronl LEEP (loop elcctrosectional excisïon proce-
dures) combined with 'sec and treat' strategies, and specific treatments for 
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hunmn oncogene, papillamavirus positive wamen, is cantroversiaL Expecta-
tions will have to be reconciled not only with data from excellent treatment 
centres, but also with data reflecting overall practicc. 
5 
Care and costs for advanced cervical cancer 
This chapter is based on M. van Baliegooijen et al 
Eur J Cancer, Vol. 28A, No. 10, pp. 1703-1708, 1992. 
Abstract 
The types, amounts and costs of hosp~tal and home care in patients who died from 
cervical eaueer are investigated, using both tlational data sourees and hospita! files. 
Our goal has b~en assessment of the savings on treatment and care of advanccd 
cervical eaueer resulting from cervical c~ncer screening. 
Hospita! costs account for 70% of the total cost per patient of Dfl 29 200. The 
amount of hospita! care dccreas"es significantly \vith incrcasing age. The average 
Ûumber of days Ûf hospitalisation per patient withad vaneed discase ·decreases from 
62 days below ag"e 50 to less than 10 days at age 70 and ·older. In-hospita! medica! 
procedures, home care and nursing home care account for 24, 22, and 8% of the 
costs, respectively. ~v!ass screening programmes fo_r cervical eaueer will result in a 
reduction in both advanced disease au~ mortality. The potential savings compen-
sate approximately 10% of the eost.s of screening. 
Acknowledgement This study waS supported by· the llvlinistry of \Velfare, Health 
and Cultural Affairs of the Netherlands. 
5.1 Introduetion 
Knowledge of the tata! amount 'of care and related medica! casts in patients 
with advanced cancer is significant bath in itself and for studies on .the cost-
effectiveness of ca neer prcvention. Our goal has been assessn.lent of the savings 
on treatment aild care of advanced ccrvical eaueer resulting from cervieal 
eaueer screening. In an earlier study on the casts and savings of cen•ical 
ca neer screening [tts, 9J we roughly cstimated the casts of treating adva~1ced 
disease. This topic is now being dealt with in a more detailed way, accounting 
for hospitalisation days, diagnostic and (palliative) treatment procedures and 
home care. 
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Table 5.1 Hospita! days for im•ash'e eerdeal eaueer 
. ·: .......... Hospita! days .............. 
lnvasive Ad vaneed Advanced Deaths from 
cervical cervical cervical ca neer, cervical cancer 
Year ca neer ca neer per death (absolute- number) 
(a)* (b)=( a )-(i) (c)'=(b)/(d) ( d) 
1987 17654 7392 24.6 301 
1988 19531 8496 25.4 334 
....................... Hospita! days ....................... 
Primary Treatment 
diagnosis . Primary Complications in survivors 
and surgical (brachy-) of primary of recurrent 
Year treatment radiotherapy treatment cervical caoeer Tot al 
(e)t (f)l (g)§ (h)ll (i)=( e )+( f)+(g)+(h) 
1987 6615 3217 245 185 10262 
1988 8033 2560 242 201 11035 
* The total number of hospit al days from admissions with main diagnosis invasive cervical 
caoeer (tco-9 code 180) or with main diagnosis metastasis (ICD-9 codes 160 to 179) and 
invasive cen,ical eaueer as second diagnosis [t8s) . 
t The number of hospital days for prima'ry diágnosis and surgical treatment of cervi-
cal c<incer, assess€d by summing up the hospita} days from admissions with invasive 
cervical carcinoma (IOD-9 code 180). as the main diagnosis and one of the possible sur-
gical diagnm:;tic or primary treatment procedures (including cervical or uteral biopsies, 
curettages, exconisations and hysterectomies) as one of the oper<itions cocled [t88J 
The number of hospita! days (BrDays) for primary (brachy)radiotherapy {IilCgo:J.-
volt radiotherapy is given in an outpatient setting) is calculated using the formula: 
Br Days = (700- Hys) x 1.6 x 5, in which 700 is thè estimatcd yearly incidence of inva-
sive cancer, Hys is the yearly number of hysterectomies performed for invasive cervical 
caoeer [tas], 1.6 is the average n~nnber of brachytherapy sessions for a woman who is 
rccciving primary radiothcrapy, 5 is the estimated number of hospita! days ·per session 
of brachytherapy {tas] 
The number of hospita! days for complications after· primary therapy (Hys x 0.03 x 
10) + ((700 - Hys) x (0.04 x 9)]. in which 700 is the estimated yearly incidence of 
invasive cancer, Hys is the yearly number of hysterectomies perfoç!fied for invasive 
cervical caoeer [tssJ, 0.03 and 10 are the risk of a complication and the number of 
hospita! days for a complication requiring a supplemcntary Ilospital admission after 
radkal hysterectomy {SJ, 0.04 and 9 days are the risk of a complication and number 
of hospita! days for a complication requiring a supplementary hospit al admission after 
primary radiotherapy [SJ 
11 The number of hospital days for treatment of recurrent invasive cervical cancer in 
wamen that survivc iS: deaths x 5% x 12days, in which deaths is the number of deaths 
from cervical caoeer, 5% is the estimated cure rate in wamen with ad vaneed disease 
[SJ, 12 is the estimated number of hospita! days per ad mission for curative treatmerit of 
recurrence (s) 
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5.2 Material and· methods 
The rele~.mnt episode of care starts at the first diagnosis of recurrence or metas- · 
tasis after primary therapy and alwayS ends with death. If women receive no 
primary curative treatment, because of poor prognosis at the time of primary 
diagnosis, the ep~sode stuclied starts· with primary diagnosis. From here on, 
we will use the term 'advanced cérvical cancer' for all cases. 
5.2.1 In-hospita!· care. 
We analysed national data on the number of admissions and length of stay in 
Du.tch hospitals. for patients with ad vaneed cervical cancer during the years 
1987-19881"'1 (see Table 5.1 for details). 
For additional information, especially on number and type of medica! proce-
dures, a file study was performed in the Dr Daniel den Hoed Clinic in Rot-
terdam, which is one of the two· caneer eentres in the Nctherlands, with an 
associated radiotheraPY center. From the medieál registration, the files of· 
40 women who died from cet·vical carcinoma during the period 1 June 1987 
to 31 December 1988 were collected. This registration also includes outpa-
tients never admitted. Five cases have been exduded from further analysis 
because of incomplete informatiOn on stays in ether hospitals. In the remain-
ing 35 cases, primary therapy had been radical hysterectomy (8 women) or 
radiotherapy (22 women), or no primary curative therapy had been applied 
because of advanced disease with poor prognosis (5 women). 
For the major eost categories, \~e used estimates of the ~ctualn~som·ce costs. 
This is the case for nursing cósts per hospita! day (excludingeosts of medica! 
procedures) 120<1, and for ra.diotherapy. The costs ofradiotherapy arebasedon 
a special study on the costs of radiotherapy in bteast eaueer i"'i, but taking 
differences between breast cancer and cervical eaueer tt:eatment into ·account. 
The costs of the other medica! procedures were approximated by the tariffs 
charged. 
5.2.2 Nursing home care 
. The average length of stay in nursing homes has been estimated from national 
data .concerning nursing homes a:dmissions [t89J, covering 80% Ûf all Dutch 
nursing homes (1986-1988). The data stuclied concerned a selection ofwomen 
dying in a nursing home and having neoplasm of the female urogcnital tract 
{NFUGT) and metastasis registered as firsttwo diagnoses (in any order). 
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Figure 5.1. A ve1·age munber of hospita! days and cwerage casts Dfl) of in~ 
lwspital medical procedures per patient i11 different age groups 
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5.2.3 Home care 
Patients who stay at home c·an receive informal·and professional care. Informal 
care is defined as care providèd by relativcsj neighbours, friends and volunteers. 
Professional care in the Netherlands is mainly provided by dis.trict nurses, 
hOme helps, general practitioners and private nUrses. 
The available data enabled us to discern two successive phases to assess the 
tot al amount of home care provided: a I ow-care phase and a terminal phase 
·in which the level of care inereases rapidly. To estimate the total amount and 
cast of care in the two phases, information is required coÎ1cerning the length 
of the phase, the proportion of patients receiving different types of home care, 
the intensity of care, and the casts per unit of care. 
Low care phase. Information about the amount of care during the !ow-
care phase has been based on data collected in 1986, 1987 and 1988 by the 
National District Nursing Association 1"'1. The data arebasedon a 4% sample 
of the Dutch population, which is representative with respect to agc and sex 
composition .. Froril this registry, we selected data on patients with eaueer 
of the female genital tract as main diagnosis. To estimate.only the·care for 
patients in the low-care phase, we excluded the patients reearcled as terminal 
patients by district nurses. 
National data about.home help only provide information a bout the average 
level of care by age-group 1"1. Dlagnosis-specific information on home help 
was availablc from one organisatioi1 !9sJ. 
p, 
0 
V 
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Casts per hour of care were calculated using average wages per type of health 
care worker, derived from financial tepol'ts of the Intensive Homecare Project 
(IHP) [127[ and from the national associationsof district nursing, home helpand 
general practitioners [t57, s9, 145,_1511. These financial reports also provided the 
material costs. 
Terminal phase. The IHP·, whose services will be cailed 'intensive home 
care\ in operation in an experimental set_ting since 1987 in three regions 
in the Netherlands, provided data concerning intensive home care !144, 111 1. 
This project concern& mainly eaueer patients whodie within a relatively short 
period and who would need hospita! or nursing home care in the absence of 
this project. This type of care is available for 24 h per day. The arnount of 
care, delivered by district nurses, ·home helps, general practitioners, private 
nurses, and inforrnal help was registered daily. We used data from 1988 about 
care for all32 patients with eaueer ofthe female genital organs (cervical cancer 
was nat classified separately). 
Next t.o this a significant part of the terminal patients rcceive 'regular home 
care', ~vhich is restricted to a maximum of 2.5 h of district nursing and 8 h 
of home help per day. Data on this group of patients were abtairred from 2 
sourcès: a study of district nursing care în Amsterdam and data a bout the 
level of care for patients in the last week befare entering the IHP ll27J. 
5.3 Results 
5.3.1 In-hospita! care 
National data on the number of days of hospitalisation for the years 1987-1988 
are presented in Table 5.1. The average number of days of hospitalisation for 
advanced cen•ical eaueer estirnated for the years 1987 and 1988 is 25 (see 
column (c)). 
Average age at death for the 35 wamen in the file study was 53 years. This is 
lower than the average age at deat.h from cervical cancer on a nationallevel: 
65.3 years in 1987 and 66.1 years in 1988 1"1. Of the 35 patients,' 15 (43%) 
died at home, which is nat significantly different from the percentage (50%) 
reported from Dutch national data on cervical eaueer deaths JssJ. The average · 
duration of theepisode of advanced discase was 11 months. 
The hospita! data frorn the 35 cases in thc file study are presented in Table 5.2. 
The averag~number ofhospital a'dmissions per pa ti ent was 4.2 and the average 
length of stay was 10.3 days. Chernotherapy cycles requircd rclatively short 
admissions of 2-5 days. On average, the length of stay .in hospita! was 43 
days per woman. This number decreases markedly with increasing·age (see 
Figure 5.1). Below age 50, the average number of days is 62, but the 7 wamen 
older than 70 years had a mean total duration of stay of only 8 days. This 
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Table 5.2 l\-Iedical record study of advanced cenrical cancer* 
Procedure 
Outpatient visits 
Radiotherapyf 
Surgeryf 
Chemotherapy cures 
CT-scans 
X-rays {IVP excluded)§ 
IVP 
Echosenpies 
ECG 
Other diagnostics 
Intercollegial consultations 
diagnostic punctions 
Biopsies 
Exam under narensis 
Labdratory 
Tot al 
Hospital days 
. of which in intensive care 
Mean na. 
per woman 
13.1. 
0.5 
0.7 
1.8 
. 1.9 
4.8 
0.7 
1.2 
0.9 
0.9 
1.3 
1.3 
1.2 
0.7 
53.0 
43.4 
0.5 
Casts per Casts per 
procedure (Dfl) patient (Dfl) 
17 225 
5100 2625 
2080 1486 
I 075 1935 
435 821 
57 272 
110 66 
Hl 165 
•15 41 
325 279 
66 83 
199 251 
95 117 
380 250 
27 1456 
10070. 
% Of 
tata! casts 
2.2 
26.1 
14.8 
19.2 
8.2 
2.2 
0.7 
1.6 
0.4 
2.8 
0.8 
2.5 
1.2 
2.5 
14.5 
100.0 
* Outpatient visits, diagnostic and treatment procedures, and hospita! days in 35 wamen 
who died from cervical eaueer (Daniel den Hoed Clinic) 
t Referring to a whole course of treatmentj 18 out of the 35 wamen had radiotherapy 
+ Including the urinary tract {13), the digestive tract (7), laparotomi_es (2), radical hys-
terectomy (1), brain surgery (1) and cordotomy (1) 
§ 65% Of the thorax, 18% of the abdomen, pelvis and Iu mbar spinal column 
age trend should be kept in mind in camparing the hospita! data to national 
data, since the wo men in the file study were relatively young. Standardisation 
of the mean duration of stay on the age distribution of cervical canCer deaths 
in the Netherlands results in a much lower estimate of 29 days for the average 
duration of stayin hospita! {and an extra 0.3 days in intensive care), which is 
in reasanabie agreement with the study on national admission data, although 
it is slightly higher {29 vs 25 days); 
For each patient in the file study, the total casts of all in-hospita! medica! 
procedures {excluding the casts of hospitalisation) have been calculated (see 
Table 5.2). The average casts are Dfl 10 070 per patient. The main con-
stituents are casts ofradiotherapy {26%), chemotherapy {19%), surgery {15%) 
and Iabaratory casts {15%). 
In the costs of hospital procedures, again, a marked agc-trend was found, very 
similar to the trend in number of days of hospitalisation (see Figure 5.1}. For 
wamen who died befare age 50, the average casts amount to Dfl 14 000, but for 
wamen over age 70 the casts are only Dfl 2300. Standardisationfor the age dis-
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tribution of all cervical canccr deat.hs in the Netherlands results.in an estimated 
average ofDfl 7100. After primary treatment, 4 out of the 35 women received 
only radioth.erapy, 4 only surgery, 1 only chemotherapy, 4 radiotherapy aild 
chemotherapy, 6 radiotherapy and surgery, 2 chemotherapy, 4 all three trcàt-
ment modalities and 10 none of thcm. For the group of 25 wom'en who had 
radiotherapy, surgcry and/or chemotherapy, the avcrage costs of in-hospita! . 
procedures are Dfl 13 700 and the average number of hospita! days is 39. 
Radiotherapy, surgery and chemotherapy then account for 27%, 15% and 20% 
of these casts, respectively. 
The total in-hospita! cost for advanccd cervical cancer is based on the sum of 
the age-standardised costs of procedures (Dfl 7100) and the costs of hospitali-
sation. Assuming 27 hospita! days (an intermediatc' between the 2 described 
estimatcs), a cost per hospita! day of Dfl470 for normal care (medica! proce-
dm·es excluded), and Dll1880 for intensive care l'"l, the costs for hospitalisa-
tion amount to Dil 13 250 per patient (sec Table 5.3). 
5.3 .. 2 Nursing hotne care 
The average length of stay in a nursing home for thc 95 \yomen who died from 
ad vaneed eaueer of the urogenital tract during the period 1986'-1989 was 230 
days. 61% of these women came from hospitals. From the data on hospita! 
admissions, it appears that each year between 4 and 16 women with advanced 
cervical cancer enter a nursing home after leaving. the hospital. On the basis . 
of these figures we assumed that 5% of the approximately 300 women whodie 
from cen•ical cancer in a year in the Netherlands are admitted to a nursing 
home because of ad vaneed discase for an average 230 days per patient. 
Accounting for the costs per nursing home day (Dil 200), these estimates 
mount up to the avcrage costs of nursing home care of Dil 2400 per patient 
with ad vaneed cen•ical cancer. This is 8% of the total costs of care for these 
patients (see Table 5.3). 
5.3.3 Home care 
The cstimates concerning the four relevimt variables (phase length, participa-
tion in different types of home care, intensity of care, and ·co~t.s per hoür) are 
presented in Table 5.4. 
Phase length. The 32 women with metastases of the female gènital tract in 
the IHP rec~ived on average 3 weeksof intensive home care, which we accepted 
as the lengtil of the terminal phase. The average duration of the I ow-care phase 
should therefore be 10 months: the total pcriod of ad vaneed discase according 
to the hospita! patient files (11 months), minus the terminal 3 weeks. 
Participation. In the data from the regions covered by the IHP, we found 
that 27% of the terminal patients receivcd intensive home care. We extrapo-
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Table 5.3 Estimatcd eosts of diagnosis and treatment of ad\'anced eerdeal 
cancer 
Costs per patient· (Dfl) % Of total costs 
In-hospita! care 20350 70 
hospita! days 12690 43 
intensive care 560 2 
fn-hospital procedures 7100 24 
N ursing home care 2400 8 
Home care 6440 22 
Total care 29200 100 
lated this pe.rcentaie to all wamen dying from· cervical cancer, as nationwide 
coverage of intensive home care is to be implemented in_ the near future. The 
percentage of women dying at home with regular care (23%) follows as the 
remainder from the total number of deceased minus the number of patients 
dying in hospitals and nursing homes (approximately 50%) 1"1, and at home 
with intensive terminal care (27%). 
Intensity. No data were available with respect to private nursing during the 
terminal period in patients who did not participate in the IHP. The amount 
of informal care in these patients has been estimated at 43 h per week, similar 
to patients rcceiving intensive home care. In view of the much lower amount 
of professional care, this may. well be an underestimation. 
Total costs of home care. Combining the estimates presented in Tab/e 5.-f 
results in average costs per patient, shown in· Table 5. 5. The average total cost 
of home care pel' pa ti entwithad vaneed cervical ca neer is Dil 6440. More than 
60% of these casts _are incurred·by the intensive terminal home car~. 
5.3.4 Total costs of advanced disease 
The total costs of (professional) care for a patient with advanced cervical 
eaueer are Dfl 29 000 (see Table 5.3). From the hospita! costs, the hospita! 
days account for 45% of the total costs, and in-hospita! procedures for 24%, 
which amounts to Dfl 20 350, over two-thirds of the total costs. Professional 
home care accounts for Dfl 6440 per patient, or 22% of the total costs. 
5.3.5 · Savings by cervical cancer screening 
As stated before, our concern has been to study the costs and effects of cervical 
eaueer screening, which demands an asses~ment of the savings resultii}-g from 
deaths avoided. We calculated the impact of these savings on the total èosts 
of screening using our model for cervical cancer rns, 9J. In the{:le calculations 
· 5.3. Results •17 
Table 5.4 .!h'erage values for episode Jength1 participation il1 different types of 
home care1 intensity of care, aiJd casts per lwur1 for cervical cancer patiellts lJal'Îng 
admnced disease 
Episode length 
Participation 
District nursing 
Home help 
Private nursing 
General practitioner 
Informal care 
Low care episode Terminal episode 
Intensive care Regular care 
10 months 3 weeks 
22% each month 
22% each month 
NA 
NA 
NA 
27% 23% 
Care intensity {hoursfweek) 
District nursing. 0.6 29 8 
Hom.e help 5 20 10 
Private nursing NA 19 NA 
General pràctitioner NA 1.5 1 
Informal care NA 43 43 
Casts per hour {Dfl) 
District nursing 75 81 86 
Home help 36 47 42 
Private nurSing 61 73 69 
General practitibner 110 110 110 
NA ~o data available 
wc used detailed cost estimates on screening and primary diagnosis and treat-
ment· described elsewhere [us, 9J, and the cost estimates of care for advanced 
disoase presented in this article. The results are presented in Table 5.6. In 
the ~etherlands, a hypothctical screening policy in which wamen are invitcd 7 
times between ages 37 and 73, aSS\Illling a participation rate of 65%, will cast 
325 million guilders in the period 1988-2015. The effectiveness of screening is 
reflected in a decrease of the casts for .care of advanced disease from Dfl 164 
(128 + 36) million to 127 (99 + 28) million. The saving of Dfl 37 million rep-
resents 10% of the casts of screening plus the incr~mental casts of diagnostic 
and treatment procedures for primary disease. The casts per life- year gained 
. are Dfl. 21 700. 
5.3.6 Sensitivity analyses 
The ma in uncertainty in our analysis of national hospital data on the number 
of hospita! days is the number of ad mission days per brachytherapy session in 
primary therapy (see Table 5.1). Assumilig an average stay of 3 days, which 
is a minimum per scssion, this would increase the number of hospital days pqr 
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Table 5.5 
cancer* 
Al'Crage costs for llome care per paticnt witll advanccd eerdeal 
Type of care Low-care episode Terminal episode Total period Total.costs 
Intensive Regular 
District nursing 500 1910 480 2890 
Home help 770 760 290 1820 
General practitim1er NA 130 80 210 
Private nursing NA 1120 NA 1120 
Material casts 400 400 
Tot al 1270 3920 850 400 6440 
lnformal care (h) NA 35 30 65 
* Casts per type of care and episode in Dfl 
NA No data available 
women dying from cervical eaueer from 25 to 27 days, which would even be 
more close to the number found in the file study (29 days). 
Wc accepted the ( age-corrected) outcomes for the co'sts of treatment proce-
dures of the eaueer clinic as represeutative for the cmTent aud fut~re practice 
on a nationallevel. However, the role of chemotherapy in ad vaneed cervical 
eaueer is still the subject of rpndomised trials. We calculated the results in 
case chemotherapy could be abandoned, accounting for the resulting savings 
on admissiou days. The total casts of treatmeut and care of ad vaneed cervical 
eaueer would then deercase from Dfi 29 200 to Dil 25 100 (-14%). The propor-
tion of wamen receiving district nursing aud home help in the low- care phase 
is very uncertain. Halving the propoition of district nursing results in Dil 6120 
costs of home care, a decline of only 5%. Our estimate of the proportion of 
wamen receiving home help 'vas quite conservative. Doubling this proportion, 
a quite dramatic change, gives the total casts for home care in advanced eer-
vical eaueer of Dil 7060 and only a 2% risc in the total costs. Appraisal of 
the informal care would probably have more impact. It is possible by use of 
shadow prices {2t3J. However, wethink that the bulk of informal care is giveu 
in the low-care phase, for which no data are available. 
5.4 Discussion 
For estimating the amount of in-hospita! care one should collect empirica! 
data froni different settings: eaueer treatment centres, uuiversities and other 
major hospitals, and smaller local hospitals. This was not possible because 
only cancer treatment eentres systematically follow the vital status and cause 
of death of all patients. Without such a complete follow-up, selecting patients 
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Table 5.6 Cost-effcctj\'Cness of an efficient policy of cervical cancer screening, 
assumü1g tot al costs of ad vaneed disease per woman of Dfl 29 200. 5% discount 
.ra te 
Casts (million Dfl) 
Screening, an_d diagnostic and treatment 
Procedures fór primary disease 
Care of advanced disease 
In-hospital care 
Home care 
Total casts 
Life-years gained 
Casts (Dft) per life-year gained 
Screening 
policy* 
556 
99 
28 
682 
13321 
21 713 
No early Difference 
detection in casts 
230 326 
128 -29 
36 -8 
393 289 
* Screening wamen 7 times between 37 and 73 (evcry 6 years) during the period 1988-
2015 in thc Nc~herlands, attendance rate 65% 
who died would retrieve mainly patients who died in hospitals. Next to this, 
in most hospitals out patients are not recorded in the medica! registration. 
Patients without any hosp"ital admissions would be missed when analysing 
data from these hospitals. 
For the totallength of stayin hospitals, by far the most important cost com-
ponent, we analysed two independent sets of data, one on a national basis, one 
from a specialised centre• The difference between the results was small (25 vs 
29 hospita! days), suggesting that average medica! practice in respect to treat-
ment of advanced cen•ical eaueer differs little from the pi'actice in specialised 
cancer treatment centres. 
We found a clear association between agè and number of hospita! days; and 
also between age and treatment casts. 1\·eatment costs are probably lower at 
higherage because of the risks and ad verse effects of treatment that will often 
not be counterbalanced by the low chance o~ remission. 
Riley et ali"'icompared medica! costs in different age groups of elderly patients 
in the last year of life with cause of death. For all sites they report lower 
costs for patients with eaueer in age-group 85+ than in age-group 65-74. For 
patients with eaueer of the genital organs this dect·ease was 40%, from US$ 
9126 to US$ 5440. Our data show that this t.rend starts in younger age groups. 
_,Ve had to assess th.e costs of home care for ad vaneed cervical ca neer by data on 
patients with neoplasma of the female genitai tra ct. Ho wever, the differeilce in 
the.amount of intensive home care between different cancer·sites is very small 
ll44J, therefore tlüs is not a major s~wrtcoming. 
50 Cllapter 5. Casts for ad\'anced eerdeal cancer 
____ _.___ 
\Ve only found one study in which the casts of ad vaneed ccrvical cancer are 
assessed from empirica! data: an analysis of the l'vicdicare file in the USA [eJ. 
The different cost components are nat presenteel in thi$ stüdy. The total casts 
of care for the period following primary therapy until death are US$ 17 700, 
which is higher than in our study (US$ 1 is approximately Dfl 2). The US 
tariffPer hospital-day however, is approximat9ly twice the Dutch tariff, which 
could already level riff the difference. We eaulel nat find any study in which 
the amount qf care in advanc·ed cervical eaueer patients is presenteel explicitly. 
In the present study, onlJ; the medical casts have been assessed. Advanced 
ca neer, teading to death, alSo causes a psychological burelen and social casts 
(loss of productivity and' casts of informal care). Effective mass screening 
programmes for cen•ical calleer will rcduce both. On the other-hand, cervical 
eaueer screening a lso affects a larger number of wamen in a negative. way 
because of false-positive test results and deleetion of regressive intraepithelial 
neoplasias. 
The casts of hospita} and hmnc care in ad vaneed cen•ical ca neer are substan-
tial. Nevertheless, in cervical cancer screening the sav_ings on the treatment 
of advanced cervical eaueer cannot compensate the cast~ of screening. Ta 
answer the question ,vhether cervical cancer screening is expensive, the cost-
effectiveness should bè camparcel with that of other medical interventions. 
Such a camparisou shows that the casts per life-year gained are intermedi-
ate between breast. cancer screening, which is cheaper per life-year gained, 
and ·hypertension treatment in _men and hemt transplantation, which is more 
expensive (1811. 
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Gomparing the predictions of a cervical eaueer 
natura! histbry model with incidence and 
mortality trends after the introduetion of 
screening 
M. van Baliegooijen et al, subn\itted for pubHeation 
Abstract 
Background: Knowledge a bout the natura! history of cervical eaueer am;l its pre~ 
cursors is essential for the planning and evaluation of cervical canc.er screening 
policies. One way of studying the natural history·llas been the use of quantitative 
models for cstimating the duration of preclinical stages a~1d the sensitivity of the 
PAP smear fro.m population data on cervical eaueer and scieening. The validity 
question addressed in this paper is how compatible these esti.mates, combined with 
an assumed full cure after treatment for pre-invasive stages, are with the observed 
trE::nds in cen•ical eaueer im;idence and mortality in the Netherlands after the intro· 
duetion of screening. 
Material and Methoäs: The MISCAN simulation modèl has been used to pre·· 
dict age·specific incidcncc a"nd mortality trends- for the period 1965-1992 in fhe 
Netherlands on the. basis of thC observed screening pattern. In the simulations, 
we accounted for autonomous trends in cervical eaueer risk eStimated from Dutch 
pre·screening mortality data. Estimates of the duration of preclinicat· discase (mean 
15.7 years) and the sensitivity of the screening t'est (80%) were basedon screening 
data frrim British Cotumbia, Ca!J.ada. The predicted incidence and mortality were 
· compared with observed trends. 
Results: Predicted incidence and mortality rates .were found to éorrespond rea-
sonably well with- obscrved trends in cohorts for which the risk of cercical cancei' 
could be estimated from pre·screening data. Predict.ions are too high if no effect 
from screening on incidence and mortality is assumed. 
Conclusjon: The ~greement between prcdictions based on previously derived nat· 
ural history assumptions and the incidence' and mortality trends since the start of 
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Figure 6.'1 Schematic presentation of t!Je disease model. Pre-clinical stages, 
clinical stages, screen detected stages and discase specifi.c mortality. Bhth and 
mortality from othercauses are not represented 
no cervical neop!asia 
pr~·clinicaf !B 
(!ocal) 
screening 
screen-detected stages 
screen·detected 
pré-invasive cervical 
screen-detected IA 
(micro-invasive) 
screen-detected IB 
(local) 
screen-detected ll+ 
{non-local) 
d = duration, 5 = seMitivity 
d.eath from cervical cancer 
impro~melll 
in survf{a/ 
screening in the Netherlands, provides further support for au estimated duration 
for detectable preclinical progressive cervical eaueer of approximately 16 years, an 
estimated sensitivity of the PAP smear of a bout 80% 1 and a full cure after treatment 
for pre-invasive stages. 
6.1 Introduetion 
The natura! history of cervical cancer has been stuclied extensively, not only 
to attain a better understanding of the disease itself but also to learn more 
about the way in which screening works. Cervical cancer screening leads to 
detection and treatment of intraepithelial neoplasia. A reduction in incidence 
and mortality is expected because intraepitheliaf neoplasia is considered to 
he a pre-invasive precursor of invasive cancer and appropriate treatment is 
assumed to result in almast a 100% cure (i"'· "i). An additional mortality 
reduction is expected frorn the detection of early invasive cases which have a 
relatively good prognosis. 
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Screening forcervical catleer has been shown to redttee the inciçlence of inva-
sive cancer in screened wamen (see for example {43, 1oo, 8tJ) and the nationwide 
cervic~l cancei· mortality (142, t2üJ, Hmvever, seriÓus doubt has been expressed 
over whether mass screening does redtice mortality in the UK alid New Zealand 
(173)[82], 
The objective of this paper is to test whether èarlier derived natura! history, 
sensitivity and cure-rate assumptions art:: compatible with incidence and mor-
tality trends in The Netherlands over the past 30 years. In order to predict 
these trends, the assumptions were combined in an integrated model for cervi-
cal cancer screening which includes the serisitivity of the PAP smear, the inci-
dence and duration ofpre-invasive and early invasive lesions, and th~ screening 
pattem in the Netherlands since the start ofmass screening in the early 1970's. 
The assumptions made on dnration of pre-clinical detectable disease and test . 
sensitivity stem from an analysis of screening from British Columbia [t59J. The 
model was calibrated to the incidence and mortality in the Netherlands befare 
the start of screening. 
VVe used the model for predicting trends in cen•ical carteer incidence and mor-
tality after screening started and compared these predictions with observed 
recent incidence data and with mortality in 1978'-1982 and 1988-1992. In 
addition, we used the model to predict mortality for the hypothetical situa-
tion where screening would have ha'd no effect.at all in the Netherlands. This 
made it possible to campare predictions withand without screening effect for 
their agreement with observations. 
It was considered that a good fit between the observed and predicted incidence 
ahd mortality trends would imprave the credibility of the model. This is 
important, because weusethese models to assess ·the percentage reduction in 
mortality effectuated by screening (see Sectimt 6.4), and to campare different 
screening polides with regard to the public health effects and casts, see for 
example Koopmanschap et al [ÜsJand Chapter 7. 
6.2 Methods and materials 
'Ve used the micro-simulation program ~USCAN to model cervical cancer screen-
ing and .predict itS effects {89). In micro-simulation, fictitious individual ure-
histories are generated on the basis of probability distributions and other 
parameters spccified in the model. Each life-history is characterized by a date 
ofbirth and the ageof death from other causes. Same life-historics may include 
an age at which a hysterectomy is performed for reasans other than cervicál 
cancer, after which tlie woman is na langer at risk. In case the woman develops 
cervical cancer, the life-history indodes clinical diagnosis and survival. For 
each life-history, screening tests are carried out at specified ages which in Case 
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Table 6.1 Û\'erview of tlw model parameters and the data sets used to estimate 
them. Tlw upper part concerns tl1e discase model (sec Figure6.1), the lower part 
describes the situation in the Netherlands 
Model parameters 
Data used for estimation 
The disease model 
Duration of pre-clinical cervical neoplasia (1) 
Sensitiuity of PAP smear for pre-clinical cervical ncÜplasia 
British Columbia data 
Survival (2) and improvernent in prognosis 
Pre-screening ratio of incidence to mortality, stage spcciflc survival data 
Age~ and cohortspccific incide11ce of disease 
Age- and cohortspecific pre-screening mortality data and accounting for (1)+(2)+(3)+( 4) 
Age- and cohort-specific ccrvical cancer risks ( 4) 
Pre-screening mortality data from the Netherlands {1950-1975) 
The situation in The Netherlands 
Births per cohort 
Deaths from other causes 
National demograpbic data 
Hyster~ctomies for otlwr reasans (3) 
National hospita! rcgistry 
Screening pattem in the Netherlands in 1970-1992 
· VarialiS data on Uw screening uptakc in the Netherlands (see text) 
of a (true) positive test, result in detection and subsequent treatment, which 
in turn. may lead to a change of the disease history. The predicted effects 
of screening for cervical cancer depend on the quantification of the different 
components of the model. Figure 6.1. gives an overview of the coniplete discase 
model. Table6.1 showshow the model assumptions were basedon previous 
analyses. Table 6.2 gives an overview of the main parameter values. The 
~ssumptions and parameter val u es will be explained below. 
6.2.1 Year of bit·th, death from other causes, hysterectomy 
The distri bution of the year of birth follows from the size of the birth cohorts in 
The Netherlands. Death rates for the Dutch female population were directly 
adapted from demographic data f"f. Ammal age-specific rates for total hys-
terectomies were obtáined fronl the I{ational Hospital Adn)ission Registration 
(186}. 
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6.2.2 It~cidence of progrcssiv.e pre~invasive cancer 
The life-time risk of developing progressive cervical eaueer di!fers between 10-
year birth-cohorts (see Figure 6.2 a). The estimates result from a log-liiiCar 
(APC) analysis of pre-screening mortality rates availablc from 1950 onwards, 
in which age; period and cohort factors are assumed to operate independently 
[«[, For wamen born after .1915, mortality has been included in the APC. 
analysis until 1974 because of substancial pat:ticipation in screeningafterit 
starled around 1970. Mortality has been included up to 1989 for older cohorts. 
The APC model adequately explains pre-screening mortality rates (p = 0.8). 
Linear trends can in the APC model be explained by bath cohort effects and 
period effects. We chose to attribute them to cohort effects, assuming no 
trerld In the period factors, i.e. we assumed no major improvements in stage 
distribution or ti·eatment of clinical cervical cancer over the period considered. 
Data to investigate this assumption are not available for the fifties and sixties 
in the Nctherlands. In the south ofSweden, where pre-screening data on stage 
distribution alid stage-specific survival have been available since 1930, there 
·was impravement in stage distribution and stage si>ecific survival befare 1950, 
but not after 1950 (Sparen 1995). In the national data of Sweden however, 
the improvements in survival occurred 10 to 15 years later. Thus, survival 
improved by approximately 10% after 1950 ["'[. In the discussion, we wil! . 
address the possible impact of such an impravement on our results. 
The cervical eaueer risk as estimated from the APC-analysis is more or less 
constant for cohorts born between 1903 and 1927, and then decreases sharply 
for younger cohorts. The ligure suggests stabilization for the cohorts born after 
1940, but for these cohorts, the estimates arebasedon very smal! numbers of 
cases (sec Figur·e. 6.2 a). 
The age-distribution of incideri.ce of progressive pre-invasive nèoplasia was 
back-calculated from tbc age-components of the mortality derived in the APC-
analysis. In this back-calculation procedure we used the distribution of the 
duration between onset of pre-invasive lesions and deathfrom cervical ca neer. 
This duration includes the total duration of the preclinical stages, and the 
duration between clinical diagnosis and death combined with thc probability 
of death from cervical cancer (see below). The resulting incidencehas a peak 
in age-group 30-34 years (see Figure 6.2 b). 
6.2.3 Pre-clinical discase stages and their duration 
The stages aild possible transitiol).S in preclinical disease are prescntcd in Fig-
ur·e 6.1. The first stage is screen-detectable pre-invasive neoplasia ( conespond-
ing with CIN: cervical intraepithelial neoplasia), with a mean duration of 
11.8 years ltó9l~ Regression is pössible from"this stage. Regression is an impor-
tant aspect of the discase process when thc model is used for evaluation of 
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Fi~ur·e 6.2 Incidence of progressivc pre-invash'e cervical neoplasia by birth 
cohort and by age. The !iiJurës coHespond tO t}Je number of cases on 1Vhich the 
estimates were bBsed 
(a) The cumulative incid(mce of progressive pre-invasive c.ervical neoplasia by birth-cohort 
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ad verse effects and costs of screening. Hm'vever, dctection of regressive di~ease 
does notaffect incidence of invasive cen•ical eaueer nor subsequent mortality. 
Therefore, only progressive lesions have been included in the present analysis. 
In invasi:ve canCel\ the screen-detectabl.e stages IA, IB and II+ (correspond-
ing with FIGO definitions) are distinguished. l\1Iicro-invasive eaueer stage IA 
is asSumed never to give symptoms (cxcept for accidental findings,- micro-
invasive stage IA ca neer i~ only dctected by screening), hen cc in t.he situa-
tion without screening it .is always foliowed by a preclinical stage IB. Stage 
m sometinies heemnes clinical, and sametimes progresses to stage II+ befare 
symptoms develop (sec the next pat:agraph on clinically diagnosed cancers). 
To account for variability, the duration in the pre-invasi'_'e and invasive pre-
clinical stages is assumed to follow a Weibull probability distribution (with 
shape parameter 1.9). The total mean duration of 3.9 years for invasivc pre-
clinical discase {see Table 6:2) has been obtained from the ratio of det~ction 
rates at the first smear in the data from British Colombia and clinical incidence 
befare screening started 121, t59J. In the Dutch pilot screening prqgramme a sim-
Har ratio was found between incidence and detection ratcs of invasive eaueer 
at tlre first screening, and 54% of the invasive cancers detected at first smears 
were in stage-JA{7tJ, suggesting that preclinical stage IA and stage m+ haye 
approximately thc sameaverage duration. 
6.2.4 Survival of clinically diagnosed cancers 
In clinical discase we us~ a subdivisio~ into stagesmand II+. In the absence 
of population based data on clinical stage-distribution in the Netherlands, 
we used data from Dutch hospital regist.ries {I07Jand Nonvegian populat.ion 
registries i"l. In the pre-screening period, both data sets sl10wed a clearly 
more favourable stage distribution for younger age groups. We assumed that 
the proportion of stage IB. arnong clinically diagnosed cancers decreases linearly 
from 58% at age 30 to 26% at age 70. 
In agreement wit.h the Norwegian survival data l5oJ, we assumed that let.hal-
ity is highest in the first years following diagnosis, and that after 5-7 yeats 
mortality is already relativcly small (sec Table 6.2). We adjusted the age-
specific long-:term survival to the ratio of cen'ical cancer mortality to cervical 
cancer incidence, using Dutch mortality and incidence figm·es from the pre-
screening period in the Netherlands (1968-19'72 and 1965-1969 respectively) 
{sec Table 6.2). 
6.2.5 Survival of screen deteCted cases 
Ctlre is assumcd to be complete for screen-detected pre-invasive lcsions. Scre€n-
detection of invasive cancer is also assumed to impröve survival. This imprave-
ment depends on the stage at detection (see Tab/e 6.2), and is modeled as a · 
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Table 6.2 . Assumptions about the natura/ }Jjstory of cervical cancer and its 
pr~cursors (a-c) and about the screening effect (d-e) 
(a) Duration of preclinical stages 
Stage Mean duration {years) 
Pre~invasive neoplasia 11.8 
Micro-invasive IA 2.0 
Pre-clinical IB --+ clinical IB 1.9 
Pre-clinical IB ---t pre-clinical 11+ 1.0 
Pre-clinical II+ 0.9 
Total pre-clinical 15.7 
(b) Survival: long-term relative survival by clinical stage 
Age IB 11+ 
<25 0.699 0.200 
30 0.812 0.500 
50 0.812 0.500 
>65 0.624 0.000 
(c) Sm·vival: duration of sundval of wamenwhodie from cervlcal cancer 
Time since diagnosis Probability of surviving 
1.5 years 
4 years 
7 years 
99 years 
Screening effect: 
0.616 
0.153 
0.077 
0.000 
(cl) Survival in screen detected cases: reduction in risk of dying of cervical 
cancer by stage in which (pre)cancm· is detected 
Pre-invasive neoplasia '100% 
Micro-invasivc IA 80% 
Pre-clinical IB 40% 
Pre-clinical 11+ 20% 
Screening effect: 
(e) Sensitivity of the Pap smea•· by stage 
Pre-invasive neoplasia 80% · 
l\'ficro-invasive IA 85% 
Pre-clinical IB 85% 
Pre-clinical 11+ 90% 
rednetion of the risk forcervical ca neer patients of dying from screen-detected 
· cervical calleer compared to theii· risk of dying from the cancer in the situation 
without screening. For example, if the probability of dying from cervical eau-
eer for patients of a partienlar age is 60% without screening, then detection by 
screening in stage IA wil! rednee this probability by 80% {see Table 6.2) to only 
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12%. This 80% impravement for stage IA was found to reproduce the reported 
97% 5-years relative survival for this st~ge I"l. For the screen detected stage 
n+, the stage-distribution within stage I!+ in a period with little screening 
(1970-1975) was compared to the stage-distribution in screen detected Ir+ 
cases 1111, Accounting for survival at stages II, lil and IV, this resulted in an 
estimated 20% impravement of prognosis. For screen detected stage IB, an 
intermedia te impravement of prognosis of 40% was assumed. 
6.2.6 Sensitivity 
When a woman with disease is screened, the test. result can be either true posi-
tive or false negative. The estimated sensitivity for the pre-invasive detectable 
stage is 80% [169J. Sensitivity for invasive prE;!-clinical stages was assumed to 
· be somewhat higher (see Table 6.2). False positive results, which are impor-
tant in a complete ev~luation of screening, are not considered in this analysis 
because they do not affect clinical incidence or mortality. 
6.2. 7 The screening pattern 
In the simulation of the Dutch situation, screening is assumed to start in 
1970. PAP smears are·assumed not to have been taken below age 20. In order 
to describe the screening uptake in the female population, data on the total 
number of smears are oflimited value. Data on the dis.tribution of smears over 
the female population.and on individual patterns in frequency of screening 
are alsó needed. But such inform3.tion on the pattern of individual screening 
in the Dutch poptdation is scarce. Fol' prediCting the impact of screening 
on incidénce of invasive eaueer and on mort?lity, the annl.tal number of first 
smears is especially important, because fhst smears are expected to have the 
highest impact. The assumed proportion of wo men whohad at least (me smear 
over the perioçl1970-1991 is given in Table 6.3. As indicated, the proportions 
for the years 1976 and 1991 were basedon empirica! data I"· "I. We decreased 
the fraction of ever screened wamen as reported by the 1991 national health 
survey by a factor 10%, assuming an association between non-response to this 
survey (44%) and non-participation to screening. After this correction, the 
highest coverageof 83% is found in the 1939-48 birth cohort. After accounting 
for the hysterectomies for reasous other than cervical cancer, this corresponds 
with a coverage of apprüximately 90%. We assumcd that 10% of wamen 
never participate in screening, and therefore 90% is a maximum coverage. In 
the Dutch cervical screening pilot regions (1976-1986) the coverage per 3-
year round never exceeded 80% of the target population I0 ~1. Literature on 
screening coverage rarely addresses the question of 'ever' participating at. PAP 
smear screening [1soJ. Usually data concel·n smear utilisation in e.g. the Jast 5 
years [97, 111, 14J, In these population based studies, the reported coverage rates 
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Figure 6.3 Obsen'ed .and simulated in~idence and mortality rates in tlw 
Netherlands befare (a and b) and after (c, d and e) screening started. Obsen•ed 
data: CCR 1973 f"l (a), NCR 1992 f"'l and 1993 i'"l (d), CBS 1994 rn1 (b, c and e) 
(a) pre-screening incidence 1965-1969. 
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vary between 65 and 80%. Wc also assm.ned that the 10% never attending 
wamen are at a thrE;!e times higher risk for cen•ical eaueer than attenders. 
A high risk for non-pa"rticipants 'vas reportcd in Deninark 11SJ, Norway (134i 
and British Columbia (27J, In British Columbia the risk for participants was 
estimated at 0.74 of the average risk [t59J, 
In the simulation, the probability of a secoud smear varies from 90% in wo men 
m1der age 40 at their first smcar, to 10% in wamen over age 60. Of these secoud 
smears, 93% are taken within 3 yeats. Among wamen who had at least two 
s~1ears, 90% will have another smear within 3 years. These assumptions are 
based on the following data. In the Netherlands, invitational screening was 
combined with opportunistic screening throughout the period under consider-
ation {1970-1992). Thc majority ofthe wamen w.ho had PAP smcars attended 
the organized screening program, in which wamen between age 35 and 53 were 
invitedat 3_year intervals. Of the wamen who attended the 3- yearly screening 
program, 90% had either attended thc preceding round or reported to have 
had a PAP smear outside the program recently I6SJ. This was measured around 
1980, when coverage was increasing. 
6.2.8 Reference data 
In the Netherlands, a nationwièie cancer incidence registry was only in oper-
ation from 1989 onwards. Data from this registry were uscd for the years 
1989-1990 [154,.1~>sJ, when incidence \vas affected by screening. For the pcriod 
1960-1971, which represents t.he situation befare screening, incidence data are 
available from three loc al registries in the {rural) province of Friesland and in 
the ei ties of Rotterdam and The Hague I40J. National incidence figures have 
been calculated from these regional incidenèes. Regional differences have been 
accounted for by using ditierences between thc age-standardized mortality ra te 
for these three regions and for the total country for the period 1968-1978 1"1 
as a proxy. 
Nationwide age-specific cen•ical eaueer mortality rates have beer:t available 
since 1950, and are used for the periods 1968-1972,1978-1982 and 1988-1992 
1''1. The last two periods represent test data, and the first (pre-screening) 
period was part of the data used to calibrate the model. 
6.3 Results 
Using the model described above, we made predictions of the cervical eau-
eer incidence and mortality in the Netherlands during the period 1965-1992, 
starting duringa situation without screening and taking the effects of sereens 
caried out since 1970 into account (thin solid lines in Figures 6.3 and 6.4). 
For comparison, we also made predictions assuming no effect of screening at 
all { dasbed lines in Figurcs 6.3 and 6.4). 
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Figure 6.4 Obsenred and predicted cenricai cancer mortality in tnro birth 
cohorts (1920-39, and 1940-49). Observed data: CBS 1994 1"1 
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6.3.1 Pre-screening incidence a'nd mortality in 1965-1972 
Pre-screening incidence and mortality rates are rcproduced in Figure 6.3a and 
6.3b. Notice that we used the observed rates of this period to calibrate the 
mopdel (see lvlethods and lvlaterials). 
Because the ratio of mortality to incidence showed a dip in age-group 60-64 
(not reproduced in the smoothed model assumptions), predicted incidence 
in age group 50-69 is 10% lower than observed. In age group 75 and over, 
ob~erved mortaiit)r is equal to or higher than the observe'd indèlence, which 
indicates· that there is a registration problem in the oldest age groups. For the 
other age-groujJs, there are no systematic or statistically significant diffetences 
between simulatei:l and observed mortality in the period 1968-1972, except for 
a too high simulated mortality in age-group 40-44. The higher simulated rate 
beiow age 35, cori·esponding with the birth cohort 1940-49, is basedon a very 
small number of observed cases. 
The pre-screening ratio between mortality and incidencc is shown in Figure 6. 5 
(the thin '1969' lines). This ratio reflects .the lethality from cervical eaueer 
and .the ligure shows the strong age-depeüdency of lethality. Up to age 60, 
the simulated ratio is close to the observed data. The deviation in age groups 
60-69 and 70-79 have been discussed above. These higher age-groups had 
hardly any scre.ening in the subsequ~nt years, and are of minor importance in 
evaluating iuddeuce and mortality in 1988-92. 
6.3.2 Post-screening incidence and mortality: wamen aged 50+ in 1990 
For wamen aged 50+, the predicted incidence and mortality around 1990 are 
fairly good (Figure 6.3d and 6.3e). They are not statistically different from 
observed incidence and mortality, except fora too low simulated incidence in 
age-group 65-69. 
In the intermediate period (1978-1982) (see Figure 6.3 c), màrtality is pre-
dicted correctly in age-group 40-49, but too high in age group 50-69. Since 
there are no incidence data from this period, we cannot discern between too 
little incidence rednetion or too little impravement in prognosis. A possible 
explanation is.that the simulated screening activity in the 1970s was too low 
for wamen born befare 1930. Correction of the divergence would neei:l 50% 
instead of 30% of wamen with a first smear by 1976 in women barn between 
1919 and 1928 (see Table 6.3}, and 21% instea cl of 9% in wamen born befare 
1918. Another explanation would be that the simulated short term screening 
effect is too sma11. From the paramet~rs we-investigated in this analysis, i.e. 
the duration of the detectable pre-clinical phase and the sensitivity of the test, 
the duration is of little help in this respect. A langer duration hardly affects 
the short term effects of screening on mortality. A shm-ter duration deercases 
the effect on mortality, particularly the long term effects, but also the short 
• 
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Figure 6.5 Observed and simulated eerdeal cancer mortalUy/incidence ratio 
fo1· the Netlierlands in a prescreening period aud in a recent period. Pre-screening 
period: 1968-1972/1965-1969 (m01·tjinc). Recent period: 1988-1992/1989-1990 
(mort/inc). Obsen•ed data: CBS 1994 1"1 (mortality), CCR 1973 /<Dl and NCR 1992 
[1S3Jand 1993 [lS-tJ(incidence) 
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term effects. A higher sensitivity on the other hand, will ii1crease the short 
term effect on mortality ( and also the long term effects, but toa smallerextent 
because of repeated screening). To explain the total difference between pre-
dicted and observed mortality around 1980 in this way, an unrealistic 100% 
sensitivity is required. 
In Figure 6.4, mortality trends are shown by cohort. The solid lines again 
denote the observedmortality (bold line with marke.rs) and the model-predicted 
mortality (thin line). The cohort on top (cohort 1920-39) corresponds with 
the wamen aged 50-69 in 1990. This cohort is especially interesting: it has 
the highest screening exposure in the 1970's (see Table 6.3), and it also has 
enough pre-screening mortality to assess its background risk accurately. For 
this cohort, the predictions are close to the observations, except for a slightly 
higher initial1evel·and a somewhat more distinct decrease over time in the 
simulation. The predicted trend without screening effect (dashed line) clearly 
diffm:s from the obscrved trend;· its initial increase reflects the age-pattern of 
cen•ical eaueer mortality. The model prediets a 37% rednetion in mortality in 
1990 in this cohort. 
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6.3.3 Post-screening incidence and n1ortality: wmnen aged <50 in 1990 
In wamen under age 50, the predicted incidence and martality aröund 1990 
are cleady toa low (see Figure 6.3 d and 6.3e). One could suppose that 
this deviation in the predictions is due to a toa strong rcdudion in incidence 
and mortality caused by screening. However, even rates predictcd without 
screening effect ( dasbed lines) are toa lmv. 
The same discrepancies appear in thc cohort-wise represen~ati'on of mortality 
in the <50 womenîn (see Figure 6.4, cohort 1940-49). This cohort corre-
sponds to wamen age 40-49 in 1990, and is the youngest cohort for which· 
pre-screening mortality data were available. From 1973-77 onwards, the sim-
ulated mortality rates are clearly toa low and even the simulated rates without 
screening effect are below ar at most equal to the observed level. In1968-1972, 
the predicted mortality is toa high, but the abserved rate is anly based on 5. 
cases. After this initia! period, there is a remarkable parallelism between the 
abserved and predicted (with screening effect) lines. Tagether with the fact 
that the discrepancies between observed .and predicted incidence rates follaw 
the same pattern, it corroborates the hypothesis that the discrepancies could 
be ·most parsimoneously explained by a higher risk for the cohort concerned 
than estimated. 
The predicted and observed mortality to incidence ratios for .1990 (see Fig-
ure 6.5) reftect the eft'ect of screening on lethality. The agreement between 
preelietion and observations is good for ages under 60. The model predicted 
lethality is toa high in age-groups 60-69 (as it was already in the pre-screening 
period) and 70-79 (where screening has had little effect). The mortality to 
incidence ratio in the predictions without screening, effect wh~re there is no 
impravement in prognosis in early detected invasive cancers, is too high. 
· 6.4 Discussion 
The analysis of the British Columbia data that resulted in the parameter esti-
mates descrihing the n·àtural hîstory, was based on clinical incidence befare 
screening started and on detection rateS by rank and interval sincelast screen-
ing. Gustafsson et al deduced their assumptions on natural history from trCnds 
in incidence and mortality, accounting for screening practicc ( using incidence 
of carcinoma in situ as a proxy measure for screening intensity) tsaJ. The 
results of these two analyses are consistent. The parameter values dcrived by 
Gustafsson (duration of the pre-invasive detectable stage 13.3 years, duration 
of invasive pre-clinical stage 4 years) are similar to ours (11.8 years and 4 
years respcctiVely). In an earlicr analys~s [t6tJ, we found these quantifications 
for duration of and test sensitivity for pre-invasive disease to be consistent 
with international data on interval cancers after negative.smcars [too[. 
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In thc present analysis, these assumptions on duration and sensitivity- have 
been tested agaii1st screen-affected incidence and mortality trends in the Nether-
lands. Such an independent test of acervical ca neer screening model descrihing 
the natura! history of cervical eaueer has not been publisbed before. 
In estimating age- and cohort-factors in the risk of dying from cen•ical can-
cer, we assumed that no period trend occurred in this risk during the period. 
considered (from 1950 until the start of screening). We already mentioned 
that in Sweden, although-not in all regions, there was some impravement in 
survival after 1950, suggesting a downward period trend {199, 1121. There was 
no change h~ stage distribution, but the stage specHic survival improvcd, pre-. 
sumably by au improverneut in treatment. We could have explained part of 
the downward trend in pre-screening mort~lity in theNetherlands after 1950 
by a period trend. When this trend is assumed to have continued until the 
end of the period for which we made predictions (1992), predictions willnot 
be affected. Only if we assume that the impravement in treatment of clinical 
eaueer stopped after e.g. 1970, our predictions are affècted. The ·predicted 
incidence and mortality level wil! become higher in 1980 and more pronounced 
so in 1990. Hence, the difference between the observed rates and predicted 
rates without screening effect will be larg~r. The predictions with scre.én-
ing effect will still be closer to the observations than the predictions without 
screening effect, but they also wil! be too high. 
The baseline estimates of the cohort risks in wamen barn between 1940 and 
1949 were basedon a reasanabie number ( 41 cases) of cervical cancer deaths in 
the pre-screening period up to 1975. The marked difference between predicted 
andobserved time trend for this cohort as shown in Figure 6.4 strongly suggest 
that the underlying cervical cancer risk increases over time. It could be that 
in this period and in this cohort, period and cohort factors have not acted 
independently. Tentatively, knowing the role of sexual behaviour and genital 
HPV infection as a risk factor forcervical cancer, it could be argued that this 
increase is related to the markeel increase in STD's in thc late 1960s and in thc 
1970s (following introduetion of oral anticonceptives) rn. "L Transmission of 
STo's is rhuch lower in older age groups, and it seems reasanabie to assume 
that this sexual revolution has had only lirnited impact on the cohot'ts barn 
·bef om 1940. 
Estimation of cohort factors for wamen barn after 1950 is impossible because 
of insufHeient baseline data from thc pre-screening era ( only 2· cen,ical cancer 
deaths befare 1975). ·Cohort trends from the turbulent pattem in the pre-1950 
cohórts can be extrapolated to mOre recent cohmts in many different direc-
tions, and has astrong influcnce on the predictions for younger age groups,.up 
to age 40 in the more recent periods considered. Indeed, the predictions differ 
considerably froin observed data and the camparisou for 1988-1992 rnortality 
suggest that in these cohm·ts the underlying risk of ccn,ical cancer was also 
higher than the very low level at young age in wamen barn between 1940 and 
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Table 6.3 Assumed fractions of t!Je. Duteli fenwie popu1ation t'JJat had a !hst 
smear by birtll cohort and calendar year. All tlle presented fractions have been 
incorporated in tlw model (between the éalendar years presented, linear intrapola-
tion is used) 
19761 19813 19883 19912 
Year of birth % (mid-age) % (mid-age) % (mid-age) % (mid-age) 
1889-1918 9% (71)4 14% (73)·1 16% (77)4 17% (78)4 
1919-1928 30% (53) 44% (58) 52% (65) 56% (68) 
1929-1938 39% (43) 52% (48) 63% (55) 76% (58) 
1939-1948 28% (33) 48% (38) 66% (45) 83% (48) 
1949-1958 10% (23) 33% (28} 57% (35) 78% (38) 
1959-1968 0% (13) 5% (18) 18% (25) 53% (28) 
1969-1978 0% (3) 0% (8) 0% (!5) 9% (!8) 
1 Based on survey data from a starting mass screening program in three regions of the 
Netherlands {24% of the Dutch population) (EVAC [67J) 
2 Basedon data.from the Dutch National Health SurVey, in which 2700 wamen over age 
16 reported on their PAP smear consumption (de Bruin e.a. [29J) (see text) 
3 Int.rapolated betwéen 1 and 2 , accounting for the v~rying intensity of programme screen-
ing over the calender years (see text) 
4 Calculated with 84 years as upper age limit for getting a first smear 
1949. For the bitth cohort 1940-1954, calibration of the risk to an exact fit 
of cervical eaueer mortality in 1988-1992 leads to a clearly higher level than 
shown in Figure 6.2. Th is higher level is camparabie to the risk of wamen bom 
in 1930-1939, but ·stilllower than those barn in the twenties. 
· When nat accounting for any incidence and mortality reduction caused by 
screening, thc fit between observed and predicted incidence an~ mortality is 
mtlch poorer than when accounting for the assessed screening effects. The 
mortality rednetion from screening is estimated to be 32% for the Netherlands 
in 1992. · The rednetion is pdmarily limited to this ligure because of a Jack 
of coverage. rviany wome.n, especially at older age, did nat have previous 
screening at all m: only very infrequently. Nioreover, in the ffiodel, it is asSumed 
that 10% of wornen will never participate in screening and these wamen have 
a threefold risk compared to participants. Coverage has increased in more 
recent years, but it wil! take more time befare this can be fully exprcssed in 
mortality reduction. Using the model described in this article, we have also . 
predicted mortality rednetion in a cohort of wamen who all participate in 
screening from age 30 to 60 every 5 years. The predicted.reduction in cm:vical 
cancer mortality is 75%. The 25% residual mortality is mainly due to ihe fact 
that there is no screening over 60 {17%) years of age, and the remaining eight 
percent is devided between no screening umjer age 30 {3%), imperfect test 
sensitivity {3%) and screening every 5 years insteadof annually from age 30 
to 60 {2%). 
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. Table 6.4 Obsenred ançl simulated incidence and mortality rates per. 105 
wamen for various periods between 1965-1992. Simuiateel witl1 the model as 
described in the h1etlwds and 1\Iaterials and accounting for screening effect. Tlw 
figures correspond with Figure 6.3 
Age groups 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 
Prescreening period 
INCIDENCE 
Period 1965-1.969 
Observed rates1 0.20 1.49 10.4 20.3 44.3 49.9 49:0 33.5 40.7 29.2 28.0 25.9 na 
Model rates 0.27 3.03 10.9 21.9 46.5 54.7 47.0 33.4 26.8 28.0 29A 30.5 25.5 
Observed cases 7 27 57 133 153 154 108 118 75 58 39 na 
MORTALITY 
Period 1968-1972 
Observed rates 0.01 0.25 1.4 4.4 8.1 14.6 18.2 16.6 18.2 18.9 21.2 24.9 31.2 
Model rates 0.05 0.45 2.0 4.1 10.4 15.5 17.0 17.0 16.9 19.3 20.4 21.1 23.5 
Observed cases 0 6 27 84 153 277 307 271 275 247 219 180 129 
Period after the introduetion of screening 
IN CID EN CE 
Periotl 1989-1990 
1 Observed rates 1.21 4.91 12.5 18.5 15.3 13.4 15.2 10.5 15.3 20.5 21.4 19.5 17.6 
Model rates np np np np 8.6 9.2 12.7 11.2 15.9 16.4 21.0 ni ni 
0 bservcd cases 15 62 148 208 175 117 117 77 108 137 117 92 59 
MORTALITY 
Period 1978-1982 
Observed rates 0.14 0.71 1.1 ·2.7 3.6 6.6 9.3 10.5 13.2 12.8 16.3 17.3 19.1 
Model rates np np 0.8 1.5 4.0 5.7 11.2 12.9 14.7. ni ni ni ni 
Observed cases 4 20 32 61 72 125 174 193 212 191 210 171 118 
Period 1988-1992 
Observed rates 0.06 0.57 1.7 2.8 3.0 3.6 4.2 5.3 8.0 11.6 13.0 15.0 18.3 
Model rates np np np np 1.6 2.2 3.7 4.7 8.5 11.0 14.8 ni ni 
Observed-cases 2 18 51 79 86 81 82 98 141 196 181 188 154 
1 Standardized, see text 
na Not available 
np No predict.ion, cohorts without pre---screening mortality data 
n; No independant data: the observcd data are used for the calibrat!on of the model (see 
the description of the APc-analysis in the 1-fethods and Matcrials section) 
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In çonclusion, this analysis provides fmthcr support for the estimated duration _ 
of dctectable pre-clinical cervical eaueer of around 16 years, for the cstimatcd 
sensitivity of thc PAP smear for this pre-clinical phase· of around 80% and a cure 
ra te for pre-invasive disease of close to 100%. Thc present model can thercfore, 
in our opinion, be used for assessmcnt and comparison of the effects and costs of 
different screning strategics. ·For cos-effe-ctiveness calculations, also regressive 
lesions should be addcd. For application in other countries, the Dutch data 
on incidenc~ level and cohort-specific risks, demography, hysterectm~lies for 
other reasans and screcing pattern have to be replacêd by the pertinent ones 
· for the region concerned. 
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The effects and costs of cervical eaueer 
screening: the scientific background to 
lengthening the pap smear screening interval 
from 3 to 5 years in the Netherlands 
This chapter is basedon the results presented in: Cm·vical cancer screening: 
Age-ranges and intervals. An updated cost-effectiveness analysis (in Dutch). 
Baliegooijen M. van et al. 1993. Report Erasmus University Rotterdam. 
Abstract 
Objective: As part of a total re~evaluation of the Dutch cervical cancer screening 
. programme, new gûideliiies were developed f~r the age-range and intervals for PAP 
smears. To this end, a cost-effcctiveness analysis ~vas conducted. Although the 
Gaverument stated that the exîsting _ number of 7 sereens per won-ia u should be 
maintained, other numbers have also been evaluated in ?rder to be able to assess 
incremental cost-effectiveness. 
Methods: A validated cervical eaueer screening mod~l was implemented in the . 
I\'liSCAN micro~simulation programme for eaueer screening evaluation. Predictions 
of the effects and costs of different combinations of age-iangcs and intervals were 
made for polides with 5 to 10 PA-P smears per woman and the policy implications 
considered. 
Results: For 7 screenings per woman, thc optima! intci-yal was cstimated at scven 
ycars and the optima} _age-range at 27-69 years. The incremental costs per life 
year gaincd compru:cd with an optimal. policy of 5 screenings wcrc approxim'ately 
bfl 35 OOÖ. Even for 10 screenings, the optimalinterval did not fri.ll below five years 
because a broad age range appcars to he mpre· important for effectiveness t.han a 
short interval between screenings. A_t a Dutch national consensus meeting, a 5-year 
interval was considered the maximum acceptablc length fo~ PAP smear screening. 
\Vithin _this constraint, the optima! age-rànge for 7 screenings is from ±30 tot ±60 
years. 
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Conclusions: 'Vhen seven PAP smears are ofl'ered per woman during her life1 
the optima! screening interval is estîmated at 7 years. The interval in the new 
national guidelines has been reduced to fivc years because of the expccted lack of 
accep~ability of longe-r screening intervals. · 
7.1 Introduetion 
The European Committee's guidelines t<>tadvise that wamen should be affered 
PAP smears for cervical eaueer screening every 3 to 5 years .. The ·guidelines 
of the US prevent.ive Task Force f203J recmnmend an interval of 3 years. Unt.il 
recently, in North and West Europe, only Finland [96[ and partsof the United 
Kingdom [t5sJ haye a 5-year interval. In the Netherlands, the screening_ interval 
has been 3 years sirree programme screening started in 1976. Recently, it 
was decided to change this to a 5-year interval, starting fron11996 t;,J, In 
this chapter, the analysis that corroborated this decision and its role in the 
discussion wil! be described. 
Befare 1996, the cervical ca neer screening policy in the Ne'therlands was based 
on offering 7 PAP smears per woman in the age range 35-53years. The change 
in bath the interval and age range was part of a total re-evaluation ofthe man-
agement of the national cen•ical cancer screening programme, including follow- . 
up strategies, organisation, evaluation and financing. This re-evaluation began 
in 1991 and resulted in new guidelines in 1993 [sotwhich were ratified by the 
Minister of Health in 1994. 
There were several reaso"ns to reconsider t.he age-rangé and interval. For exam-
ple, many clinicians argued that the statting age of 35 years should be low-
ered. Sirree they were generally nat in favour of lengtherring the 3-year inter-
val period, this· would have ilnplied an increased number of screenings per 
wo man and an increase in costs of around 30%. Cost effectiveness calculations 
in 1088 estimated the casts per life year of efficient policies incorporating 7 
screening ÎI1Vitations at approximately Dft 25 000 fUsJ. The incremental costs-
effectiveness ratio of moving toa policy .with more screenings would be much 
higher. This compared unfavourable with the estimated Dfl 8 000 pei· life-yem· 
gained in breast éancer screeniüg as performed in the Netherlands (from 5ü-
70 years, every 2 years) !tl6J. The Gaverrunent did nat agree that the cen•ical 
eaueer screening programme should be intensified and proposed that a pro-
gramme with at n~ost 7 smears per \\roman should be. financed. In practice, 
this meant that exactly 7 smears per wo man would be perfol'med as the parties 
in\rolved were not in favour reducing this numher. 
Although the Gaverument had imposed a policy eaustraint of 7 smears per 
wom_an, the question remained as to what weregood combinations of age-range 
and interval from a cost-effectiveness pcrsJwctive. Using nèvly available data 
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we estimatcd the incremental cost-effectiveness of policies using other numbers 
of sn~ears and also considered policies \vhich incorporated 5_:_10 screenings. 
'Ve used the micro-simulation programme r>.USCAN to model cervical cancer 
screening and preeliet the casts and effects for different age.-range and interval 
combinatfans [881, The cervical cancer. sct:eening módel is an extension of the 
moelel used for analyzing cervical cancer screening data from British Columbia 
['"1 and was adapted to the situation in the Netherlands (see'["[ and Chapter 6). 
A problern with the evaluation of screening according to an agrecd policy is 
that _in the Netherlands, as in many other European countries, 'opportunistic' 
preventivesmears are being cm-ried out in addition to the organized, invitation-
bascd, screening progranune. In the cost-cffectiveness calculations, we have 
chosen t_o considcr the situation withÓut opport~nistic screening. Quality of 
. life considerations are also not accounted for in the analysis. The possible 
conscquences Ûf these simplifying assumptions for the results and conclusions 
wil! be discussed. 
7.2 Matm·ials and methods 
7.2.1 Cost-effectiveness calculations 
The casts and effects were estimated fçn· a screening' programme which starteel 
in 1993 and is intended to mn until 2020 {27·years) in the Dutch population. 
\Ve assume<;l a situation without opportunistic screening and with an atten-
dance ra te of 75% in wo men at risk (with cervix uteri) until age 50, decreasing 
with 0:5% per year after age 50. This is in accordance with coverage of the 
total PAP smear activities obsen~ed in the Netherlands in 1994 P41. The simu-
laled effects have been accounted for until all wo men who could have benefited 
from the progranurie died. Both casts and effects were discounted to 1993 {the 
year in which the predielive calculations start) at a rate of 5% per year. 
7 .2.2 Assumptions determining the effects _of screening 
A description of the cervical eaueer screening model and h_ow it was tested 
against obscrv~d trends in cervical cancc~· incid€nce and mortality in the 
Netherlands between 1965 and 1992, is given in Chapter 6. Thcrc are some 
differenèes between the model used in the present chapter and the model 
described in Chapter 6. These differenccs are described in Appendix A. 
Important assumptions in the model are that the average duration intraepithe-
lial neoplasia) is 11.8 years, that the average duration ofpre-clinical invasivc 
cervical cancer is 4 year~, and that the sensitivity for pre-invasive canccr is 
80% ('W(. 
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Table 7.1 Costs of asscssment and treatment of saeen detected and clinical!y 
diagnosed cervical neoplasias pm· case by stage, in Dfl 
Stage Casts 
CIN 3 500 
FIGO IA (micro-invasive) 9 550 
FIGO IB (Jocal) 20 250 
Frao II+ (non-loéal) screendetected 191001 
FIGO II + (non-local) clinically diagnosed 17 4501 
1 The difference in casts for screen detected and clinically diagnosed stage u+ cervical 
canters is caused by the less favourable stage-dist.ribution in clinically diagnosed cases, 
generating a lower number of radical hysterectomies and a higher number of radiother-
apeutic treatments. The casts of the latter treatment. are a bout 35% lower 
The risk in the youngest cohorts (born after 1938) could not be assessed from 
pre-screening mortality data (Chapter 6). Using the model, the cohort risks 
were calibrated to the obset'ved mortality in these cohorts between 1988 and 
1992. 
The main unfavourable side effects of cervical eaueer screening are caused by 
falsepositive test-results and detection of regressive disease. Regarding false-
positive test-results we assumed that 5% of at tending wo men on averageneed 1 
repeat smear before they return to the regttlar screening schedule, and that 1.6 
per thousand attending women are referred fora colposcopy and a biopsy after 
which no cervical neoplàsia is found. We assumed that 70% of the Cl!'llesions 
that start before age 35 will regress spontaneously, and that this percentage 
is lower (40%) between age 35 and 54. All iteoplasias statting after age 54 
are ass~med .to be pl'ogressive. All these assumptions on false positive rates · 
and regression are based on positive rates, follow-up practice and detection 
rates for histologically confinned neoplasias from the period before 1985 (see 
Appendix A). 
We assumed an attendance rate of 75%; 10% of the population never attends 
and has. a risk 3 times higher than the attenders. 
The effects of screening policies are predicted for screening in the period 1993_: 
2019, and rclated to the situation without screening from 1993 onwards. The 
impact of screening activities in the Netherlands before 1993 was takeninto 
account. The number of life-years gained was considcred as the effect measure. 
The number of smears was used as a proxy ·ror the casts of a sci·eening policy. 
This simplified approach could be adopted because we had previously found an 
almost linear relation between total costs (iitcluding changes in costs of diag-
nosis and treatment of cervical ca neer) and immber of smears [9oJ, Predictions 
have been Iuade for about 80 polides with different age-ranges, intervals and 
numbers of smears per woman (see Table 1.9). The evaluated polides have 
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been compared to identify efficient policies. A policy is considered effident 
when there is no alternative policy offcrÎlig the same or lower casts and more 
life-years gained, or with lower casts and the same amount oflife-years gained. 
This means that in Figure 7.1, fora policy to be effident there should be no 
other polides in the upper-left quadrant of the cost-effectiveness point. For 
the efficient polides, detailed cost calculations have b.een made on the basis of 
the following cost assumptions. 
7.2.3 The costs 
Resource casts were assessed for PAP smears, colposcopic evaluations and 
radiotherapeutical treatments. For the otlwr relevant medica! procedures (e.g. 
biopsies, local treatments including cryocoagulation, conisations, and total 
and radical hysterectomies), tariffs charged in the Netherlands were used 1"1. 
The costs are presented in Dutch Guilders (price level1993). 
The fixed casts for coordinating and evaluating the cervical eaueer screening 
programme at a national, regional and locallevel were assumed to be Dil 6 mln 
annually. The other casts of the screening programme are variabie casts and 
were estimated at Dil 58 per smear. This includes the costs for the personal 
invitation (Dfll.80), registration in the PALGA (Dutch Nètwork and National 
Database for Pathology) (bfl 2.60), material (DIIl.OO), taking of the smear 
(DII.16.00), time (Dfl5.30) and travelling (Dil 2.50) for the woman, the cyto-
logie evaluation (Dfl 27.30), and the costs of 2% of smears that are repeated 
because of insuflident quality. The costs of the cytologie evaluatiori depend 
on the number of smears evaluated annually in the laboratory. Tbe weighted 
average cost per smear for the 63 laboratorles basedon approximately 500 000 
sme1ns annually was Dfl 27.30. 
The conesponding ligure based on 250 000 sn1ears was Dfl 30. 70, and for 
750 000 smears Dil 26.50. 
Othèr casts accountedfor were Dfl 88 per repeat smear aftera positive srnear, 
and Dfl 870 per referral to the gynaecologist in false positive cases. The costs 
of assessment, treatment and follow-up procedures after treatrnetit per woman 
with CIN or invasive cervical eaueer are presented in Table 7.1. The casts of 
treatment of recurrence and pa1Ii3.tive care per woman ,vho dies from cervical 
cancer were assessed at Dll30660 1"1. Indirect costs (e.g. loss ofproductivity) 
other tl1an for the screening itself (see the above mentioned Dil 5.30) have not 
been taken into account. 
7.3 
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Table 7.2 Efflcient ·combinations_ of age-range and interval nritll 5 to 10 PAP 
smears, and of the new and ·thc old policy of the Duteli screening programme 
Annual Number of $tarting last A ge- Interval Average label in 
number of screenings a ge a ge range screening age Fig.7.1 
Pap smears* 
Efficient polides 
316 000 5 27 67 41 10 47 
382 000 6 27 67 41 8 47 } 
438 000 7 27 69 43 7 48 { 
502 000 8 27 69 43 6 48 l 
609 000 10 27 72 46 5 49.5 [ 
Dutch policy implemented in 1996 
478 000 7 30 60 31 5 46 G 
Dutch policy used until 1996 
505000 7 35 53 19 3 35 u 
* Assuming 75% attendance rate 
Results 
The number ofprimary smears (as a proxy for the costs) and life-years gained 
for the respective combinations of age-ranges and intervals (see Tab/e 7.9) are 
shown in Figure 7.1. In this figure, the effident polides are indicated by an 
arrow. These effident polides are described in Table 7.2. Their distinguishing 
characteristic is. a braad age-rangc. Compared to less intensive efficient screen-
ing polideS (with 5 or 6 screening-ages), the main diEferenee of more intensive 
efficient screening policies. is a shmter interval. In all efficient policies, screen-
ing starts at age 27, and the age of the last screening is hardly affected by the 
number of screenings per woman. The fact that the startingage of 27 did not 
change at all might have been influenced by t.he fact that we did notmake pre-
dieticus for screening in women older than 69 years ( except for polides with 10 
screenings), thus also Hmiting the startingage for the respective combinations 
of intervals and number of stilears. 
The casts of the effident polides and of the old and new Dutch policy (com-
pared to the situation without screening) are given in Table 7.3. The cost of 
screen-induced follow-up in false positive and non-invásivc cases is largely com-
pensated for by the savings from prevented treattilent in invasive cases and 
care for advanced disease. The total extra casts compared to the situation 
without screening mainly consist of the costs of screening.· in Tables 7.4 (no 
discounting) and 'l. 7 (5% discounting), the effects of the polides are presented. 
The predicted nondiscounted number of deaths from cervical cancer prevented 
per screening j;ear is 150, 180 and 210 respectively for the three polides pre-
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sented. Discounting at 5% will have a much larger impact on health effects 
than on casts. It will reduce the casts with 20-25%, but the livés saved with 
66% and the life-years gained even with 82%. The cost-effediveness i·atios 
are given in Table 1. 5. The casts pèr life~year gained increase gradually from 
Dil 22 000 per life year gained in the case of 5 sereens to Dil 28 000 in the case of 
10 scrcens. The incremental casts per life-ycar gained when moving toa more 
intensive policy, increase much more steeply, from approximately Dfl 35 000 
(from 5 to 7 smears) to approximately Dll56000 (from 7 to 10 smears). 
7.3.1 Sensitivity analysis 
For the polides with 7 screenings, we explored the hifluence of the following 
key assumpt_ions on the optimal combination Óf age-range and interval: i.e. 
the average duration of detectable preinvasive disease, thc false negative rate 
of the PAP smear for preinvasive disease, attendance, the risk in the yÓungest 
cohorts, and the discount· ra te. For each parameter, high and low va lues as 
listed in Table 1.6 were explored. For policies with 7 screenings, the age-range 
and intèrval of elileient combinations were only slightly affected, with the 
follo\~ing exceptions. 
The length of the optima! interval is inlluenced by the average duration of 
the precinvasive stage and by the attendance rate (both a shotter duration 
and a lower attendance make shmter intervals relatively more attraçÜve). 
When the assumed average duration of pre-invasive discase is shortened by 5 
years (6.8 instead of 11.8), the cost-effectiveness of policies with 5 ;md 7-year 
intervals beconle similar. With an attendance as low as 40%, the difference in 
cost-effectiveness between 5 and 7-year interval policies also decreases. The 
optimal starting age is influenced by the average duration of the pre- invasive 
stage, by the assumed risk in the youngest cohorts, and by the discount rate. 
Assuming a shorter pre-iiwasive duration favours higher stmting ages, shifting 
the op ti mal age-range slightly upwards. Thestarting age is a bout 5 years 
· younger when wamen barn after ~939 are taken into account as they have a 
risk three times higher than the base-line assumptions. Such a high risk is 
not very likely in the Netherlands (see Chapter 10). Withno discounting, the 
optima! starting age dropped by about 3 years. 
7.3.2 The role the results played in the decision on the new guidelines 
The decision ön the new guidelines for age-ranges and intervals \vas made in 
a nationàl conSensus meeting where all professionals and institutions involved 
(general practitioners, pathologists, gynaecologists, epidemiologists, munic~­
pal and regionat health cate cent.res, and t.he gaverument) \yere represented rs9J, 
The results reported above were presented at the meeting, pointing out that 
the effi~ient interval for a policy with seven screenings iS estimated at seven 
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Table 7.3 Casts in ~Mln Dil of cfflcicnt combinatlans of age-ranges and inter-
mis witli Ü1creasing number ofsmeafs, and for tlw 11ew (Jabelled Gin Figure7.1} 
and old (labelle.d f! in Figure7.1) nationally recon;mended age-ra;Jge and inter-
val combination, for·a 27 year eerdeal cancer screening programme in tl1e period 
1993-2020. Furtl1er assumptions: attendance 75%, no opportunistic screening, 5% 
discount 1·ate for effects alld costs 
········· 
Efficient ......... ...... Used ...... 
Label Figure 7.1 { G u 
Number ·of smears 5 7 10 7 7· No screening 
Ages1 27(10)67 27(7)69 27(5)72 30(5)60 35(3)53 
Annual number of 
sm~ars (0% disc.) 316 000 438 000 609 000 478 000 505000 0 
Casts 
Screening 412 527 683 564 590 0 
Repeai smears 24 34 45 36 38 0 
Referred, no ci_N +2) 7 10 10 10 10 0 
CIN2 56 68 83 77 62 0 
Invasive carcinoma2) 202 187 177 184 196 264 
Advanced dis.ease3) 150 141. 133 147 154 193 
Total casts 851 968 1131 1018 1050 457 
Differences with the situation without screeni_ng 
Screening ·112 527 683 564 590 
Repeat smears 24 33 45 36 38 
Referred, no CIN +2) 7 10 14 11 12 
CIN 2 56 69 79 66 51 
Invasive carcinoma2) -63 -76 -87 -71 -58 
Advanced disease3 ) -43 -52 -60 -45 -39 
Total casts 394 511 674 561 594 
1 Starting age (interval} last age 
2 Casts of assessment and treatment 
3 Casts of treatment of recurrence and pallialive care in wamen who die from cervical 
eaueer 
years and the optima! age range at 27-69 years. However, most attenders to 
the meeting considered 5 years to be the maximum acceptable length for the 
interval between subsequent PAP smears. It was envisaged that a langer screen-
ing interval ~vould lead to many extra smears between programme.screenings. 
Because the policy should incorporate 7 smears, discussiori focused on thc 
optima! starting and finishing age between first and last screening of 30 years 
(5 years interval x 6 intervals per woman). lt appears that the startingage 
goes up and the last age is down relative to the optima! age-range of 27-69 
years. The cost-effectiveness results are in favour ofpolièies startit1g at around 
age 30 to age 40 (see Figure 1.1). Over this range, the cost-effectiveness ratio 
seems relatively stable. 
7.3. ResultS 79 
Table 7.4 Effects and casts of efflcient combinations of age-ra11ges and intervals 
wîth increasi~g number of screenings, and for t.he new (la belled G in Figure 7.1) 
and old (labelled U in Figure7.1) nationally rccommended agc-ra11ge and inter-
\•al combination, for a 27 year cen•ical cancer screening programme in tlie period 
1993-2020. Casts in Dil. Furtller assumptions: attendance 75%, iw oppo1·tunîstic 
screeniJ1g, 0% discount rate 
.......... Efficient .......... . ...... Used 
Label Figure 7.1 { [ ·a u 
Number of smea'rs 5 7 10 7 7 No screening 
Ages1 27(10)67 27(7)69 27(5)72 30(5)60 35(3)53 
Annual number of 
smears (0% disc.} 316 000 438 000 609 000 478 000 505000 0 
Casts 
Total casts (x Ml'n) 1939 2100 2339 2182 2258 1442 
Effects 
Deaths from 
cervical Cancer 16611 15799 15057 16169 16831 20 731 
Lost life-years from 
cervical cancer 310211 291917 277 840 294179 308 247 413003 
Differences with the situation without early detection 
Totat casts (x Mln) 497 659 898 740 816 
De·aths prevented 4120 4932 5674 4563 3900 
Life-years gained 102 792 121086 135163 118 824 10<1756 
1 Starting age (inter:at) last age 
:More opportunistic screening takes place in young age groups when pro-
gramme screening starts at age 35 compared. to age 30. Therefore, the policy 
offering PAP smears every 5 years for women.between.ages 30 and 60 was chosen 
for the revised national eervical cancer screening programme. 
After the consensus meeting, we reconsidered policies incorporating 7 screen-
ings per woman and an interval of 5 years, élnd calculated the Cost-effectiveness 
when accounting for the true casts instead of the number of smears {see 
Table 7.8). This re-analysis confirmed that the camparisou between the poli-
des had been only slightly infiuenced by taking number of smears as a proxy for 
the tot al net casts: the difference in casts per smear between the 'yçmngest' pol-
icy (starting at age 20 years) and the 'oldcst' policy (starting at age 40 years) 
waS less than 2%. The randoni. error of the lncremental cost-effectiveness 
ratio's of polides with different starting agcs is rather large (sec the bottam 
row of Table 7.8). Nevertheless it seems that changing from the policy that 
starts at age 30 to one starting at a younger age is rclatively unfavourable. 
The cost-effectiveness ratio of polides that start at age 30, 35 and 40 are not 
very different. Of these policies, if one accepts this level of cost-effe~tivencss, 
the logica! policy is the one with the largest effects, i.e. the policy that starts 
at agc 30 years. 
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·Table 7.5 Cost-elfecth'eness ratios (GERs) of efficient combii1a.tions of age-
ranges and inten•als witl1 increasing number of screenings, and for the new (Iabelled 
Gin Figure7.1) and old (labelled U in Figure7.1) IJationally reeommendeel "age-
range and inten,al combinatiOit,. for a 27 year cen'ical cancer screening programme 
in tlw period 1993-2020. Casts in Dfl. Further· assumptions: attendance 75%, no 
opportunistic screening, 5% discount rate 
. . . . . . . . . Effident ......... ...... Used ...... 
Label Figure 7.1 { G u 
Number of smears 5 7 10 7 7 
Ages1 27(10)67 27(7)69 27(5)72 30(5)60 35(3)53 
Annual number of 
smears (0% disc.) 316 000 438 000 609 000 478000 505 000 
CERs compared with the situation without screening 
Costs per death prevented 287 274 308 624 348 888 383 329 477 361 
Casts per life-year gained 21 854 ·23 840 27 679 27 602 33 276 
CERs compared with the efficient policy with less smears 
Incrementa:I casts (x Mln) n.a. 117 163 
Incremental deaths prevented n.a. 285 276 
Incrementallife-years gained n.a. 3416 2914 
Incremental casts per l.y.g. n.a. 34 250 55 937 Not effident 
95% CI because of 
of 
stochastic output 
1 Starting age (interval) IB.st age 
n.a. Not available 
. 32000 
to 
37000 
51000 
to 
62000 
7'.3.3 The new policy compared to the old policy and the optima! policy 
In comparison with the previous policy, it is predicted that the new policy, 
using a 5% discount rate, will result in 18% more deaths being prevented and 
14% morelife years gained (see Table '/. 7}. In addition costs wil! be 6% lower. 
Compared to the optima! policy of 7 PAP sniears per woman, the number of 
deaths prevented for the new policy is 12% lower, the number ofyears gained 
. 5% lower and the costs 10% higher. According to our predictions, this suggests 
that while the new policy is not optima! it marks a considcrable improvemènt 
over the original policy. 
7.4 Discussion 
In practice, opportunistic screening will certainly. occur. One reason why we 
did notaccount for this in our predictions, was that it is instructivc to eXplore 
the cost-effcctive~ess of pure policies. ·But thc main reason was that it is 
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Table 7.6 Sensitil'Îty analysis: b"aseline1 lol\' and lûgl1 assumptions for selectcd 
parameters 
Parameter 
Baseline Low High 
assumptions assumption assumption 
Average duration of pre-invasive dctectable neoplasia 
11.8 years 6.8 yea~s* 16.8 years* 
Sensitivity of tbc screening test (pre-invasive neoplasia) 
80% 60%. 90% 
At tendance 
75% 40% 90% 
Cumulative incidence of progr~ssivc ncoplasia in participating wamen barn· aft er 1938 
1.2% Three times baseline 
Discount rate 
5% 0% 
* The disease onset is shifted t'o five years older and younger respcctivcly to compensate 
the influence of the changes in duration on the age of incidence of invasivc cancer and 
rnortality 
very diflicult to predict the interaction between an organized policy and the 
frequency and age-distribution of opportqnistic screening. In the decision pro-
cess as dcscribed, the like~y impact of o"pportunistic sCreening has tentativcly 
been taken into account. A. langer interval-tban 5 years was expected to gen-
erate much more opportunistic 'in between; screeniilg, and a startingage over 
30 togeneratea large amount of opportunistic screening in young age. 
·v/hen the nuiuber of PAP smears per woman is given, a screening policy is char-
acterized by the startingage and thc lengthof the interval between subsequent. 
screenings. 'Ve will discuss possib1e inftuences of the methods we used and of 
remaining uncertainties about parameter quantifications on the conclusions 
reached on starth1g age and interval. 
7.4.1 The lengthof the screening interval 
The optimal screening interval, fora given number of screenings, depends toa 
large ex tent on the assumed duration of detectable pre-invasive disease ( CIN) 
before it becomes invasive. The estimate of 11.8 ycars that we used for the 
average duration of CIN is basedon a na lysis of data from British Columbia '"'l 
and tested against data on interval cancers from the IARCstudy [t6t, tooJ. Our 
estimate is intcnnediate compared to estimates by Braakmeyer and Day in 
1987 l"l (6.4 to 28years including invasive pre-clinical duration), Gustafsson 
in 1989 i"l (13:3 years fot CIS) and Bos in 1997 i"l (16 years including invasive 
pre-clinical duration) .. "'hen the average pre-invasive duration was shortened 
to 6.8 years, the optimal interval between s?v~n screenings still did not drop 
under 5 years. 
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Table 7.7 Effects and casts of efficient' combînatîons of age-ranges a11d inten'als 
wit.h incrcasing number of screenings, and for the new (Jabclled Gin Figure7.1J 
and old (la belled U in Figure 7.1) nationally recommended age-range and inter-
''al combînation, for a 27 year cervical cancer screening programme in the period 
1993-2020. Casts in Dfl. Further assumptions: attcndance 75%, no opportunistic 
screening, 5% discount rate 
. . . . . . . . . Efficient ...... Used ...... 
Label Figure 7.1 { G u 
Number of smears 5 7 10 7 7 No screening 
Ages 1 27(10)67 27(7)69 27(5)72 30(5)60 35(3)53 
Annual number of 
smears (0% disc.) 316 000 438000 609000 478000 505 000 0 
Costs 
Tot al costs (X Iv11n) 851 968 1131 1018 1050 457 
Effects 
Deaths froin 
cervical cancer 4847 4562 4286 4 754 4975 6219 
Lost life-years from 
cervical cancer 51833 48417 45503 49534 52029 69868 
DUferences with the situation without early detection 
Total costs (x Mln) 394 511 674 561 594 
Deaths prevented 1?72 1657 1933 1464 1 2•!4 
Life-ye.ars gained 18035 21451 24365 20334 17839 
1 Startingage (interval) last age 
7.4.2 The starth1g age in screening 
The, optima! starting age is inlluenced by the discount rate chosen. Without 
any discounting, the estimated optima! startingage of 21 years (see Table 7.2} 
would drop approximately 3 years. Discounting means that effects and casts 
that occur in the future have less impaCt on the calculatcd cost-effectiveness. 
Discounting therefore decreases tl~e advantage of presenting acervical eaueer 
death in a youngcr than in an older woman, because the life-years gained 
far in the future çount less. :rvloreove_r, the time lag between the detection 
of pre-invasive discase and the time the woman otherwise would have died 
from thè neoplasia, is on average longer in younger age groups than in older 
on es. Discoouting is generally advised for cost-effectiveness ana!yses, although 
recently there has been a tendency to reemumend a lower rate of 3% instead 
of t.he usual 5% discount rate [2toJ. This again supports the ciccision to chose 
the 30 to 60 years policy insteadof a policy with·7 smears and a 7 year interval 
that starts at age 35 or 40 years. 
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7.4.3 Quality of life 
Inclusion of quality oflife aspects, which have nat been considered in this anal-
ysis, would inftuence the estimated optima! age-range. C'?mpared to screenbig 
at oldcr age, screening at a younger age would, according to our analysis, gen-
erate more negative as wellas more beneficia! side effects ( other than mortality 
· reduction). One important factor in this respect is thc asSumed higher occur-
rencc of"regressive discase at younger age. This assumption '''as basedon the 
analysis of the British Columbia screening data i"'i, but was not confirmed by 
other analyses [83, 24J, rviorc'onset-of regressive lesions at youngcr age mcans 
more detection, diagnosis and treatmcnt oflesîons withoUt prevent.ing invasive 
eaueer or death, and therefore morelossin quality of life (and more casts). On 
the other hand, the high overall survival at young agc is favourablc for extra 
gains in _quality of life in younger age: relativ~ to the mortality reduction, the 
rednetion in incidence is higher than in older age. Assessment of the quality 
of life impact on the optima} stmting age ~-equires health status measurcment 
and valnation of the burden for wamen caused by the detection of pre-invasive 
disease and by the diagnosis of invasive cervical eaueer (see also Chapter 10). 
If the number of screenings per woman is fixed, accounting for quality of life 
impacts of screening would hardly have any impact on the optlmal.length of 
the interval. 
7 .4.4 Cost-effectiveness level 
Foi· assessing whe"ther cen,ical cancer screening is a good investment, the 
(increment~l) casts per life year gained need to be compared withother health · 
care interventions. Therefor<dt is important to know hüw sensitive the esti-
mates for the cost-effectiveness of cervica:l eaueer s~reening is for thê'assump-
tions made. A very important assumption in this respect is the discount rate 
applied. Since there is a iüng duration between casts and effects in cervical 
canéer screening, the casts per life-year gailwd increase·with an increased dis-
count rate. For inst3nce, at 5% discounting, the casts per life-year gained of 
the new Dutch policy is estimated at Dfl 28 000. This èompares with Dil 16 000 
at 3% discounting and only Dfl 6 000 at a zero discount ra te. In genera!, time 
preferenee is unfavourable for ep.rly detection when it is cornpared to curative 
niedic31 _interventions, where the time lag between the intervention and its 
benefits is usually much shmter (e.g. treatment with antibictics in acute con-
ditions). The unfavourable influ~nce of time preferenee is especially strong in 
· ccrvical eaueer screening, with its long detectable pre-clinical phase of about 
.15 years on average. 
The estimated cost-effeçtiveness level is ~lso inftuenced by the assumptions 
regarding attendance. This in part is due to the fixed casts of running thc 
programme and economiesof scale. The association between attendance and 
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Table 7.8 Effects, costs aîid cost-effecthrencss ratios (GERs) of 5 polides with 7 
screening-ages and an inten'al of 5 years, fora 27 year ccn'ical eaueer screening pro-
gramme in the Period 1993-2020. Casts in Dil. Further assumptions: attendance 
75%, 110 opportunistic screening, 5% discount rate 
Label Figure 7.1 
Starting age 
Number of annual 
smears.(O% disc.) 
9 G e 
40 35 30 25 
404 000 446000 478000 499000 
a 
20 
510000 
Effects and casts: dUferences with the situation without early detection 
Total costs (x Mln) 463 515 561 595 616 
Deaths prevented 1496 1 485 1464 1402 1 275 
Life-years gained 17 56<1 19 323 20 334 20 511 19 352 
CERs compared with the situation· without screening 
Costs per death prevent cd 309 269 347 157 338 329 424 530 
Casts per life-year gained 26 334 26 673 27 602 29 024 
CERs compared with the policy starting at older age 
Iocrement al casts per l.y.g. 30 045 45 371 192 393 
95% Cl because 
of 
stachastic output 
26000 
to 
34000 
36000 
to 
60000 
79000 
to 
110 l.y.g. 
Le .. effeels 
mare costo 
No l.y.g. 
to 
na l.y.g.-
risk also plays a role: i.e. the higher the attendance, the more high risk wamen 
are expected to _ be covered by sereens [tt9J, \Ve assumed 75% attendance in 
om· base-line calculations, which is much higher than the attendance rates 
of 35 to 50% reported from regions in the Netherlands over the last 5 years. 
However, 75% ofthe wamen of the target age-group had a PAP smear in the live 
years preceding 1995 1141. Niany of these wamen had opportunistic PAP smears 
outside thC screening programme. Since our prcdictive calculations apply to 
the situation without opportunistic screening, an assumed at tendance rate of 
75% would be a high estimate. On the other hand, the better organization of 
the new screening programme is expected to increase the coverage of screening. 
Large amounts of opportunistic smears result in higher casts per life-year 
gained with screening. In order to prevent opportunistic screening, the Dutch 
Health Insm·ance Council has decided no langer to reimburse the casts of these 
smears. 
The casts of cervical cancer screening mainly consist of the casts of running 
the programme and thé costs of taking and evaluating the PAP smears (see 
Table 7.3}. Recently, new tariffs have been detennined forthese aspects, which 
were intended to reflect the true costs of t~1e ncwly organised screening pro-
gramme. The 1996 tarifi's result in about 30% higher casts for a screening 
programme with seven PAP smears than previously estimatcd by us. Future 
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budget analyses will clarify how realistic the new tariffs are. If we have underes-
t~mated the variabie casts of screening, the case for the decision nOt to increase 
the number of screenings will become stronger. 
In Chapter 10 of this thesis, a cbn_1parison is made between our cost-effectiveness 
estimates forcervical eaueer screening and other estimates fromlit~rature. 
7.4.5 Varying assumptions on the follow-up strategy 
The assumptions·on follow up practice havenotbeen subjected toa sensitivity-
analysis. They may have been too conservative, assuming to.o little follow-up 
compared to the recent practice (see Chapter 10 and Appendi1< A). Ideally, 
follow-up should have been varied to estimate the optima! combination of fol-
low up strategy and the screening policy. lVIare intensive follow-up for instanee 
would possibly allow for langer screening intervals. This is an important 
(but difficult) subject for further analysis, particularly in the _present situ-
ati~m where, according to the follow-up guidelines, over 10% of the wamen are 
referred for follow-up. 
7.4.6 International perspective 
Several criteria can be used w~1en choosing between ceFvical cancer screening 
policies: i.e. a target for the hcalth effects, budget constraints, or a target 
incremental cost-effectiveness level. Setting any of these targets is necessary 
and suflident for idèntifying a unique optima! policy. In the Netherlands, 
by setting the number of smears per wamen, a quasi budget constraint was 
set. This eaustraint was amongst others iilspired by ea1·lier estimates of the 
cost-effectiveness for .cervical cancer screening polides at different cast-levels. 
Apparently, in other countries otl1er criteria"than cstimated cost-effectiveness 
have sametimes playcd an important ro~e. The respective national guidelines 
on the numbe~· of sc_reenings per woman differs widely, e.g. from 27 in Australia 
f61J to six· or seven in Finland (96J and the Nethcrlands. A large number of :;;mears 
does not always reflecta higher risk levelor a higher available budget for health 
care. For instanee in Australia, the risk forcervical cancer is simHar .to the 
risk in the Netherlands. 
Large dilforences in risk level wil! influence the optima! policy. In Denmarkfor 
instance, the tisk of cervical cancer is abàut twice the risk in the Netherlands. If 
all other circuinstances are assumed to be equal, ~ doubled risk would roughly 
halve the estimated (incremental) casts per life year gained. If an incremcn-
tal cost-effectiveness of about Dfl35000 is accepted (which according to our 
calculatiof\S for .tl<e Netherlands corresponds about with moving from G to 7 
screenings), this would result in at least ten screenings in the Danish situation, 
and cönsequently in an optimal screening interval of 5 years or even somcwhat 
shorter. In most Danish counties, wamen are invited for PAP smear screening 
13 times during their life, with an interval of 3 years 12ooJ. 
86 Chapter 7. Effects and casts of cen•ical cancer screening 
7.4.7 Condusion 
For the situation in the_Netherlands but without opportunistic screening, and 
for a policy with 7 screenings per woman, a PAP smear screening interval of 
7 years is optimal from a cost-effectiveness point of view. A shmter screen-
ing interval covers a too narrow agc-range, misSing the opportunity to save 
more life-years using the same amount of resourèes with a 7-ycar intervaL 
In a Dutch national consensus meeting, 5 years was considered the .largest 
acceptable interval, which is an impravement over a 3-year ,interval, but falls 
somewhat short compared to the optima! interval in an ideal situation with-
out .opportunistic screening. A 5-year interval might be a reasanabie choice in 
reality where an amomit of opportunistic screening can he expected to increase 
strongly with increasing screening interval. 
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Table 7.9 Gharacteristics ofthe polkies for which predictions have been made1 
and their label in Figure 7.1. Startingage (SA), last age (LA), interval (I), number 
of smears per woman (#), mean age (MA) 
Label # SA LA MA 
4 
8 
1 
t 
L 
M 
Q 
s 
·3 
6 
b 
d 
m 
q 
c 
I 
0 
> 
y 
i 
k 
} 
V 
F 
J 
K 
p 
w 
z 
2 
a 
c 
• 
e 
j 
x 
335105545 
3 37 10 57 47 
425105540 
4 27 10 57 42 
4 30 8 54 . 42 
4 30 10 60 45 
4 32 10 62 47 
4 33 8 57 45 
4 35 8 59 47 
4 35 10 65 50 
5 22 10 62 42 
52485640 
5 25 10 65 45 
5 26 8 58 42 
5 27 10 67 47 
5 29 8 61 45 
53065442 
5 . 31 8 63 47 
53486652 
53555545 
5 35 6 59 47 
53987155 
6 25 6 55 40 
62586545 
6 27 8 67 47 
6 28 7 63 46 
6 30 5 55 43 
6 30 6 60 45 
63076548 
6 32 5 57 45 
6 35 4 55 45 
6 35 5 60 48 . 
6 35 6 65 50 
72055035 
7 24 6 60 42 
7 24 7 66 45 
72555540 
7 25 6 61 43 
7 25 7 67 46 
Label # · SA LA MA 
p 
( 
• 
{ 
V 
B 
E 
G 
I 
R 
u 
x 
9 
6 
I 
f 
$ 
n 
0 
• 
72666244 
7 26 7 68 47 
72766345 
72776948 
72866446 
7 29 6 65 47 
7 30 4 54 42 
73056045 
7 30 6 66 48 
7 33 4 57 45 
73535344 
7 35 4 59 47 
73556550 
73635445 
73767355 
7 40 5 70 55 
82466645 
8 25 5.60 43 
8 25 6 67 46 
82645440 
8 26 5 61 44 
8 26 6 68 47 
r 8 27 5 62 45 
l 82766948 
u 82856346 
A 8 29 5 64 47 
H 83056548 
T 83435545 
g . 9 25 5 65 45 
k 92656646 
) 9 27 5 67 47 
+ 9 28 5 68 48 
x 9 29 4 61 45 
\ 9 29 5 69 49 
D 9 30 3 54 42 
N 9 31 4 63 47 
? 93446652 
V 9 35 3 59 47 
[ . 10 27 5 72 50 
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Figure 7.1 Thc number of smears ànd ti1e number of life years gained for 
different combinations ·of age ranges and Jntermls. Tlw symbols refer to tllC polides 
described iri Tablc 7.9. Tlie numbers are per screening year ÜJ tlJe Netherlands. 
F'Urther assumptions: 75% attendance rate, no opportunistic saecning, and 5% 
discount rate 
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The 'rescreen effect in conventional and Papnet. 
screening observed in a study using material 
enriched with positive' smears 
This chapter is based on M. van Hallegooijen et al, in press in Acta Cytologica 
Abstract 
Objective:. PAPNET-computer assistcel cervical smear screening is used routinely 
in the LCPL, showing encouraging results. The purpose of this paper is to study 
the rescreen effect and the PAPNET effect on enriched I~Iaterial derived from smears 
sereerred routinely using PAPNET and conventional microsopy. 
Study design: A series of 432 smears (containing 122 atypical [Ascus] and 44 
at least dysplastic [squanious intracpithcliallcsions, SIL+] ones) screencel routineiy 
with the conventional method, were rescreened using the PAPNET system. An other 
series t?f 461 smears (containing 140 ASCUS and 52 SIL+ ones) screened routinely 
with PAPNET, were rescreened conventionally. The rescreen-effect, dcfincd as thc 
effect of differences between the rescreen and the routine screening situation, was 
invcstigated by cmnparing the rescreen restilts in both series of smcars with the 
routine results in both series. The effect of using 'either metliod of screening was 
stuclied by cmnparing the PAPNET results in both series with thc results of conven-
tional screening in both series. 
Results: The rescreen effect was statistically significant both for a higher number 
o.f smears classified as negative (less than ASCUS) and a higher number of smears 
classifie<;J as high grade SIL or more. PAPNWI'-assisted scre.ening resulted in a sig-
nificantly higher number of smears classified as high grade SIL+i although for this 
. latter finding there is an unexplained significant difference between 'Conventional 
and PAPNET screened cases in thc changes made by the cytopathologist in the 
cytotechnologists, diagnoses. 
Conclusion: The reseteen effect should not be ignored when enriched material is 
used. 
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8.1 Introduetion 
Ever since the introduetion of cervical cytology as a diagnostic tooi for routine 
screening to detect premalignant and malignant conditions, various techniques 
have been sought to imprave sensitivity ancljor sjwcificity. Onc of these tcch-
niques is the recently developed computer-assisted screening methad using the 
PAPNET system 11221 •. In this computer assisted system, smears are processed 
by a nem·al network computer befare the human cytotechnologist is involved. 
This computer processing produces a digital tape with 128 images, which are 
selected as having the greatest 'likelihood of containing abnormal cells. 
Results of a study that compared the use of this new methad in a routine 
setting to convcntiona:l screening showed a deercase in .false negative rates 
(1131, However, as always \vhen a new screening methad emerges, studies to 
begin with concerned PAPNET in a rescreen~situation, using series of smears 
enriched with positive cases (23, 1o8, 122,136,137,179,182,186, t96, 2061. The.rescreen 
situation is completely different from the routine screening situation, result-
ing in a change in diagnostic pattern .[261 1 the so-called rescreen effect. The 
impact ofthe rescreen-effect is a well recognized pitfall in camparing different 
modalities of Iabaratory screening tests. The purpose of this paper is to study 
it quantitatively. 
The present study concernSarescreen study on enriched material derived from 
bath PAPNET-assisted and conventionally screened smears. This was possible 
· because screening with the PAPNET system was used routinely at the Leiden 
Iabaratory alongside conventional screening. !vloreover, for rescreening, we 
also could use bath screening modalities. This design enabled the rescreen 
effect to be evaluated independently of the technique used. 
8.2 Materials and lllethods 
8.2.1 Papnet-assisted screening 
In the PAPNET-assisted diagnostic procedure, the video images of the 128 cell 
groups selected by the computer were examined and the images öf the 16 most 
abnormal ones were marked using the available computer technology. The 16 
images were brought tagether on the video summary screen to further enhance 
the diagnostic information. The XY co-ordinates of each of these 16 images 
were utilized to localizc under the microscope the strands of material in the . 
smear that contained abnormal fragments andfor abnormal cells. As a final 
step, the cytological diagnosis was made, taking into account the diagnostic 
information presented .on the video sum1~1ary screen plus the light microscopie 
evaluation ofthe abnormal cells under a high power objective {40x). 
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8.2.2 Cytological classification 
The smears were classified as negativc, ASCUS/ AGUS (including atypical squa-
mous cells of uncertain significanee and atypical glandular cells of unccrtain 
significance, and smears shmving only condyloma, excluding benign cellular 
changes), !ow grade SIL(including light and moderate dysplasia) and high grade 
SILf (including scvere dysplasia, carcinoma in situ and invasive carcinoma). 
Since in the Dutch system smears with light and moderate ·dysplasia were 
classified into one category, we had to include moderate dysplasia into the low 
grade SIL. 
8.2.3 Screening and rescreening procedure 
Bath in the routine and the rescreen situation, the cytotechnologists were 
allowed to sign out negative and Ascusf AGUS cases. However smears signed 
out by cytotechnologists as at least low gradeSIL, were also evaluated by the 
cytopathologist, who gave the final diagnosis as presented in the tables. All 
selec.ted and available smears were rescreened by one of the five cytotechnolo~ 
gists who also performed the initia! screening. The cytotechnologists and the 
cytopathologist were blinded for the initia! result. 
8.2.4 Initia! screening material 
In a five-month period in 1993, 28 337 samples were sent to thc laboratory. 
A bout 500 smears per week.were screened using the PAPNET-assisted method. 
Th is amounted to 11117 smears or 39% of all the samples reccived. The ether 
17 220 smears were sereerred conventionally. We eaU this PAPNET-assisted and 
conventional evaluation of the smears the initial screening; it was performed 
in a routine screening situation (as opposed to the study situation). 
8.2.5 Selection Of mat~rial for rescreening 
F\·om the total of 28337 smears screened, 95.5% \Vcre classifiedas negative, 
2.7% as Ascus, 1.4% as low grade SIL and 0.4% as high grade SIL or higher 
abnormality. 1000 cases were selected for rescreening on the basis of the initia! 
cytological diágnosis; 500 'vere chosen from the sme<irs initially screened con-
ventionally while 500 were selected from the material initially screened by the 
PAPNET method. The initial diagnoses in the two selected series are summa-
rized in Table 8.1. Abnormal smears were deliberately overreprcsentcd in the 
study samples (such'that the material selected contained enough positive cases 
to campare outcmncs in these cases). All thc smcars with a diagnosis of at leàst 
SIL wereselected from both series. For ASCUS and negative smears, 120 and 180 
smears respectively were randomly selecteçl .. To campensa te for eight smears 
with SIL fcwer among the smears -initially screened with ~he P.:\PNET-assisted 
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Table 8.1 Initia} cytological.results of the smears selected aJJ(] ( ) available for 
tlle study1 
Cytological result Negative ASCUS lów grade High grade. Tot al 
SIL SIL+ 
Smears initially screened 
conventionally 180 {157) 120 {109) 142 {122) 58 (oH) 500 ( 432) 
Smears initially screened 
with PAPNET 188 {163) 120 {118) 140 (137) 52 ( 43) 500 {461) 
Tot al 368 {320) 240 {227) 282 {259) 110 (87) 1000 {893) 
1 The analys_es have been also. performed aft er ha ving corrcctcd the figures .for the differ-
ences in number of available smears per class of initia! diagn_osis,_ see results 
method, eight extra negative smears were selected for this series. However, 68 
of the conventional smears and 39 of the PAPNET-smears were not available 
for rescreening (see Table8.1} due to technica! problems, such as poor cover-. 
slipping of the smear, slide breakages, additional inununostaining and other 
irremediable Circumstances: 
8.2.6 Data analysis 
Two factors play a role in the cytological results: the méthod used ( PAPNET vs 
conventional) and the rank of the cytologie evaluation (rescreening vs initia!). 
To start with, the two series of smears were considered separately, by cross-
classification analysis of the initia! and the rescreen results (see Table 8.2 
and Table8.3 for conventional initia! screening and PAPNET initia! screening 
respectively )'. In this analysis, the two factors are confounded. 
In the next two analyses, the two aspects are put forward separately. In the 
first one (see Table 8.4), the effect associated to the rescreen situation versus 
the initial situation· is visualized. To this end, the results of the two series of 
smears were combined: allrescreen .results (cither from conventional or from 
PAPNET rescreening) were compared with. all initial screening results (either 
from conventional or fron1 PAPNET sc~·eening). 
In Table 8._5, PAPNET screening is compared with conventiorial screening, inde-
pen~ently of rank of screening. The results of thc two series of smears again 
are combined. H0wever,this time all the conventional diagnoses.(from either 
initial screening or rcscreening) were compared to all the PAPNET diagnoses 
(from eitluir initia! or rescreening). 
For the calculation of the p val u es for the differences in the number of diagnoses 
(Tab/es 8.2-8.5), we used eontingency tables and log-linear models 1"1. 
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Table 8.2 Cross-classification of cytological.resultS: com'entional initia] verslis 
PAPNET rescreen 
Papnet .................. Conventional înitial ......... : . ...... 
re screen Negative ASCUS Low grade High grade 
SIL SIL+ 
Negative 132 71 2 0 
ASCUS 19 35 12 0 
LmV grade SIL 6 3 83 
lligh grade SIL+ 0 0 25 <13 
ALL 157 109 122 •I <I 
\Vith rescreen: 
48 Negative more (+3i%), or 48 ASCUS+ less (-17%); p < 0.0001 
43 ASCUS less (-39%) 
29 Low gnide SIL less (-24%) 
24 High grade SIL+ more ( +55%); p < 0.0001 
8.3 Results 
ALL 
205 
66 
93 
68 
432 
The results of the rc~creening with ·~APNET of smear~ initially .sci·eene"d with 
the conventional methad are pi'esented in Table 8.2, and those of rescreening 
conventionally smears initially screened with PAPNET in Table 8.3. Th~ tables 
show that both upgrading ànd downgrading of the initia! diagnosis occurred. 
Upgrading from initially negative smears and smcars with ASCUS to high grade 
SIL+ and downgrading from initially high grade SIL+ to negative smears never 
occurred; downgrading from initially high grade SIL+ to ASCUS occurred only 
twice. 
A summary of the statistica! significanee of tlie upgrading and downgrading 
is provided in the bottam of Table 8.2 and Table 8.3. These outcomes depend 
highly on the sample composition in the study. They were only considered in 
.this aggregated way to campare the results of the different analyses. In the · 
PAPNET rescreen run {see Table 8.2), significantly fewer smears were dassi-
lied as positive (Ascus and higher) and significantly marc as highly abnormal 
(HSIL+) than in the same smears in the co~ventional initial run. In the con-
ventional rescreen run hmvever (see Taf)le 8.3), again the technique used in 
thc rescreen method (which is thc conventional one this time) classificd signif-
icantly fewer smears as positive (Ascus+ ). The numberof smears classified 
as highly abnormalnow is almast unchanged. 
In Tab/e8.4, where the effect ofrescreening becomcs visible independent ofthe 
methods us.ed, the ·same pattern m·ises as in Table 8.2: during rescreening sig-
nificantly fewer (-19%) smears wcrc classified as abnormal (ASCUS and higher) 
and significantly morè ( +25%) as highly abnoni1al (HSIL+) than in the initia! 
screening. 
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Table 8.3 Cross-classification of cytological results: PAPNET initia! versus con-
ventional rescreen 
Conventionaf 
rescreen 
.......... _ .......... Papnet initia! ................... . 
Negative ASCUS Low grade High grade ALL 
Sll SIL+ 
Negative 144 75 6 0 
A SC US 18 33 10 2 
Low grade SIL I 10 114 7 
High grade SIL+ 0 0 7 34 
ALL 163 118 137 43 
\Vith rescreen: 
62 Negative more (+38%), or 62 ASCUS+ less (-21%); p < 0.0001 
55 ASCUS less (-47%) 
5 Low grade SIL less (-4%) 
~ High grade SIL+ less (-5%}; p = 0.62 
225 
63 
132 
41 
461 
In camparing PAPNET with conventional screening (see Table 8.5), PAPNET 
screening classified 2. 7% (not significant) more smears as positive (ASCUS+ ), 
but 30% (significant) more smears as highly abnormal. 
We repeated all the analyses after having corrected the figures for the differ: 
ences in number of available smears per class of initia! diagnosis (sec Ta bie 8.1). 
The results were ·nat affected, neither in direction nor in statistica! significance .. 
The rescreen-effect on the riumber of smears classifiecl as negative was niuch 
larger than the PAPNET-effect. ( campare Ta bie 8.4 with Ta bie 8.5). For high 
gracle SIL+ '"e see an increase in the number of smears classified as such, bath 
in rescreening and in using PAPNET. In other words, the rescreening effect on 
this enriched material points in the samedirection as.the PAPNET effect. 
8.4 Discussion 
This study shows a significant rescreen effect both on the number of smears 
classificd as negative (less than ASCUS) and on the number of smears classi-
fied as higly abnormal (SIL+). In our view, basedon observations from thc 
workfloor, this rescreen effect wasmainly caused by thrce factors. Firstly, the 
diagnostic responsibility is completely different. The diagnosis in the rescreen 
situation will have no clinical consequence, resulting in more completely neg.:. 
ative and more completely positive cases. As a consequence there are lcss 'in 
between' cases. Secondly, hightened alertnessof the cytologist, through which 
smears with onljr few abnorm~l cells will be more easily spotted, is expected in 
a study situation. Thirdly, the material selected for this study contained 60% 
positive Smears, whereas in the initia! routine screening situation only 4% of 
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Table 8.4 Cross-classification of cytological results: in~ ti al \'Crsus rescreen 
Rescreen ........... Initia! (conventional + Papnet) ........... 
(conventional + Papnet) Negative ASCUS low grade High. grade, 
SIL SIL+ 
Negative 276 146 8 0 
ASCUS 37 68 22 2 
Low grade SIL 7 13 197 8 
High grade" SIL+ 0 0 32 77 
ALL 320 227 259 87 
With rescreen: · 
110 Negative more (+34%), or 110 ASCUS+ less (~19%); p < 0.0001 
98 ASCUS less (-43%) 
34 Lo\v grade SIL less (-13%) 
22 High grade SIL+ more ( +25%)i.P < 0.0001 
ALL 
430 
129 
225 
109 
893 
the diagnoses were positive. As a consequence, the cytotechnician suffers less 
from habituation. Habituation has roughly the opposite effect as increa:sed 
allertness. For those of us who have routinely sereerred 200 000 smears with 
the PAPNET method, it is not surprising that apart from the rescreen effect 
there is also a PAPNET effect in finding more high grade SIL+ cases. When 
PAPNET is used, there is a higher alertness that the visual information of the 
128 tiles might be diagnostically important, otherwise they would not have 
been selected out qf the 300 000 cells of the smear. In addition, there is less 
habituation because the cytotechnologist sees less benign cells. 
In this 1:escreen study, like in the routine screening situation, smears clas-
sified by cytotechnologists as at least low grade SIL, were also evaluated by 
the cytopathologist, who gave the final diagnosi~. It was intm·esting to _see 
that in thc smears rescreened with PAPNET, compared to the cytopatholo-
gist, the cytotechnologists had a tendency to diagnose low grade versus high 
grade SIL+ (thisoccurred 8 times versus 0 times the otl1er way around). In the 
smears rescreened conventionally the opposit is seen: cytotechnologists teildeel 
to diagnose high grade versus'low grade SIL (this occurred 11 times versus 2 
times the otl1er way around). This difference is statistically highly significant 
(p < 0.001). As a consequence, the PAPNET-effect which was found at the 
cytopathologist level was not significantly present at the level of cytotechnol-
ogists. \Ve have no explanation for this finding, and have not investigatcd 
it in greater detail, but it emphasizes the importance of well recorded labo-
ratory s.creening procedures. The observed rcscreen-effect was eegtal at the 
cytopathologist and cytotechnologist level. 
The problem with using cnriched series for rescre~ning studies, as was also 
done by us, is that it contains a too small numl?er of negative smears to cal-
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Table 8.5 
NET 
Cross-classification of cytological results: comrentional versus PAP-
Papnet ........... Conventional (initia! + rescreen) ........... 
(initia! + rescreen) Negative ASCUS Low grade High grade 
SIL SIL+ 
Negative . 276 89 3 0 
ASCUS 94 68 22 0 
~ow grade SIL 12 13 197 8 
High grade SIL+ 0 2 32 77 
ALL 382 172 254 85 
VVi~h Papnet: 
14 Negative less {-4%), or 14 ASCUS+ ·more ( +2.7%); p = 0.32 
12 ASCUS more (+7%)" 
24 Low grade SIL less (-9%) 
26 High grade SIL+ more ( +30%); p = 0.0005 
ALL 
368 
184 
230 
111 
893 
cufate reliably Specificity and sensitivity. Since in a routine situation, more 
then 90% of the smears are conventionally diagnosed as negativc, this cate-
gory may cm:ry a heavy weight on these calculations. The impact of small 
numbers of negative smears can be illustrated. by rescaling the outeernes of 
this study to the distribution of diagnoses in the screening situation (95.5% 
negativc smears, 2.7% ASCUS, 1.4% low grade S1L and 0.4% high grade SIL+ ). 
After such rescaling of the results of PAPNET versus coilventional screening 
(presented in Table 8.5), the 2.7% increase in smears classifled as positivc 
(Ascus+) heemnes a 85% increase. The cause for this shift is that the 4% 
decrease in smears initially classified as negative in PAPNET screening now 
applies to 96% of the smears classified as .negative in the screening situation 
(\•ersus 40% in the study matcrial). Adding follow-up data would determine 
the histologie yield of this higher number of positive cytologie diagnoses. But 
the expected prevalenee of e.g. high gradc SIL (as defined according to the 
Dutch system where moderate dysplasia counts as nat high grade) in smears 
initially called negative is only about one per thousand (assuming a preva-
lenee of high grade SIL of five per 1000 wamen and a sensitivity for high grade 
SIL of 80%). Hence, many thousands of smears initially classified as ncgative 
have to be s_creened wfth the new method to asses a change in sensitivity for 
high grade lesions. This not only holds for the assessment of the sensitivity 
of PAPNET in routine screening, bilt also in rescreening negative smêars fm; 
quality assurance purposes in cytology laboratories, using any of a numb~r of 
techniques including the 'automated' ones. 
This study clearly shows the necessity nat to ignm:e the rescreen-cffect when 
enriched material is used. 
Present evidence on the value of 
HPV testing for cervical cancer 
screening: a model-based exploration · 
of the ( cost- )effectiveness 
This chapter is basedon M. van Ballegooijen et al 
British Journalof Cancer 76(5), 651-657, 1997 
Abstract 
9 
Human papillamavirus (HPV) is the main risk factor. for invasive cervical cancer. 
·High ·risks ratios are found in cross-sectionat data on HPV prevalence. The qucstion 
raiscd is whether this present evidence is suflident for making firm recommenda-
tions on nrv-screening. 
A validateel cervical eaueer screening model was extended by adding HPV infection 
as a possible precursor of cervical i[.ltraep!thelial neoplasia (ciN). Two widely dif-
ferent model quantifications we~e constructed so that both were compatible with 
the observed HP\~ risk ratios. One model assumed a much longer .duration of HPV 
infection befm·e progressing to CIN and a higher sensitivity of the HPV test than 
thc otlHk. In one ·\tersion of the model, the calculated mortality reduction from 
HPv'-screening was· higher and the (cost-)effectiveness was much better than for 
PAP smear screening. In the otl1er version, outcomes wer€ the opposite, although 
the. cost-effectiveness of the combined HPV+ cytology test was close to that of ~AP 
smear screening. 
Although sm_all follow-up studies and studies wit.h limited strengthof design suggest 
t.hat. IIPV testing may well imprave cervical eaueer screening, only large longitudinal 
screening studies on the association between IIPV infection and the developmént of 
neoplasias can give outcomes that would enable a firm condusion to be made on 
the ( cost- )effecti\•cness of HPV screening. Prospective studies should addtess wamen 
aged 30-60 years. 
Acknowledgemei?-t This study was financcd by the Dutch Health Insurance Courr-
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9.1 Introduetion 
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:Moleculat and ep'ïdemiological studies have clearly demonstratcd that HP\' is 
the main risk factor for ccrvical eaueer pot, 21.t). These epidemiological stud-
les are case-control studies that consistent.ly show a very Iligh-risk ratio for 
HPV in \vomen with (precursors of) een•ical eaueer compared with controts 
with negative eytology 1146, 149, 66, t83J. The association between CIN and high-
risk HPV infection is stronger in high-grade than in low-grade abnonnalities 
{3o, 11, t31, 76, to9J· and is well over 90% in invasive eancers J3o, 2a1. A few small 
follow-up sttJdies also corroborate the Crudal role of HPV infections: progre~­
sion is found almast only in wamen with (persistent) high-risk HPV genotypes 
bath in normal [1so1 and in dysplastic cases (95, 174J. In a small retrospeetive 
study on archived falsc-negative smears from women with subsequent invasive 
cen•ical eaneer, the high-risk HPV types found in the cancers \vere dctected in 
· nearly 100% of the preceding smears [2o7J, 
On the other hand, test-positive ratcs for high-risk HPV types in wo men over 30 
years of age ·with normal cytology in North American and western European 
countries vary from 3% to 6% ft49, 15, 53, t8oJ. This is much higher than ean be 
explained by the life-time risk of developing een•ical eaueer in these eountries. 
For example, in the Netherlands, the rate for high-risk IIPV types in woman 
aged 30+ with normal cytology is armind 4%, while the cumulative risk for 
invasive cen•ical eaueer is around 1.5%; the risk in women aged 30+ with 
normal cytology is again much smaller. Therefore, only a fraction of the 
infections with high-risk HPV types ~vill progress to cervical cancel'. .. 
The goal of this study was to incorporate the very high observed HPV-associated 
risks ratios in a cen•ical cancCr screening Tnodel and to investigatc the con-
sequences for IIPV screening as expressed in predicted rnortality reduction, 
negative side-effects and casts. The outcome of the follow-up studies CaJTied 
out to date ha.ve been incorporated in the model in so far that HPV infections 
were assumed to preeeed HPV-infected neoplasïas. They were nat used for the 
quantifieation of the model as these studies were small or interpretation in 
quantitative epidemiological terrus was limited by thcir design. The possible 
impact 1 however, will be discussed. The present study fücusses on the quest.ion 
of whether re~ommendations a bout HPV screening can al ready be made on the 
basis of the available data and, if nat, what type of data will be required to 
deercase uncertainty. 
9.2. lo.·!a.terials and methods 
9.2 Materials and methods 
9.2.1 The data 
Test-positive rates for high-risk HPV types in women between the ages of 30 
and 60 years were estimated on the basis'of empirica! data. Polymerase chain 
reaction (PCR-)bascd HPV-positive rates on cytological material of the cervix 
from womcn with negative cytology are 4% in the Netherlands i"'i, 5. 7% in 
Portland, Oregon, USA i"l, and 4.6% in Spair1 i"'l. PCR-based HPV-positive 
rates on cytological material of women with a histologically confirmed diag-
nosis of CIN ar~ 71% in Spain. and 54% in Colombia i"'l, 75% in the USA i"'l, 
72% in the UK i"l and 59% in the Netherlands i"l. HPV rates are higher in 
high-grade than in low-grade lesions. Noting that the reportcd results are 
of the same order of magnitude, we summarized them by assuming 4% HPV 
positi\7eness in cytologically ne"gative wamen qnd 67% in wamen with CIN. On 
the basis of the worldwide study on histologicàl material of Bosch et al 1"1, 
we assumed that 95% of the invasiv~ carcinomas 'vere HPV infected, i.e. only 
5% of invasive cervical cancers developed without being preceded by an HPV 
infection. In accordance with the results of th_e Dutch study·fl41l, HPV-positive 
rates are assumed to be constant between 30 and 60 years of age. 
9.2.2 The model 
Here, the relationship betw~en HPV and cervi_cal cancer in a stoellastic microsim-
ulation screening model is described. HPV in the model rc·presents high-risk 
HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 54, 56, 58, 59, 66, 68). As 
shown in Figure 9.1, the model is basecl on thc hypothesis that the onsct of 
HPV infections found in invasive cervical cancer and in CIN has preeerled these 
ncoplastic stages: ':Vamen who go through an HPV infection either beCome 
clear from the infection or develop HPV-infected GIN, which either reg'resses or 
progresses into HPV-positive invasive cerVical ca neer. 'Vqm~n can a lso develop 
GIN withoUt an flPV infection, and this CIN again can regrcss ar progress (only 
sometimcs, see later) ·into invasive cancer. Allowing fór the possibility tha_t 
women can dcvelop CIN (with or without HPV) after having becomc clcarfrom 
HPV infection would Causc a shift between the several anus in the model, with-
out affccting the model outcon\cs presented ln tilis ar'ticlc; therefore we did 
not complicate the model in this marmer. This model is an eX.tcnsion of a 
validateel cervical"canccr sc1:eening PAP smear model tus, 119, toJ. 
Accordh~g to this model, the average duration of GIN is 11.8 years and pre-
clinical invasive eaueer is 3.9 yeai·s (see Table 9.1). The sensitivity of thc PAP 
smear is 80% in CIN and 87.5% in preclir~ical invasive carcinoma. These esti~ 
m~tes on durat.ion and sensit.ivity were derived from tbc British Columbia 
(Canada) screening data !t69J and 'vere compatible with data on interval can-
cers collected by thc IARC!too, 161J. The incidence of progressive GIN was cho-
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Figure 9.1 Tl1e stages and possible transitions in tlw HPV to CIN to invasÎ\'e 
cervical eaueer model. The discase stages tllat describe non-neoplastic conditions, 
and tl1at ha\'C been addcd to tlw validated CIN to cen'ical cancer model, have been 
slladed 
CIN + HPVIll 
95% ofthe invasive 
cervical cancers 
lnvasive cervîcal 
ca neer+ HPV !SJ 
5% o(the invasive 
cervical cancers 
sen to reproduce cervical cancer incidencc and. mortality in the Netherlands 
between 1965 and 1992. The regressi011 rate was 72% of disease onset under 
35 years, 40% between the age of 35 and 54 and very low in women aged 54 . 
and over. These estimates resulted from subtracting progressive CIN from the 
age-specific CIN detection rates observed in the Dutch population 1"'1. When 
ad ding HPV infection to the model, the part descrihing CIN and invasive cervical 
ca neer was kept unchanged; the predicted CIN and ccrvical. cancer incidences 
and prevatences were not affected. Consequently, previous validations are still 
valid. The incidence in the Dutch population accounted for is lower than inci-
dences, for example, in the UK and the USA (7.8 and 12.9 per 100 000 for the 
Netherlands and the UK respectively, in 1978-1982 1"'1 and 9.9 in thc USA 
in 1985 (16sJ). The.incidence level however did not iriftuence the comparison of 
screening strategies. 
9.2.3 Two Inodel versions 
Because only cross-sectionat HPV data were available for the quantification of 
the model, there was an identification problem for the parameters descrihing 
HPV infections. Test.:.positive rates in wamen screened for the first time a.re a 
result of incidence x duration x sensitivity. In view of this non-identifiability, 
we decided to_" construct two model quantifications that were contrasting in 
9.2. lvfaterials and methods 
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Table 9.1 Parameter values in model versioiJ A and B on the duration of 
detectable preçlinical stages- and the sensitivity of the HP\f test for these stages 
Dm·ation of stages '(ye_ars) 
HPVl11 that will develop into CIN+HPV 
HPV(2] that will be cleared 
CIN (with or ,Vithout HPV)(3](4] 
Invasive cancer (with or without -HPV)l5H6J 
Sensitlvity of HPV test (%) 
HPVI1li2l 
CIN+HPVI3l 
Invasive cancer+HPV[5} 
Model version A Model version 8 
IO 
1 
11.8 
3.9 
100 
!DO 
100 
IO 
11.8 
3.9 
50 
80 
87.5 
[ 1 Refer!' to the numbering of the diseÇtSe stageS in Figure 9.1 
HP V-screening outcomes. 'Ve varied duration and · sensitivity and adjusted 
the incidence level to the observed test-positive rates for HPV. The Jonger 
the duration of progressive (to GIN) HPV infections (stage HPV[l] in Figure 9.1) 
and the higher the sensitivity of tlre Hrv test, the more effective HPV scree;ning 
will be in reducing cel'vical cancer ·mortality. In order_ to minimize the neg-
ative side-effects (i.e. follow-up of HPV-positive wamen who wiJl not develop 
· ce1:vical neoplasia), it is- favourable to assume a short duration of harmless 
(non-progi·essive) HPV infections (stage HPvl21 in Figure 9.1). 
In model quantification A (see Table 9.1}, the extra duration of the detectable 
preclinical phase because of HPV detection was assumed to be 10 years. The 
assumed sensitivity for HPV was 100% at all stages. Long duration and high 
sensitivity made model version A vcry favourable for HPV screening. In version 
Bof the modei, the detectable preclinical phase was only 1 year Jonger than in 
PAP Smear screening, and sensitivity for high-risk HPV types was considÊ!rably 
lower than in version A. In HPV-infected neoplasia stages, sensitivity óf ~he 
HPV test was equal to the sensitivity of the PAP sniear (80% in HPV-positive 
CIN and 87.5% in HPV-positive invasive cancer}, and sensitivity w~s only 50% 
in IIPV infections without neoplasia. Compared with model A, model B was 
very unfavourable for HPV screening. The consequences of the two sets of 
assumptions for the sensitivity of the test (ar combination of tests) are given 
in Table 9.2. 
As a result of differences in sensitivity of the HPV test, the HPV test-positive 
ra te of scrapes in invasive cervical cancer cases was (100% s~nsitivity x 95% 
invaSive cervical cancers with preceding HPV infections =) 95% in model A 
and (87.5% x 95% =) 83% in model B. A high ra te is in accordance with some 
PCR stüdies on cytological material ofwomen with invasive cervical cancer (up 
to 100% 1"1), but a Jower rate has been found in other studies (e.g. 84% 1"1). 
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Table 9.2 · Sensitivity by test (o1· combination oftests)1 stage and model Yersion 
· resulting Erom the val u es [or sensitidty of tlw HPV test ghren Îl! Tablc 9.1 
Stages Any_ model version Model version A Model version B 
Cytotogy Cytology HPV Cytofogy HPV 
Olily + HPV only + HPV only 
HPV[l](2] 0 100 100 50 50 
CIN + HPV{3] 80 100 100 96 80 
CIN(4J 80 80 0 80 0 
Invasive caoeer + HPv[5) 87.5 100 100 98.4 87.5 
Invasive cancer[6] 87.5 87.5 0 87.5 0 
[ 1 Refers to thc numbering of the disease stages in Figure 9.1 
9.2.4 Simulated compared with observed HPV test-positive rates 
In both model versions, predicted HPV test-positive rates in the age group 
30-60 years was 4.01% in wamen with nègative cytology and 67% in wamen 
with C1N. 
9.2.5 Consequences of ti-ue-positive test res~lts 
In tlie simulation, 'Vamen with only negative tests at screening had a futUre 
screening·after the regtllar screening interval. \Vamen with positive cytologY 
were foliowed up and in true-positive cases this led to the detection ofneoplasia. 
\Vom:en 'Vith a negative PAP smear and a positive HPV test were assllmed to 
be foliowed up with HPV tests and PAP smears every six months. This follow-
up stopped either when the HPV infection was cleared ( after which wo men 
. go back to screening) or when there was a transition of the HPV infection to 
HPV infected CIN (the neoplasia is detected). Detected CIN was assumed to 
he managed sû that no invasive eaueer would develop. For the management 
of CIN (diagnosis, treatment and after treatment check-ups), we accounted 
for 4 years of follow-up. This ·was in aecordance with eurrent praetiee in the 
management of CIN, at least in the Netherlands !tal. 
9.2.6 Consequences of false-positive test results 
Wo men with borderline (Ascus) or low-grade abnormalities intheir PAP smears 
in the Netherlands, and also in many other countries, are foliowed up with 
repeat smears. Some of these women have negative repeat smears and are 
referred back for routine screening. Wamen with high-grade abnormalities in 
their PAP smears are referred to the gynaecologist. In a proportion of these 
wamen, no neoplasia is found. As the model was adjusted for histologically 
confirmed detection rates, these so called 'false-positive' cytological outcomes 
have to be accounted for separately. We made the following assumptions: 
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Table 9.3 Assumptions on tlle cost:'> by type of procedure, in Dfl 
Procedure Costs Costs in the 
sensitivity analyses 
Screening PAP smeara 70 
Repeat PAP smeara 100 
HPV testa 90 
PAP smear and HPV test in one screening sessiona 135 
Follow-up session in HPV-positive wamen with negative cytology 140 
Diagnostic work-up of the referral when na neoplasia is found 800 
Management of CINb [13] 3 100c 
Curative primary treatment 
microinvasive carcinoma 
IB invasive carcinoma 
11+ invasive carcinoma 
Care for advanced disease 111] 
9500 
20200 
19100 
30700 
45/155 
90/200 
280 
a Including Dfl 25 in tata! for casts for càrrying out the smcar/scrape and the casts for 
the wamen (time a.nd transport, (ns] 
b ·crN with or without HPV infection 
c Including the casts of 15% recurrcnce of disease aft er primary treatment of CIN 
Fiveper cent of the screening smears generated two_ repeat smears in wo men 
that did not have neoplasia 
Fiveper 10 000 screened women without GIN were referred to the gynaecol-
ogist lt6-tJ 
9.2.7 The casts of screening 
In order to .account for the costs and savings of early detection, the costs of 
screening, follow-up, diagnosis and treatment were considered (sec Table 9.3). 
The true resource costs were assessed fÜr the screening PAP smear, the HPV test, 
colposcopy and radiotherapy. Costs charged in the Netherlands for the other 
'medica] procedures were used. The costs are presented in Dutch Guilders, for 
which the US$ exchange rate during 1995 was, on average 1.61. 
9.2.8 Screening strategies 
In both model versions, the effects and casts have been calculatcd for several 
screening strategies for women between the ages of 30 and 60 years. We made 
predictive calculations for 3-yearly cytology and for six alternative strategies. 
'Vithin the.se alternative strategies 1 we considcrcd two screening test (or com-
bination of tests) and three screening schedules. The screening tests were: 
cytology plus HPV test and HPV test only. In the three screening schedules, 
wamen wer~ screened between 30 and 60 years of age: every 3 years (11 screen-
ings per woman), every 5 years (seven screenings per woman) and every 10 
years (four screenings per woman). 
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9.2.9 The cost-effectiveness calculations 
Calculations were made for a cohort of women ":ho attended all screenings. 
Effects, costs and savings of the screenings were accounted for from birth to 
death. Outcomcs were presentcd per 1000 women ai-Id have not been dis-. 
counted. 
9.3 Results 
9.3.1 Mortality reduction, years in follow-~p and cost-effectiveness 
The model predictions of the main effects and costs of the different combina-
tions of frequency and types of screening tests are summarized in Tab/e 9.4. 
For each of the two model versions and for ~ach of the two alternative screen-
ing tests (cytology plus HPV test and HPV test alone), only the pólicy with the 
lowest screening frequency that had the same or higher mortality rednetion 
compared with 3-yearly PAP smear screening is presented . 
. . According to the model version A, which was favourable for HPV~screening, the 
combined test (cytology plus HPV test), even if performed only once every 10 
years, reduced mortality more (9l% vs 79%) than 3-yearly Pi\P smears. Costs 
were 37% lower, mainly because of the less frequent screening, and costs pet 
life-year gained decreased by 41%. The number ofyears in follow-up was 26% 
lower, and the years in follow-up per life-year gained decreased by 27%. For 
10-yearly screening with thc HPV test only, mortality rednetion was a lso higher 
than for 3-yearly cytology and only a little lower (89% vs 91%) than for the 
combined test. The costs for HPV only were very low, only 31% of the costs of 
3-yearly PAP smear screening. Casts pc,r life-year gained wen~ 69% lower. The 
number of life-years spent in follow-up was less than half (because the repeat 
smears of the borderline cytology do not occur in screening for HPV), and this 
also counts for the number of life-years in follow-up per life-yeat: gained. 
The results of model version B, which was unfavourable for HPV screening, 
were quite different. Combined screening performed every 5 years yielded a 
slightly higher mortality rednetion (80% vs 79%, it was predicted at 77% with 
10-yearly combincd screening) than screening \Vith cytology every 3 years, and 
was 63% more costly, resulting in 60% higher costs per life-year gained. The 
. number ofyears in follow-up were 2.5 times higher, as were the numbcr ofyears 
in follow-up per life-year gained. In the predictions for screening with the HPV 
test alone, even a 3-yearly interval did not. result in a mortality reduction as 
high as with 3-yearly PAP smear screening (the 1 year extra detectable phase 
for which sensitivity is 50% is outbalanced by the 5% progressive lesions that 
are not detectable because they are HPV negativc). Costs per life-year gained 
and years in follow-up per life-year gained were 1.8 and 2.6 times as high 
respectively. 
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Table 9.4 l\1odel outcomes: effects and costs of different screening polides in 
nromen between 30 and 60 years of age, two model versions. OnJy the least frequent 
HPV screening strategies witl1 the same or lligher mortality reduction compared to 3-
yearly PAP smear screening are presented. All figm·es are Per 1000 women screened, 
except for percentages (in brackets) 
Any A B 
model version model version model version 
Cytology Cytology HPV Cytology HPV 
only + HPV only + HPV only 
3-yearlya 10-yearJya 10-yearlya 5-yearlya 3-yearlya 
Favourable effects 
Mortality rednetion (%) (79) . (91) (89) (80) (76)b 
Life-years gained (%) 65 (88) 68 (93) 66 (90) 66 (89) 62 (85) 
Unfavourable effects 
Years in follow up 700 520 290 1760 1790 
Casts (in Dft X 1000) 
Screening 650 460 300 800 830 
Fellow up of HPV-positive cases 60 60 361 470 
Fellow· up of false positive cytologyc 95 35 0.2 65 1.5 
. DiagnOSis and treatment 
CIN !80 120 80 170 140 
Invasive and advanced. cancer ~!90 -220 ~210 ~195 ~185 
Tata! costs 740 460 230 1200 1250 
Ratios (per life-year gained) 
Years in follow-up !1 8 4 27 29 
Casts !1400 6800 3500 18300 20100 
a At primary screening interval 
b Using the HPV test only, according to model B, one would have to screen more frequently 
than 3-yearly to result in at least the same mortality rednetion as 3-yearly cytology 
c At screening.and during follow-up of HPV-positive cases 
Basedon the model version A calculations, a decision might be made to replace 
PAP smear scree.ning_ with HPV screening with a long~r interval. This woulel 
lead to a greater mortality rednetion at lower casts in terms of resources and 
·negative side~effects. However, the model version B calculations suggest that 
PAP smear screening should nat be rep la eed by any of the stuclied HPV screen~ 
ing strategies; cûsts and negative side-effects increased, while prevention of 
mortality did nat improve. 
9.3.2 Sensitivity analyses 
':Ve also calculated the costs of IIPV screening assuming that HPV-positivc 
wamen with negative cytology would be foliowed up every 3 years instead of 
every 6 ·months. The resulting total casts of HPV screening were lower, in 
106 Cllapter 9. Present e\rjdence on HPV screening 
_____ ____. 
Table 9.5 Sensitivity analysis: casts per life-ycar gaincd with. alternative cost 
assumptions, as percentage dUferenee witl1 tlw costs per life-j.rear gainedof 3-yeárly 
cytology 
Any A B 
model version mqdel version model version 
Cytology Cytology HPV Cytology HPV 
o'nly + HPV only + HPV only 
3-yearly 10-yearly _ 10-yearly 5-yearly 3-yearly 
. Baseline cost assumptions0 11400 6800 3500 18300 20100 
-40 -70 +60 +80 
Alternative .cost assumptionsb 
IIPV test, Dfl 45 -60 -90 +25 +20 
IIPV test, Dfl 155 -10 -40 +llO +160 
HPV follow up, Dft 280 -30 . -60 +110 +l<IO 
a HPV test Dfl 90; HPV follow-up, Dfl 140 
b These changes in assumptions do· not affect the casts per life-year gained of 11400 of 
3-yearly cytology 
· particular according to model B in which cost-effectiveness of the combined 
test was dose to the cost-effecÜveness of PAP smear' screening. However, less 
intensive follow-up in HPV-positive wamen would, with CUlTent knowledge, not 
be an acceptable option. 
Economies of scale play an important role in the casts of an HPV test .. Our 
estimate was basedon a situation with, on average, 12 000 PCRs per year per 
laboratoi·y. If the testing was concentrated in fewer laboratories, the test 
would become cheaper. :Morcover, new developments can cause an increase 
or decrease in the casts of routine HPV tests. Therefore, ·calculatioils .were 
rèpeated under the assuinption that the Iabaratory casts per IIPV test of D11.65 
were iess than one-third, i.e. Dil 20, or doubled to Dil 130. The total casts per 
test, ineluding the Dil 25 for carrying out the smearfscrape consequently will 
be Dil 45 and Dil 155, respectively, for the HPV test and Dil 90 and Dil 200 
for the combined test (PAP smear + HPV test). In our basic calculations, a 
follow-up session for HPV-positive wamen was restricted to an .HPV test and a 
PAP smear. We repeated the calculations with twice the casts per follow-up 
session (Dfl 280 instead of Dfl 140). This would be approximately the casts 
incurred when a colposcopy is added. 
The results are summarized in Table 9.5. Option~ that were more cost-effectivc 
than 3-yearly PAP snrear screening remained more cost-effective and those that 
were less cost-effective also remainedless cost-effective. The conclusions were, 
therefore, not affected by considerable changes in the assumptions about the 
casts of HPV screening. 
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9.4 Discussion 
We produced two model versions that b.oth explained tl1e .high observcd risk 
ratios for high-risk HPV types in wamen with cervical neopla~ia compared with 
wamen with normal cytology. In addition, they were both compatible with 
the 'clearance, rates in repcated i-II;V tests observed in wamen with normal 
cytology. In model A, this clearance resulted from a short duration of harmless · 
HPV infections. In model B, the low sensitivity of the HPV test explained why 
woman that were HPV positive·at a fitst screening willaften be HPV negative 
at the next one. The effects of HPV screening predicted by thc two model 
versions widely differed. Hence, the high-risk ratio~ alone were inconclusive 
for the outcomes expected from HPV screening. 
The flrst non-cross-sectiorialevidcnce for the crudal role of high-risk HPV infec-
tions for the deyelopment of cervical cancer i1as been found in observational 
follow-up studies. These studies show only progrcssion to high- grade neo-
plasias in the presenée of (persistent) HPV infections. This concerns wamen 
with nornial ttsoJand abnormal {95, 1741 cytology. Alth\mgh the~e studies are 
very important for showing that IIPV infection precedes the (progression of) 
neoplasia, they are toa small {tso] or have an inadequate design [95, 1741 för assess-
ing the duration between HPV infection and the development of CIN, and the 
sensitivity of the HPV test. Nevertheless, they suggest that the sensitivity 
for. progressive HPV infections is high and, in that respect, theJi- support our 
. favourable model version A more than the unfavourable model B. Th is support 
emphasizes how worthwhile it is to carry out the rcquired large prospective 
studies on the association between HPV and cervical neoplasia that hopefully 
will confirm the 'preliminary' findings. 
The presented diseasé model has a number of simplifications. It does, for 
example, not discm·nlow-grade on high-grade pre-invasive lesions, while HPV-
negative CIN catmot become HPV positive. These simplifications, howcver, are 
not important for the results, and model refinements will be of litt]e help as 
long as adequate longitudinal data on HPV Jeteetion are not available. 
The results of the cost-effectiveness calculations concerning the polides that 
cOmbine HPV testing and PAP smear screening are complex and their anteomes 
could not have been predicted easily. For the calculations concerning polides 
using only the HPV test, it is not surprising that when ·it takes 10 years for HPV 
infe.ctions to produce CIN, HPV screening can imprave PAP smear screening. 
This is clearly not the case when HPV infection preeed es CIN· changes only by 
1 year. But it is important to realize that these widely different assumptions 
are both compatible with the observed very strong association between HPV 
infection and·cervical cancer~ even if it is accepted that the HPV infection pre-
eerled the ncoplastic changes that led to the invasive carcinomas. The work 
of Jeukins et al (l03J, who also assessed the effectiveness of HPv testing as a 
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Figure 9.2 Simulated results of a hypotlietically obsermtional study using 
model A and B: age-specific llistologically confirmed CIN detection rates at PAP 
smear screening in wamen who 5 years prel'iously l.1ad pad a negative PAP smear, 
by HPV status 5 years prel'iously and age group at present screening 
Model A 
" 
" 
Model B 
I 
§_., 
i 
~ 
J 
u 
lHI 
• 5 years previously: cytology -/HPV+ 
o 5 ye~rs pr~viously: cytology -/HPV-
.,. 
... 
9.4. Discussion 109 
primary screening tooi by usii~g a steebastic model, illustrates this issue. The 
authors did not vary the parameters that are crudal for the outcomes. They 
used assumptions 0~1 t.he sensitivity of the IIPV test that were vcry sim~lar 
to those in our model version A. In the sensitivity analysis, thc simu.lated 
screening·situation was further improved (by assumiág that 100% of the can-
cers develop in the presence of high-grade HPV), but lower sensitivity was not 
tested. As far as duration is concerncd, Jenkins' assumptions are intermediate 
to ours. Although the authors agreed that selection of the progression param-
eters ( which determine the duration of stages) was not unique, they did not 
vary the progression rat~ of HPV infection and thcreforc did nat dcsc"ribe thc 
complete range of possible ( cost-)effectiveness of I!PV screening. 
To explorc thc· impaCt of ·Iongitudinal data, wè simulated an observational 
cohort study with the two model versions A and B. In the simulation, wamen 
who entered the study with negative cytology have a PAP smear 5 years later. 
Pre~iicted CIN detectiqn rates in wamen who at entry were IIPV negative and 
those who were HPV positive were discerncel (see Figure 9.2}. As the descrip-
tion of cervical neoplasia ( CIN and invasive ccrviçal cancer) of the model was 
the same in both model versions, the detection rate for CIN at PAP smear 
screening 5 years after negath'e cytology was the same. In version A, how-
ever, almast 70% of the wamen with histologically confirmed CIN (low and 
high grade) came from previously HPV-positive wamen, whereas in model ver-
sion B this was only 20%. This reflects a higher predictive value for Juture 
CIN of a positive HPV test in version A. The fact that longittldinal m1tcomes 
. clearly differ in both moelels means that different longitudinal outcomes can 
be consistent with present cross-sectional data, and that, once such longitu-
dinal data are .available, at least one (and probably both) of moelels A and 
B can be rejected. The range of cümbinatiöhs of parameter values on dura-
tion of HPV infections and sensitivity of the HPV test that are compfttible with 
observed data will strongly dect·ease, and better predictions can be made of 
i'esults expected from HPV screening. 
Although the cross-sectional data showastrong association between I!PV and 
cervical neoplasia, the results are insu~cicnt to arrive at recommendations 
on screening. The discussion, therefore, on the represcntativeness of the test-
positivo rates that we aimed at in our simulation ( 4% in cytologically negative 
women, 67% in wamen with GIN rind from 83% to 95% in \vamen with inva-
sive cervical cailcers) is premature~ Nonetheless, it is interesting to assess 
the influence of lower or higher observed HPV test-positive rates. In wamen 
· with invasive canccr, the higher HPV positiveness, the better this will be for 
the effectiveness of HPV screening. Higher test-positiye rates in women with 
normal cytology and in wamen with GIN, however, can only mean that more 
wamen who qo not develop cervical cancer will-be' HPV positive (all women 
that will devclop HPV-positive cervical eaueer are already assumed to be HPV 
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positive befare the development of the cancer). These women will unneces-
sarily be detected and followed up, and the negative side-effects and cost of 
follow-up will increase. In otl1er w6rds, given that HPV infection precedes, 
for example, 95% of the progressive neoplasias, lower HPV prevah:~nce in the 
cytologically negative wamen and in wamen with CIN _ implies less harmless 
and less costly !IPV screening. 
A modelling approach, as presented in this paper, is useful for a joint armlysis 
of cross-sectional, longitudinal and other relevant epidemiological data. We 
will adjust our model as sooil as new evidence becûmes available. 
Data from large PCR-based cohort studies will accumulate in the forthcoming 
years. The fa ct that many of them are solely focussed on young women should 
he of major concern. The Gapenhagen study [1°91 is restricted to wamen under 
30 years of age, and the median age of the women in the Poitland study is 34 
years {HiJ, Screening for HRV in very young wamen would cause many wamen 
to be followed-up (because of the high prevalenee in this age group of HPV 
infections that will clear} and is therefore not advisable. Moreover, the fact 
that prevalenee is sa much higher in younger age groups is also an exprcssion 
of a different natura! history of the HPV infect i ons (at least a higher clearance 
rate) in this age group. Follow-up results from these women are obviously not 
transferable to tlre older age groups. Hence, further cohort studies should aim 
at women aged 30-60 years. 
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Discussion 
In- this chapter, I will first integrate and complete some important discussi9n 
points raised in the previous chapters. Subsequently I will discuss priorities 
for further research. 
10.1 Effects, side-effects and cost-effectiveness 
10.1.1 The effectiveness of cervical eaueer screening 
The implementation of routine cervical cancer screening was not preeerled 
by randomized controlled trials. Hence, there is no unbiased direct evidence 
indicating that scréening leads toa reduction in mortality. Effect assessment 
has to be based on evidence from non-experimental data, implying a rela-
tively broad range of uncertainty. \Vithin their limitations however, sonie 
· non-experimenta:I studies have provided convincing evidence that screening 
has redtleed the level of incidence [toa] and mortality lt26l of cervical cancer. 
V/e predicted the effects of screening by using à simulation model comprising 
all relevant aspects of cervical cancer screening. The natura! history and 
sensitivity parameters used in the predictions resulted from an analysis of 
screening data from British Colombia lt59J and have been valida.ted with the 
IARC data on cancers after negative PAP smears [t6lJ. 'Ve stuclied whether these 
estinlatecl parameters were compatible with the incidencc and mortality trend 
in the Netherlands (Chapter 6). In this analysis, we corrected for the fact 
that in the Netherlands, as in other countries [s2, 126, t6J 1 mortality had already 
decreased before screening( effect) started, maii1ly because of a decreasein risk 
in successive cohortsof wo men born between 1920 and 1940. Extrapolation of 
the effects of this decrease only partly explained the observed downward trend 
in mortality in the perioei after·screening started. \Vhen the reduction from 
screening as predieteel with our model was added, the predieteel downward 
trends in incidence and mortality were similar to the observed trend. 
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Sceptics about the effectiveness of cervical eaueer screening aften- refei' to the 
situation in thc United Kingdom especially in theseventies and eighties. How-
ever, there are two spccific explanations for non-clecreasing or even increasing 
mortality rates in thc Uniled Kingdom. Flrstly, the UK cervical ca neer screen-
ing programme experienced serious organizational problems at least until the 
late eighties !51. Secondly, the risk forcervical eaueer had been rising in wamen 
barn after 1935 [1ea, 47J. :rvlortality in \Vamen barn around 1951 was a bout twice 
as high as mortality in those born around 1941. Such a marked mortality 
increase in young cohmts was mainly seen in England and VVales and in some 
allied couutries (Scotland, h·eiand, New Zealand and Australia). It is much 
less pronounced in many other countries, e.g. the former Federal Republic of 
Germany, Finland, and the Netherlands 1"1. In contrast with the situation 
in the UK, the highest estimate for achieved mortality rcduction (60%) was 
made for Finland, where women were screened between the ages of 30 to 55 
every 5 years sin~e the mid-sixties [96J, 
It is questionable whether we can expect stronger evidence in the future on 
the effectiveness of cervical eaueer ·screening than has been available to date. 
The current evidence is strong enough to make randomized trials camparing 
screening no screening- unethical. After more than 25 · years of widespread 
screening, it will become more ànd more difficult to disentangle sáeening 
effects from otlter cffects. 
10.1.2 The starting age for cervical eaueer screening 
It has been argued that screening in the Netherlands should start at an earlier 
age than the recently officially recommended 30 years. Arguments put forward 
to support this view include the following: 
The relatively high histologically confirined deleetion rates for high 
gra~e CIN under age -30 years it63J, However, detection rates are of limited 
value: it is quite possible that higher deleetion rates in young age are caused 
by higher prevalenee of regressive lesions [t59J, 1\1oreover, since cervical cancer 
has a long pre-invasive phase, most of the cases will also be detected in time if 
screening starts at age 30. 
The cm-rent incidence peak in age-group .35-39 (see Figure 6.3d}. 
Here, the question is to what extent the current incidence peak in the age 
group 35-39 results · from an increased underlying risk of cervical eaueer in 
young bit·th cohorts, or whether it results from a decreased incidence (caused 
by screening or other factors) in middle-aged (40-69 years) women. Frorn 
camparing pre-screening incidence data with. the recent incidence data {see 
Figure 6.3a and 6.3d}, it can be conchicled that a decreasein incidence in the 
age-group 40-69 has been much more important than an increased incidcnce 
in women under age 40. 
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Moreover, it shoul,d betaken intó account that in the Netherlands, mortality 
from cervical eaueer is still much higher in older than in younger age and 
does, contrary to tlie incidence, notshow alocal peakaround age 40 years (see 
Figure 6.3e). The lower ratio ofmortality to inciderice in younger than in older 
age, also in the prescreening perio&, is an eXpression of the fact that overall 
clinical survival in young age is better than in older age. This means that 
mortality rednetion resulting from prevention and early detection of invasive 
cen•ical cancers will be larger in older age than in younger age. 
The increasing incidence and· mortality rat es in young birth cohorts 
in otlter countries [16, 47, 49, 55J, However, as mentioned in. the Previous sec- · 
tion, the magnitude ofthe increase observed in.the countries referred to (UK, 
New Zealand, Australia) is notgenerally observed in West Europear!and North 
American countriesr and also nat in the Netherlands [16J, 
10.1.3 Side-effects of screening 
Whenever medica! procedures are applied, there will be side-effects, some of 
which are unfavourable. A full evaluation of health effects con.siders both the 
aimed-at effects and the side-effects. In cervical eaueer, the primary goal is 
mortality reduction. That is why life-years gained were taken as the effect 
nle~sure for ·cost-effectiveness in this thesis. The frequency of sidC-effccts bas 
been quantified and discussed (see Chapter 2 and 3). We concluded that the . 
ratio of unfavourable to favourable effects becomes warse when the frequency 
of scree.ning iS increased and when screening is concentrated in young age. But 
until now, we have used casts per life year gained.as the cost-effectiveness ra ti~, 
and this measure does not include side-effects. I will tentatively now iiiclude 
other effect measures in the cost-effectiveness. These other effect measures are 
related to quality of life. The net health effect·of screening can be obtained by . 
correcting the life years gained for changes in the health-related quality of life. 
Therefore, all types of effect should be quantified and expressed in a common 
measure·. One methad to _achieve a common me~surc is thc quality-a_djusted 
life-years analysis. In this type of analysis, health states are valued after these 
states have bem) measured (described). The values or utilities should reileet 
the average willingness of individuals to, trade off quality against quantity of 
life. There are no reports of such measurcment and valuation in literature 
conc€rning health states produced or prevented by cervical cancer screening. 
I have therefore used outcomes of quality of life rneasurernents f9r health states 
related to breast eaueer screening performed by de Haes at al. in 1991 ["1 to 
explore the favourable and ad verse effects in quality of life of cervical cancer 
screening·. 
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10.1.4 Side-effects of screening: tentative calculations 
Thc main unfavourable effects of cervical eaueer screening occur in wamen 
who require repcat smears, wamen referred far colposcop)',)md otl1er diagnos-
tic procedures, and wamen treated far pre-invasive conditians. The current 
number of women referred and treated is higher than the figures in Chapters 
2, 3 and 5 which werc based on data fron'.t the seventies and cighties, when 
follow-up was less intènsive (see the Appendix of this thesis). Fora more up 
ta date assessmcnt, we calculated the expec~ed number. of wamen fallawed. up 
and treated from recent (1994 !><!) .cytological and histological detection rates, 
accounting for the newly revised follow up guidelines in the Netherlands. We 
combined these figures with the incidence and mortality reduction predicted 
with our model (see Chapter 7) for the recently revised screening age range 
(30 to 60 years) and screening interval (5 years), assumed 75% attendance, 
no opportunistic screening, and 5% borderline screening results·(after which 
wamen are advised to have repeat smears). The resulting ratios betw~en the 
expected unfavourable effects and the expected beneficia! effects are as fol-
lows: per preventeel death, 2800 wamen have a screening Cxam; 140 wamen 
have a periad of repeat PAP smears, 70 wamen are referred far calposcopi_-
calfhistological evaluatian, and 30 wamen are treated far preinvasive cervical 
neoplasia. But an additional beneficia! effect of two prevented cases of inva-
sive cervical eaueer can also be expected for each death prevented. Because 
the estimated average gain in life expectancy is 26 years per death prevented, 
the numbers per life year gained are 26 times lower (see leftmost column of 
Table 10.1). 
In the calculations presented here (sec Tab/e 10.1 and Table 10.2),' the loss 
in utility resulting from cervical cancer screening attendance was assumed to 
be the same as that assessed far in breast cancer screening attendancc, but it 
was applied for a period of two weeks (instead of one week for breast cancer 
screening), since this is the usual time interval befare receiving the PAP smear 
result. Th is same disutility was applied to a period of one year aftcr a positive 
smear in which wornen have (half) yearly repeat smears. This is in accordance 
with the guidelines that iniply that it takes on average one year before wo men 
either return to regular sCreening or are referred far colposcapy. 
The disutility (and its duration) caused by referral for colposcopical/ histo-
logical evaluation, were assumed equal to those for the diagnostic phase aftcr. 
a positive mammography. For the treatment of pr~invasive cervical neoplasia, 
the loss in utility was assumed to be the same as for primary surgical treat-
ment of breast cancer, but the duration of this loss was adaptcd: 2 äays in the 
case of an out:-patient trèatment procedure (cryocoagulatian or loop excision), 
1 month for conisation and 2 months for total hysterectomy, that resulted in. 
a weighted average of 2 weeks after accounting for the observed fractions for 
either treatment as prescnted in Chapter 4. 
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For the primary and palliatiye treatment and for the terminal phase of invasive 
cervical cancer, the disutility and the duration·of conesponding breast cancer 
states were used (see Table 10.1}. The calculations are expresscd in termsof 
how much quality loss and quality gain respectively is obtained per life year 
gained by screening. . 
The resulting tentative assessment of the quality of life impact shows a net 
lossin quality of life which corresponds to 16% of the gain in quantity of lifc. 
After discounting at 3% per year, thc net loss increascs to 26%, conesponding 
to a 35% increase in the cost-effectiveness ratio. Using a 5% discount rate, 
the loss in quality of life equals 44% of the gain in life years. This stronger 
impact of quality of life correction at the higher discount ra te is due tothefact 
that unfavourable effects occur in the period immediately after screening, and 
therefore are much less affected by discounting than the beneficia! effects, 
According to these tentative calculations, the disutilities with thc largest 
impact for the quality of life adjustment are the disutility of having bien-
nial repeat smears aftera mildly abnormal PAP smear, the long term disutility 
after a hysterectomy for the treatment of C!N, and the long term ga in in utility 
because ofless life-years with (treated) invasivecervical cancer. Applying 0.6% 
disutility tbraughout a one year period with one repeat smcar half way and 
one .more at the end might be an oVcrcstimation of the anxiety. The disease-
free years aft€r a hysterect"omy for CIN and those after primary tre~tment of 
invasive cervica1 cancer h~ve both been ~eighted equally to tlu! disease-frcc 
yeai·s after mastectomy for treating breast cancer. Factors that play a role 
here are ànxiety over possible recurrence; the impact for wo men of ha ving lost 
the uterus or a breast respectively, and possible kmg term physical problems 
after surgery and/or radiotherapy. Accounting for all these factors, one woulel 
expect the long term burelen of hysterectomy for CIN treatment to be on a vet~ 
age less severe than the long term burden of mastcctorlly for breast cancer 
treatment, and also less than the long term burelen of radical treatment of 
cervical cancer. To weight hysterectomy for CIN treatment as equal to radical 
ccrvical cancer treatment therefore overestimates thg loss in quality of Ufe. 
CmTent PAP smear screening in the Netherlands differs unfavourably from the 
assumptions_made in the above calculations in two respects. Firstly, although 
the coverage in 1994 was iudeed approximately 75%, the total number of 
preventive (as opposed to follow-up) smears was armmei 30% higher than in 
our calculations because many smears additional were tak~n in relation to 
the targeted age-range and interval (14J. Extra smears in symptomless wamen 
will increase the negative side-effects of screening considerably more than the 
benefits (see Chapter 2). Secondly, repeat smears (taken for reasous othcr 
than because of inadequate quality) wcre advised after 10% of the screening 
tests instea cl of the assumed 5%. 
116 Chapter 10. Discussion 
----------------------------------
Table lO.i Ji tentatÎ\'e correction for tlw quality of life impact per lifc year 
gained in eerdeal eancer screening (Erom age 30 to 60 e\'ery 5 years), using quality 
of life values for llealtll states induced and pre\'ented by brcast eaueer screening by 
de Haes et al [nJ(see Table 10.2). No discounting 
Number 
per life year 
Quality 
adjustment in 
years per life 
State gained* Duration I-Utility year gained 
Screening attendance 106 · 2 weeks 0.006 . -0.024 
Period with repeat smears 5.3 
Colposcopical/ histological evaluation 
0.471 
2.122 
1 year 
5 weeks 
Primary treatment for pre-invasive cervical neoplasia 
0.421 2 weeks 
0.642 
0.006 
0.105 
0.133 
First year after primary treatrhent for pre-invasive cen•ical neoplasia 
0.421 1 year 0.006 
0.642 
Period after total hysterectomy for pre-invasive cervical neoplasia 
2.313 All .life-ye"lns 0.053 
Bfte~ hystuec· 
tomy 
Primary treatment of invasive cervical cancer 
Micro invasive (IA) 0.01 2 months 
Loca1 (IB) -0.04 2 months 
Non-local (II+) -0.05 2 montps 
0.133 
0.133 
0.197 
3 Months - 1 year after primary treatment of învasive cervical eaueer 
-0.032 
-0.005 
-0.021 
-0.002 
-0.003 
-0.003 
-0.004 
-0.123 
-.0.000 
0.001 
O.Q02 
-0.09 10 months 0.156 0.011 
> 1 Yèar after primary treatment of invasive cervical can.cer 
-0.593 All"extra life 0.053 0.031 
Palliative treatment 
Radiotherapy course -0.02 
Surgery -0.03 
Chemotherapy cure -0.07 
Terminal phase -0.04 
Total unfavourable adjustment 
Total favourable adjustment 
Tot al quality of life adjustment 
yeau wilh 
cervicn\ cancer 
1 montlt 0.419 
5 weeks 0.383 
4 mónths 0.469 
1 month 0.712 
The average number of life-years gained per death preventéd is 26 
0.001. 
0.001 
0.011 
0.002+ 
-0.217 
0.060+ 
-0.157 
1 Direct referral after a highly positive (PAP3a mild dysplasia 4-, KOPAC P 2: s, s 2: 6 A 
2: 5, High grade SIL) screening cytology 
2 VVomen with screening cytology results that initially generate a recommendation for 
repeat smears (PAP2 and PAP3a mild dysplasia, KOPAC-P234 c345, A34, ASCUS, low 
grade SIL) 
3 (Extra) life-years with hysterectomy J invasive cervical cancer respectively per life-year 
gained 
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Table 10.2 Rclationship between the Disutility and duration of states used for 
cervical cancer screening in Table 10.1 and tlwse applied for breast eaueer screening 
by de Haes et al rnJ 
State Rel_ationship 
Screening attendance 
Disutillty (0.006) and duration (2 weeks) as assessed for breast eaueer 
screening attendauce 
Period with repeat smears 
Disutility (0.006) as assessed for breast eaueer screening attendance 
applied to_ 1 year after which the wamen either go back to screening,· 
or are refefred 
Colposcopicalf histological evaluation 
Disutility (0.105) and duration (5 weeks) as. assessed for the diagnostic 
phase after a positive mammography 
Primary treatment for pJ;e-invasive cervical neoplasia 
· Disutility (0.133) as assessed for the primary surgical treatment of breast 
cancer, duration (2 weeks) accounting for 2 days in an oui-patient setting, 
1 month for conisatiqil and 2 n10nths for total hysterectomy 
First year after Primary treatment for pre-invasive cervical neoplasia 
Disutility (0.006) as assessed for breast cancer screening altendance 
applied to one year because most recurrencefresidue oecur within one 
year 
Period after total hystereètomy for pre-invasiVe cervical neoplasia 
Disutility (0.053) and duration (all life-years after hystereetomy) as 
assessed for > 1 year after mastectomy 
Primary treatment of invasive eervical caoeer 
Disutility and dur;;ttion as assessed for breast eaueer for primary surgical 
treatment (cervical eaueer stages I~\ and IB) and primary radiotherapy 
(cervical caoeer stage II+) 
3 ~vlonths - 1 year after primary treatment of invasive eervical eaueer 
Disutility (0.156) and duration (10 months) as asscssed for mastcctomy 
> 1 Year aft er primary treatment of invasive cervical caoeer 
Disutility (0.053) and duration (all extra life years with cervical cancer) 
as assessed for mastectomy 
Palliative treatment 
Disutility and duration as asscssed for respective therapies in palliativc . 
treatment in advanced breast cancer 
Terminal phase 
Disutiljty and duration as a·sseSsed for the terminal phase of breast caneer 
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Schematic repn:sentation of tlw l1Caltl1 effects of screening Qy 
increasing smear frequency: tlle quantity of life gained, tlie quality of Jife lost and 
tlw net healtlJ effect for two screening situa~ions (represented by tlJe solid and 
daslied lines respectively) 
• • • many extra smears, very intensive follow-up 
,' 
quantity of life gained , ' 
..... ---- -- ..... - .. ,J------ ... ---
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Smear frequency I costs III=f.IJ 
Accounting for the extra negative side-elfects of both factors, the tentative 
quality of life correction on the life yeai·s gained in the calculations presented 
in Table 10.1 would become 26% instead of 16%. After discounting at 3%, 
this would con·espond to around45%, which would almast double the cost-
effectiveness ratio. This is an underestimation becausc we did nat account 
here for the extra costs. On the other hand, we did not account for the extra 
benefits either, but these are relatively smal! (see Chapter 3 for the discussion 
on tbc extra benefits of preventive smears added to the programme smears). 
Therefore, these figui·es stress the importance of the reducti9n of extra pre-
ventive smears and of balanced follow-up guide)ines for beneficia! and efficient 
screening. 
The tentative calculatieins presented here suggest that fora restricted screen-
ing situation with seven smears per wamen, littlc ex_tra preventive smcars and 
no more than 5% borderline screen results, the total health benefits of cervical 
cancer screening in the Netherlands would clearly exceed the total harm. They 
also show that for a lcss restricte·d practice as was carried out in the first half 
of the nineties, the harm in relation to the benefits rnight be substantial. 
Figure 10.1 is a graphical represcntation of the relationship between health 
effects of Screening and the fr_equency of screening. Line I represcnts the quan-
tity of life gained (e.g. the number of life years gained). This line corresponds 
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with the line through the efficient polides in Figure 1.1 in Chapter 7. Line II 
represents the relationship between the loss in quality of life and the frequency 
of screening. Line lil represents the net health effects, and results from sub-
tracting line i I from line I. Sirree the unfavourable qtw\ity oflife effects increase 
more or les·s linearly with increasing frequency of screening, while the gain in 
length of life levels off; the unfavourable effects will exceed the beneficia! ones 
at some frequency of screening (point A). The level at which the inet·emental 
net health effects from increasing the frequency of screening becomes .negath~e 
(point B) then has already been passed. All policies to the right of point B are 
. inadmissible. The crudal level from a cost-effectiveness pOint of view is the 
one where the extra casts of increasing the screening frequen_cy will become 
too high in relation to the extra net health effects (for exarnple at point C). 
The tentative calculations presertted above suggest that for the Netherlands, 
point A willnot be reached by screening women 7 times. The dashed lines in 
Figure 10.1 represent the influence of many extra smears and/ or very intensive 
fellow-up on the health effects. These lines show that in trying to maximize 
incidence and mortality rednetion beyend a certainlevel, health effects in fact 
are diminished. 
In. order to make a better estimate of the position of line lil, a better es ti mate 
of the positiàn of line n is required. To this end, cer\'i.cal cancer screening 
impacts on quality of life have to be systematically investigated, with the aim 
of expressing these impacts in quality adjusted life years. 
10,1.5 Of.her recell.t ·cost-effectiVeness studies 
on cervical cancer screening 
In order to trace possible gabs or flaws in our cost-effectiveness analysis, we 
looked critically at differences with ether puplisbed cost-effectiveness studies 
on cervical ·cancer screening. The most important studies and their n~ain 
results are listed and compared to our MISCAN results in Tables 10.3 and 10.4. 
· We will discuss the respecth•e studies seperately below. A summary of the most 
important differences is given in Table 10.4. The studies differ in perspective 
(e.g. some predictions cöncer"n a cohort_ of wamen, others· a population), in 
methodology (e.g. the discount ra te) and in local characteristics (e.g. the 
background risk for cervical eaueer and the costs of medica! procedures in the 
area undcr consideration). 
The background risk of cervical cancer that we derived for the Netherlands is 
considerably lower than in any of the ether studies (see Table 10.4). This is 
partly due.to differences in incidence and mortality befare screening was intro-
duced, \Vhich were higher in e.g. Denmark and the UK than in the Nether-
lands. Another part of the difference is that we found that part of the dGcrease 
in cervical cancer incidence and mortality observed in the Netherlands since 
screening started is nat due to screening and would have occurred · anyway 
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Table 10.3 Results of otlwr cost-effectÏ\'Cness studies on cen'ical ca neer screen-
ing compared to our results. The discount ra te (%) is indicated between brackets 
.. .. .. . . . . . Study ........... .... _ ... Policyi ....... . ........ Results ......... 
Costs per 1'1fe year g~ined (Dfl) 
MISOAN 1993. (Chapicr 7) 7,30-60 (5) 27000 (5%} 6000 (0%) 
Hristova and Hakama 1997 7,30-60 [5) -5000 (0%) 
Gyrd-Hansen et al 1995 7,30-60 [5) . 7000 (5%) 
Eddy 1990 16,20-74 [4) 20000 (5%} 
Number of smears per invasive cervical ca neer case prevented 
MISCAN 1993 (Chapter 7) 7,30-60 [5) 
Sherla,v-Johnson 'et al 1995 16,[8-64 [3) 
Mortality reduction .with 7 smears2 
MISCAN 1993 {Chapter 7) 7,30-60 (5) 
Gusta:fsson and Adami 1992 7'28-66 [var) 
1 Number of smears: starting age-ending age (interval] 
2 Independent of discounting 
250 (5%) 1300 (0%) 
600 (0%} 
50% 
76% 
(compare the dasbed lines in Figures 6.3 ajb with Figures 6.3 dje in Chap-
ter 6). The last explanation for the difference in background risk, is that 
we accounted for the amount of screening that took place in the Netherlands 
before 1993, the first year of the predictions of effects and costs of screen-
ing. The baseline risk in a screended population is ofcourse lower then in an 
unscreened population. 
In Tab/e 10.5, we present cost-effectiveness ratios for the Dutch situation, when 
we adjust the MISCAN model for'the differences listed in Table 10.4. This,was 
carried out to explore to what extend these differences could explain differences 
in predicted cost-effectiveness ratios. A detailed overview ofthe adjustments is 
given in Appendix B. No te that remaining differences in the adjustcd screening 
polides ( age range and intervals) may to Same extend explain or hide remaining 
differences in cost-effectiveness. 
10.1.6 Systematic discussion· of the studies 
Hristova and Hakama 1997 
Hristova and Hákama '!96J estimated .the casts per life year gaiiled for screening 
as performed in Finland· (between age 30 and 60 every 5 years) for the Nordie 
countries. They used the mortality reduction cstimated for Finland on basis 
of the observed mortality trends. The number ofinvasivc cancers was assessed 
at approximately twice the number of dea~hs from een•ical eaueer prevented. 
The number of detected CIS. was assumed to be three times the number of 
prevented invasive eancers. 
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Hristoya and Hakama arrived at negative cost-effectiv~nesS ratio, bccause the 
savings from preventing cancer' cases and death cases were-larger than the 
costs of screening. In our analysis ( and in all other analyses discussed here) the 
screening casts were larger than the savings. The difference is nat explained 
by differences in screening costs, but by a combination of a higher number 
of (advance~) cancer cases prevented and higher treatment casts per case of 
(advanced) cancer in the Nordie study. Fora more detailed comparison, we 
considered the figures the authors presented· for Den mark. The higher effects 
are explained by a higher background incidence (rate ratio 2.4) and a higher 
mortality reduction (90% versus 50%). Also, the savings per invasive cancer 
and per advanced case preventeel are 60% higher. 
The estimated 90% mortality rednetion results from a combination of a high 
estimate of the background risk of dying from cm·vical eaueer and a low 
estimate of the future mÜrtality in sereerred wamen. The estimate for the 
background risk is based on pre-screening mortality data from Denmark, and 
results from the fact that mortality increased from 1955 to 1960 in most age-
groups. Sucb an age-indeperident increase is suspect for a flaw in the data. 
The estimate of future mortality rates in screened wamen are basedon Finnish 
mortality trends after' screening startcd and results from the assumption that 
an increase in mortality rednetion in a sereerred cohort of wamen gocs oit with 
age, whereas one would expect that the mortality reduction levels off. 
The higher the diagnosis and treatment casts per detected pre-invasive case 
for the Notdie countries (DH 8000 versus DH 3500) combined with a higher 
detection rates for pre-invasive discase results in higher casts for the manage-
ment of detected pre-invasive disease .. Hówever, these high casts are almast 
entirely compensated for by the lower unit costs for smears (Dfl 20 for the 
Nordie countries versus Dft 70 for the smear plus DH 6 for false positives for 
the Netherlands) (see Table 10.,(}. Ifwe account for the differences mentioned, 
the ~viiSCAN mOdel will alsb prcdic~ savings forcervical capeer screening instead 
of costs (sec Table 10.5). 
Gyrd-Hansen et al 1995 
Gyrd-Hansen et al!s6J estimated the cost-effectiveness "of cervical eaueer screen-
ing for the Danish situation. The (!isease Ihodel used by Gyrd-Hansen incor-
porated a pre-clinical detectable phase whieh precedes clinical cancer, which 
has a certain duration and for ,vhich screening has a certain sensitiv_ity. This 
model \Vas very simHar to the model used in our study. 
The four times lower costs per life year gained (DH 7,000 per life-year gained) 
can to a high extent be explained by the higher background incidence (factor 
3.4) and a higher assumed attendance (80% vs 75%) combined with no dif-
ference in risk between attenders· and non attenders. If we account fOr these 
differences, our MISCAN model produces a CER of DH 4000 per life year gained. 
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Table 10.4 1Hetlwdology and parameter mlues uscd in the respectÎl'e eerdeal 
cancer cost*effecti\'~ness analyses 
Study 
Country 
~dodelfapproach 
Discounting 
Policy1 
Background risk ratio 
Previous screening 
At tendance 
Relative risk at tenders 
Sensitivity 
Regression 
?vlortality reduction 
MISCAN Hristova Gyrd-Hanson 
Netherlands DenrTtark Denmark 
Population Population 
5% 0% 
7:30-60 (5) 7:30-60 (5) 
•! 2.4 
. Yes No 
75% l 
0.74 NA 
80% 
Yes Yes 
50% 90% 
Population 
5% 
7:30c60 (5) 
3.4 
No 
80% 
I 
? 
Yes 
? 
Casts per screening smear (Dfl} 
Eddy 
USA 
Cohort 
5% 
16:20-74 (4) 
1.8 
No 
100% 
1 
Modelled 
diUerenth· 
Yes 
88% 
Waugh Sherlaw-Johnson 
UK UK 
Population Cohort 
O% 0% 
14:20-59 (3) 16:18-6•1 (3) 
versus 
9:20-60 (5) 
±2 3.5 
Yes No 
l 70% 
NA 1 
J ? 
NA Yes 
-3 -4 
Gustafsson 
(Sweden) 
Cohort 
0% 
7:28-66 (var) 
NA 
No 
75% 
J 
Yes 
75% 
Screening smears 70 20 71 
? 
? 
152 Costs "'"' not indud.,d in the analyxex 
False positives 6 J 
Management of CTN .8 80 
Savings per invasive cervical cancer case prevented (Dfl) 
Initia! therapy 19000 53 0002 ? 
Cost.~ per advanced caoeer prevented (Dfl) 
Advanced eaueer 31000 ? 
J 
? 
34000 
44000 
76 
J 
24 0002 
1 Number of smears: starting age- endlng age (interval in years) 
2 Medica! casts per invasive case 1 ii1cludîng treatment for advanced cancer in some of the 
wamen. For the Netherlands we predicted one case_ of-ad vaneed Cancer per 2.2 cases of 
invasive cancer, and the conesponding tot al casts are Dfi 33 000 
3 8% Incremental mortality reduCtion of 3-yearly vs 5-yearly screening 
4 64% Incidence rednetion 
1 Lacking information in the publications consulted 
NA No Assumptions 
A more detailed comparison between this Danish mo.del and ours was not pos-
sibie because of incomplete information on this moeiel in thc English literature. 
Thc assumed duration of pre-clinical discase and the .sensitivity of the smear 
for this disease phase werc not given. However, the model predieteel the IARC 
rates for int~rval carcinomas fairly well and so does our model ft6tJ. Hence 
we do not expect important differences in the prevention of invasive cancers. 
The total clinical survival was similar to ours. The survival in screen-deteeteel 
invasive cancers seems to be higher in thc Danish assumptions, but since the 
number of screen-deteeteel ·cancers is low in ccrvical cancer scr~ening, this will 
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Table 10.5 Tlle cost-effectivencss mtio calculated from the MISCAN predictions 
adjusted for t!Je differcnces (see Table 10.4) between tlw rcspectÎ\'e studies and our 
analysis. For ~!!SCAN we present predictions for tlle policy (sec Table 7.8) that was 
ciosest to the policy in tlle other study. Parameters adjusted for are tl1e background 
risk, tlw mortality reduction and the costs. Tlw discount rate (%) is indicated in 
brackets. The details of the adjustment are gil'Cll in Appendix B of this tlwsis 
. . . . Other studies .... . ............. MISCAN .............. 
Study Policyl Results Policyi Unadjusted Adjusted 
results results 
Casts per life year gained (Of!) 
Hristova and Hakama 1997 . 7:30-60 [5) -5 000 (0%) 7:30-60 [5) 6000(0%) -2 000 (0%) 
Gyrd-llansen et al 1995 7:30-60 [5) 7 000 (5%) 7:30-60 [5) 27 000 (0%) 4 000 (5%) 
Eddy 1990 16:20-74 [4) 20 000 (5%) 10:27-72 [5) 28 000 (5%) 21000 (5%) 
lncremental casts per life year gained .J-yearly versus 5-yearly screening (Dfl) 
Waugh et al 1996 14:20-59 [3) 24 500 (0%) 9:30-54 [3) 33 000 (0%) 20 000 (0%) 
versus 
9:20-60 [5) 
_Number of smears per prevented invasive cancer case 
versus 
6:30-55 [5) 
Sherlaw-Johnson et al 1995 16:18-64 [3} 600 (0%) 10:27-72 [5) 
1 Number of smears: startingage- ending age [interval} 
1300 (0%) 
not have a very big impact on the ( cost-)effectiveness. The casts per smear 
were the same (Dfl 71 and Dfl 70 per smear), but the casts offalse positive test 
results (in our predictions Dfl 6 per smear) were not available for the Danish 
analysis (there are 0.62% false positive results, which was less than in our anal-
ysis, but the associated casts wet'e not given). The regression rate assumed by 
the Danish authors is somewhat higher than in our model, but the casts per 
detected CIN/CIS were not given. Information on the savings per invasivc case 
prevented were also lacking. 
Eddy 1990 
Eddy [es] estimated the cost-effectiveness of ccrvical eaueer screening in the 
United States. The author also used a disease model withapre-clinical disease 
- clinical cancer sequence, similar to our model: 
The policy with the lowest number of smears in Eddy's analysis was 16, for 
which the author predicted a cost·effectiveness ratio of Dfl 20 000 per life year 
gained. In. our analysis, the highest number of smears was 10, with an es ti-
. mated Dfl 28000 per life year gained. The cost-effectiveness ratio increases 
with higher screening frequency, indicating that for simHar screening poli-
des the difference in cost-effectiveness will be much more then 40%. We 
350 (0%) 
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will use our predictions for this policy with 10 smears to make a compari-
son with Eddy's predictions in more detail. \\'hen we campare the effects 
and the costs,_ it bccomes apparent that part of the dUferences are masked 
in the cost-effectivencss ratio: both thc effects and the costs are higher in 
Eddy's predictions. Higher effects eau bc cxplained by an assumed higher 
ba.ckground incidence for thc USÁ compared to the Netherlands (factor 1.8) 
and by a higher mortality rednetion (88% for Eddy's model versus 58% for 
MISCAN). This higher mortality rednetion is almast completely explained by 
the fact that Eddy i:onsidered wamen who attcnd all screening rounds and 
assumed that these wamen are·at average risk. The higher cûsts are explained 
by higher costs per smear (DH 152 vs Dfl 76, both including the diagnostic 
costs offalse positives). These higher costs are only partially compensated by 
the higher savhlgs per prevented case with invasive or advanced cancer. The 
casts for diagnosis and treatment of dctected pre-invasive discase were also 
considerably higher in Eddy's calculations (Dfl 11000 vs Dil 3 500). However, 
although Eddy assumed.regression it was not clear how much. Thcrefore the 
total impact of the difference in casts per detected case with a pre-invasivc 
lesion is unknown. If we account for the differences mentioned ( using our inci-
dence of regressive C!N), the casts per life-year gained calculated with MISCAN 
for the policy with 10 smears per wamen are lowcred to Dil 21000. This is 
higher than the Dil 20000 estimated by Eddy for 16 smears per wamen. A 
further differencc between the two moelels is that we accounted for the screen-
ing that took place in the Netherlands in the two decades befare the start 
(in 1993) of the period for which wc made our predictions. Without his his-
tory of screening, our model WC?Uld probably iudeed predict a clearly lower 
cost-effectiveness ratio than Eddy's. 
A difficulty in camparing Eddy's results with ours in more detail is that Eddy's 
predictions concern a cohort of women 1 and not ~ and more realistic - a· 
population duringa defined period of time as in MJSCAN. In partienlar the 
discounting poses problems 1 because it is not clcar from Eddy 1s pubHeation to 
what point in time effects and casts have been discountcd. 
Waugh et al 1996 
\Vaugh et· al [2os, ~o9J estimated the incrcmental casts per life-year saved from 3-
yearly screening compared to 5-'yearly screening at Dfl 24 500. This was based 
on an analysis of the screening history of 24 invasive cases, concluding that 2 
cases would probably have been prevented if the interval would have been 3 
insteadof 5 years. The autors assumed that this éorresponded to one case of 
death prevented. Accounting for the fact that the effectiveness estimate was 
based on two cases only, the authors calculated a 95% confidence interval for 
the CER of Dil 5 000-50 000 per lifc year gained. 
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Waugh et al compared two polides with the same age-range, and consequently 
the policy with a 3-year interval had 55% more (14 vs 9) smears per woman 
than the policJ~ with a 5-year interval. For purposes of comparison, we could 
use the sameapproach in MISCAN, by camparing a policy with age-range 30-54 
years and an interval of3 years {9 smears per woman) toa policy with age-range 
30-55 years and an interval of 5 years {6 smears per woman). Since the authors 
from the UK did not include discounting, we also looked at undiscounted 
results from t-.USCAN. Camparing the two polides mentioned, the-incremental 
costs per life-years gained were estimated at Dfl 33 000 using MISCAN for the 
Dutclr situation. The mortality rednetion increases by 8%, which is equal to 
the 8% incremental mortality reduotion estimated by Waugh et al. The total 
number of lifetime smears is rnuch largcr in \Vaugh's study, and therefore 
one would expect a much higher ir~cremental n~ortality i·eduction than for 
the polides compared by the UK study. However, tlre effects in Waugh's 
study were based on two cases only. Therefore, although the point estimate 
for effectiveness was more favourable, the confidence interval.of the authors 
results easily include our estimate. 
The background inddence in Wàugh's study population was approximately a 
factor 2 higher than we assumed in our calculations. As far as the casts are 
concerned, the .casts per smear (including casts of false positiVe smear results 
and the management of CIN) were Dfl 74 in Waugh's analysis versus Dfl84 in 
ours. On the other hand, the savings per invasive eaueer case prevented were 
also lower {24 000 vs 33 000, both in cl u ding tlre costs of ad vaneed disease). 
After adjusting our model for the differences mentioned, th~ incremental CER 
with at zero % discounting of 9 smears with a 3-year interval versus 6 smears 
with a 5-year interval becomes Dfl 20 000 (sec Ta bie 10.5}. Because of decreas-
ing incremental effectiveness, this incremental CER will become higher when 
we compare exactely tlre same two polides (with 14 and 9 smears) that have 
been considered in Wangh's paper. 
Sherlaw-Johnson .et al 1994 
Sherlaw-Johnson i"'i and colleagues estimated the inddence rednetion and the 
number of smears t:teeded for screening wamen aged between 18 to 64 ycars 
every 3 years {16 smears per woman) for the United Kingdom. To this end, 
the authors used a disease model with a pre-clinical.disease- clinical cancer 
sequence. 
Although wethink that inddence reduction is not the most appropriate effect 
measure f~n· cast-effectiveness analyses, we _are áble to campare these anteomes 
with ours. Fram the predictians the.authars pi·esent (zero discounting), it can 
be calculated that arotmd 600 smears are needed per invasive case prevented. 
Without discounting, th.e number of smears per invasive cancer prevented for 
the Dutch situation and for the policy of 10 smears per women is assessed 
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at 1300. The assumed background incidence in the UK analysiswas 59 per 
100 000 wo men aged 18 and older, which was 3.5 times higher than the back-
ground incidence in our' analysis. The estimated incidence reduct.ion was 64% 
versus 50% in our analysis. But if we calculatc the incidence reduction for 
70% at tendance in wamen of average risk in the Dutch situation, the mortality 
rednetion increases to 63% as well. If we adjust MISCAN for these differences, 
we predict approximately 350 PAP smcars per prevented case of invasive can-
cer, which is lower than the 600 smears predicted by Sherlaw-Johnson et al. 
A lower number is expccted because of decreasing incremental effcctiveness, 
since our predictions concern a policy of 10 smears per woman, and Sherlaw's 
for 16 srilears per woman. 
Gustafsson and Adami 1992 
The study of Gustafsson and Adami [s4J is not a cost-cffectiveness analysis, 
but is nevertheless intm·esting to campare with our analysis. The authors esti-
mated what are effi.cient poli ei es vlith different numbers of smears per woman. 
To this end, they used a disease model with a pre-clinical disease - clini-
cal cancer sequence. The predictions did not focus on an existing population 
although important parameter valüe estimates werc based on SwediSh data. 
The analysis did not include casts or tot al numbers of smears. The outcomes 
which we can campare with ours are the mortality reduction for the efficient 
policy with 7 smears Per wamen, and the ch~ractei-istics of this policy. The 
es~imated mortality reduction of a the optimal p.olicy of 7 smears per woman 
in Gustafsson's analysis was around 75% versus 50% -in our analysis. The 
difference is partly explained by the difference in the assumption of 'smear-
·efficienCy', defined by Gustafsson as the proportion of the prevalent cases 
of pre-clinical dise~se that is eliminated in an invited cohort of wamen, and 
assumed to be 75%. In our model this corresponds with sensitivity x atten-
dance mte x the risk in attenders cornpared to the avemge risk, that is 80% x 
75% x .0.74 = 44% for first smears in a w~mans life, and evenlower in smears 
with a higher rank. The mortality rednetion for an efficiency of 50% and 25% 
according to Gustafsson would be around 60% and 40% respectively. 
In identifying an efficient policy of 7 smears, Gustafsson a lso consideréd poli-
des with variabie intervals between smears. The authors argue that since the 
prevalenee curve for pre-invasive disease shows a peak in young age (around 
35 years) in the situation without screening, it will be more efficient to screen 
with shorter intervals in younger than in older age. \Vhen they optimized for 
the number of cancers prévented, the efficient policy of 7 smears was to screen 
wornen at age 28, 32.5, 37, 42.5, 49, 57, and 66 years. The respective intervals 
are 4.5, 4.5, 5.5, 6.5, 8, and 9 years. The optima! starting and endingages are 
similar to ours (28 and 66 years versus 27 and 69 years). The a11thors report 
that optimizing on life-years gained instead of incidence reduction did not 
make much difference for the charaderistics of optima! policies. \Ve a lso made 
10.2. Priorities lor further researcli 127 
predictions with a policy with smaller intervals in younger than in older age, 
similar to the one suggested by Gustafsson and Adami. Undiscounted, this 
resulted in more· life years gained than the conesponding policy with a fixed 
interval of 7 years, but with a 5% discount ra te, the advantage of using variabie 
intervals disappeared. Gustafsson et al optimized without discounting. 
10.1.7 Conclusions 
The camparisou with other ~tudies did not reveal gaps or ftaws in our cost-
effectiveness analysis. In fact it confirmed the comprehensiveness and sound-
ness of our study. Three irnportant features of our analysis were nat present 
in most of the other analyses. Firstly, we accounted for an· autonoh10us trend 
(independant of screening effect) towards a lower risk for cervical cancer that 
continueel after screening started. Secondly, the already relatively low back-
ground risk for cervical cancer in. the Netherlai1ds was further reduced in 
our calculations because we assumed that only 75% of the population would 
attend, and that the non-attending women as a group were at a higher risk 
than attenders. Thirdly, we accounted for the fact that when the predictions 
. start the population is already screened to a certain extent, resulting in a 
lower prevalenee of pre-cli,nical disease and thus a lower base-line risk for eer-
vical cancer. As a result, the mortality rednetion in the total population and 
the number of life years gained in oi.tr predictions are modèst, and the cost-
effectiveness of cervical cancer Screening estimated for the Dutch situation was 
less favourable than the other estimates for other countries. 
The comparison made shows that cost-effectlveness results should be inter-
preted with caution. Large differences may occur ·nat only because of true 
differences in epidemiûlogy of cervical cancer, the screening policy evaluated 
and the cast of screening and trcatment of cervical caricer, but also because of 
methodological differences between studies .. 
10.2 Priorities for further research 
10.2;1 Optimization of follow-up strategies 
The ongoing tre'nd towards more acth•e follow up of (very) mild cytological 
abnormalities is of major co~cern. In the Netherlands in the seventies, cyto-
logical PAP class 2 was considered to be a negative outcome, not needing any 
follow up ''·-'."1. In the eighties, it was stated that a PAP 2 result should 
be foliowed ·by a repeat smear after one year 120SJ, Recently, it was decided 
at a national level that the repeat sinear should be made at an interval of 6 
montl1s {59J, Si mil ar trends l1ave occurred in otl1er countrics !169, 1:21. 1:24, 63, 31, 74J, 
Consequently, the proportion of wamen referred for at least cytological follow-
up ( and after flirther cytology sametimes also for colposcopy) has increased 
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Table 10.6 Rates·of positive smears (i.e. smears witll a follow-up addce other 
than regulat screening) in different pcriods ( excluding smears of inadequate quality). 
Country In the early days of screening Recently 
Norway Ostfold, 19_60-1968 [169) 0.6% National data, 1972-1994 (21] 5.5% 
USA ~ .. "Iassachusetts, 1975 [63] 0.2% Me Neil, 1995 {t39J 3%-10% 
or higher 
Netherlands Utrecht, 1982 (178] 0.8% National data, 1994 (14] 10% 
strongl!Y over the last decades from less than 1% in the sixties to 5%-10% in 
recent years {see Table 10.6 ). 
Nowadays in medicine in general, and certainly also -in (cancer) screening, 
major changes in diagnostic or treatrnent procedures must be supported by 
solid evidence for its (cost-)effectiveness, preferably frorn randornized con-
trolled trials. No such evidence has driven the intensification of follow-up 
strategies. The unfavourable side-effects of follow-up have nat been described 
\veil, although this could be remedied by collecting long term and complete 
follow- up data. Most probably, unfavourable sicie-effects increase with more 
intensive follow-up. Assessment of the extra benefits of more acth'e follow-up 
is less easy. Ideally, randomized trials could measure differences in mortality, 
or at least in incidence. But the incidence rate of invasive cancer in women 
with low grade cytological abnormalities intheir PAP smears is very low for any 
of the alternative follow-up strategies. Study populations of hundred thou-
sands of wamen with abnormal smears would be required. Such large studies 
would nat be considered. In the USA, a randomized trial (the ALTS-trial) is 
currently taking place, iilYestigating the effects of different follow-up strategies 
for smears with ASCUS (atypia of squamous cells of undefined significance) and 
lmv grade SIL (sqmlmous intraepitheliallesions) (t.39J. However, for financial 
and other reasons, it was not possible to use decreasein clinical cervical eau-
eer or mortality as effect measures. lnstcad, a surrogatc endpoint has been 
chosen, missed detection of high grade SIL, which makes the interpretation 
of the results very problematic. Same strategies are more likely to miss less 
high gradc SIL than oUters. Even if one assumes that this neceSsarily incurs 
a rednetion in cancer incidente and mortality, it will remain uncertain as to 
how many (deaths from) cervical cancer will be prevented. Possibly, after 
extrapolation of the extra detection of high grade SIL to extra prevention of 
eaueer and death, even the upper-hand ofthe confidence interval for the incre-
mental benefits of intelisifying the follow-up may result in an unfavourable 
cost-effectiveness ratio, thus rejecting the intensive follow-up strategy. Such 
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an a na lysis would be importanttostop further intcnsification of thc fellow-up. 
It will nat however provide an estimate of what could be an optimal follow-up 
strategy .. 
In the Netherlands, we wil! usc the data retrieved from the PALGA (with a high 
national coverage of eervical eytology and histology over thc past 10 years) to 
perfarm a dcseriptive study of thc fellow up praetiee and its outeomes. This 
will, at least for the Dutch situation, show the long-term conscquences for 
wo men (in terms .of numbers of repeat smears and biopsies etc., llumbers of 
years in fellow-up) of the fellow-up practiee. These non-experimental data are 
not appropriate for answering the question on the differences in effectivencss of 
different fellow-up strategies: anteomes (e.g. eaueer ratcs during fellow-up) 
may be (and probably are) biased bceause at least part of the variatien in 
intensity of fellow-up is nat random with respect to outeome. Wamen with 
more intensive fellow up, by self selection and by the physicians selection, 
probably as a group do not have the same risk for cervical eaueer compared 
to wamen with less intensive follow up. Again, it cannot be excluQed that 
an analysis would provide a minimum for the incremerital casts per life-year 
gained by intensifying the follow-up that is so high that the appropriateness 
of intensive fellow-up should be seriously questioned. 
Meanwhile, studies have begun startcd to investigatc to what extent HPV-
detection performcd on a cervieal scrape could solvc the problem of the fellow-
up of 'borderline' smears (sec the paragraph 'human papillama virus (HPV)' 
bclow in this chapter). It is hoped that wamen with boi-dcrline cytology but 
a negative HPV-test would nat requirc follow-up othcr than further screening 
after the regular screening interval, and that only wamen with persistent pos-
itive tests for high risk HPV-types nccd referral for colposcopy and biopsies. 
Wc await the results of these studies. 
10.2.2 The influence of screening on quality of life 
For estimating the total effects of screening, it is necessarj to assess the inftu-
ence of the various positive and negative side-effects of screening on the qual-
ity of life. This influenec is nat wel! known. Same work has been publisbed 
tm. "'·"[,but in order to assess the casts per quality adjusted lifc ycar ( QALY) 
gaine~, which is a more complete measure for the balance between. benefi~s, 
negative si de effects and casts than the cost per life ycar gained, more thorough 
quantification is requircd. In a previous seetion ('Side-effcets of screening') of 
this chapter, I uscd crude approximations on the basis of utilities asscssed for 
hcalth states produced and saved by brcast eaueer screening. It is·important 
to determine values for quality of life specially for hcalth states relatcd to 
Cervical cancer screening. 
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10.2.3 Computer-aided screening 
Improving 'the test-characteristics of the cyto-morphologic evaluation of the 
smear could lead to a higher sensitivity without increasing the false positive 
rate or to a higher specificity without losing sensitivity. Automated patten1 
recognition has become a serio~s option over the last decade, and several sys-
tems for computer aided e~raluation of PAP smears have been developed and 
tested 1"1. A new methad for cytological evaluation is usually initially tested 
in rescreening studies on Series of smears enriched with positive cases. The 
results of such studies on e.g. PAPNET, one of the computer aided cervical 
smear evaluation systenls, are encouraging, but of limited value when routine 
screening is concerned, because of biases whic.h are inherent in these experi-
ments ( Chapter 8). One study on larger series of smears with a more or less 
routine mixture of negative and positive smears has been published Jll3J and 
others are in progress. The results will provide a better estimate of the per-
formance (both in terms offalse negatives and false positives) of PAPNET and 
other computer-airled screening techniques. 
A long with estimates for the decrease in casts because of time-saving for the 
cytotechnicians, and estimates for the increase of casts because of the technol-
ogy used, this should provide insight into the cost-effectiveness of these new 
techniques. 
10.2.4 Human Papillama Virus HPV 
After HPV infections have been found to be strongly associated with the pres-
enee of CIN and invasive cen•ical cancer in cross-sectionat studies {149, 183, t4a, 66J, 
attention has been focused on HPV-detection as a poSsible discriminatot between · 
hannless and pre-caneerous neopla.stic morphological changes J124J. It has 
also been suggested that HPV-screening could be used in primary screening. 
Almast all (95% or more} invasive cen•ical cancers are HPV-infected [141, 26J, 
The hypothesis is that only a smal! fraction of the invasive cancers develop 
without ha ving been preceded by an IIPV infection. This is corroborated by 
longitudinal epidemiologie studies on pre-invasivedisease Jt8o, 95, t74J, Cross sec-
tional data also ~how that only a small fraction of the infections with oncogene 
HPV genotypes are foliowed by the development of invasive cervical ca neer. In 
the Netherlands, the prevalenee of oncogene IIPV is rel~tively high (at least 
10%) in young (age <30 years) wamen, and much lower (around 4%) after 
the age of 35 years 1'"1. This decrease in prevalence, and the fact that the 
life_-long cumulative risk for having cervical cancer diagnosed in the situation 
without screening is around 1.5%, shows that most of the HPV infections are 
cleared and not foliowed by progression to cancer. The cmTent hypothesis is 
that an HPV infection is a necessary but nat sufHeient step in the cascade of 
events that leads to invasive cailcer, in other words that cervical cancer is a 
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Table 10.7 Possible designs for longitudinal studies on t.lw effects of HPV-
screening in combination witll PAP smear screening 
........... Type of study .......... . . ........ Effect-measure ........ . 
la Observational tetros[lective high grad{l: CIN 
lb Observational retrospective invasive cen•ical caoeer 
2a Observational prospective high grade CIN 
2b Observational prospective invasive cervical cancer, only pos-
sibly in meta-analySis, powe.r prob-
ably not sufficient 
3a Intervention, prospective high grade CIN 
randomized 
3b Intervention, prospective invasive cervical caoeer, only pos-
randomized sible in meta-analysis, power prob-
ably not sufficient 
rare complication of HPV infection [14oJ. The exploration of the possible role of 
HPV.:.detection in poptdation based c;ervical eaueer scrceniilg as presented in 
Chapter 9 is based on this hypothesis. In this scenario, HPV-positive wamen 
are foliowed-up until the HPV infection is dcared or cervical intraepithelial 
neoplasia has developed ( and is then treated). The exploration shows that, 
from a cost~effectiveness point of view, the cmTC~lt data do not give clear évi-
dence fo.r or against HPV-screening. Only further longitudinal data can give 
the information required: how long befarehand eervieal eaueer is preeerled by 
~:m HPV infection and what is the sensitivity of an HPV-test in a eervical scrape 
during this period. 
In Table 10. 7, various alternative designs. for longitudinal studies for further 
evalû.ation of HPV-screening are displayed. One 2a typestudyin wo men over 30 
years of age has been published ''"i. In this study, the relativerisk of developing 
CIN 3 within 3 years aftera negativc PAP smear was significantly higher in high 
riSk HPV. positive women than'in negative wamen, with a point estimate of 116 
times (95% CI 13-990). The total number of cases however (7 GIN 3 cases) 
is too small to allow for a ( cost-)effectiveness analysis of HPV-scrcening, so 
larger studies are required. Conclu~ive information a bout the cffectiveness of 
HPV-screening c·an only be attained if invasive cervical cancei· is the effeet-
measure. In a prospective study (2b and 3b type studies), this would require 
a study population of hundred thousand of wamen and a fellow-up period 
of s.everal years. Thcrcfore, research is eurrently focused on the testing of 
archived smears from cases with cervieal eaneer (and smears of controls) for 
IIPV (ib type studies). This is another way of investigating to what extent 
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invasive qucinomas have been preceded by detectable HPV infections. The 
results of two retrospective studies so fm-' have been published. Chua and 
Hjerpe found 60%· of smears to be HPV-posit.ive on average 4 years befare 
diagüosis ofinvasive ccrvical canccr in30 cases vcrsus 11% in the agc-matched 
controls i<>J. Walboomers at al. reported 96%-100% of smears to be HPV-
positive in 24 falsc negative smea1:s made on average 2.4 years before. the 
diagnosis of invasive Cervical eaueer in 16 cases (207J(no matebed controls). 
Befare implcmenting HPV-teSting on a rcgular basis in a population screening 
programme, fmther information is also needed concerning the acceptability, 
the feasibility and the outcomes in a real life situation. This can only be 
accomplished in an intervention study. For these questions, a 3a type study 
design is sufficient, and a number of this type of studies is under way: studies 
are· (planned to be) undertaken in the Nordie countries and in the Netherlands, 
in which wamen with negative cytology and wamen· with 'borderline' smear 
results are foliowed-up by HPV-tests in the intervention arm and not (negative 
smears) Ür by repeat smears (borderline smears)_in the non-intervention arm. 
Studies type la are a lso underway, and may provide a link between type 1 and 
3 studies: to cmnpare the expected yield of high grade CIN, on the basis of the 
findings in the retrospective observationalla type studies, with the observed 
yield in 3a type intervention studies. 
~vleanwhile, there is hope that an effective HPV vaccine will be developed (73, 2011, 
If indeed IIPV infections have a conditional role in the etiology of cervical 
cancer, and if a vaccine at low cast becomes available, vaccination could replace 
early detection. In countries where already mass-screening for cen•ical cancer 
is practised, starting with vaccination would possibly mean that screening can 
be phased out when cohortsof wo men that became sexually active before the 
vaccination started have become older than 60 years of age. 
10.3 International and national perspective 
10.3.1~ International perspective 
The con.clusions of this thesis, which are summarized in the m~xt chapter, are 
basedon an analysis' of important international datasets and extrapolation of 
the results of this analysis to the Dutch sltuation. In principle, this can also 
be clone and tosome extent has been done for other countries (sec paragraph 
'Other recent cost-effectiveness studies on cen•ical cancer' above). The fo1low-
ing general conclusions however can be made: the coverage of the screening is 
the most important factor for the ( cost-)effectiveness of screening; more than 
se\•en smears per \voman in a cervical cancer screening programme is only 
reasanabic from a èost-effectiveness point of view if the background risk for 
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cervical cancer is much higher than in the Netherlands or if financial consider-
ations are different. When the number of smears is indeed restricted to 10 or · 
less, a braad age-range is more important than a short ( <5-7 yeai·s) intervalj 
extra (opportunistic) smears outside the target age-range and frequency have 
an ad verse effect on th_e cost-effectiveness of screening. 
Even if the nation al authorities are a ware of these conclusions and their impli-
cations, thc prq~lcm is implementation in daily practicc. Th~s particularly 
holds for the intensity of screening. As far as the interval between subsequent 
screenings is concerned, it seems that there is a favourable international trend 
to less frequent screening. As far as the number of women followed up_ is 
concerncd, this number until now has only iücreased. 
In a situat_ion with a centrally erganizeel screening programme with aü invita-
tional system, it is already difficult to control the screening practice. It wil! be 
even more diflkult in a situation with only opportunistic screening. Part of 
the problem in both situations is that many professionals (in partienlar gen-
eral practicioners, gynaecologists ahd pathologists involved) are afraid, also 
because of possible law. suits, t.o 'nJiss' cases. Good· management of cervical 
eaueer screening requires ·a coqsensus between these professionals, and offi-
cial quality assurance guidelines to back up the physicians. These guidelines 
should have legal status in order to prevent law suits threatening the quality 
of screening. 
10.3.2 Ongoing evalaation of the Dutch·national progr;>mme 
Cervical eaueer scr-eening needs close. evaluation, because screening practice 
can easily becorne ineffective or inefficient. In 1991, the Dutch Govermnent 
decided that complete cvaluation of_thc national cervical cancer screening pro-
gran~ma should be conditionat for th'e programme to be continueel [t92J, -Since 
then, major efforts have been put forward to amelioi·ate the data collcction 
and registration. As a result, a much more complete evaluation Is ah'eady 
currently possible. The maiq remaining data problems are the lack of reliable 
information on the reason why the smear was taken (i.e. was the smear taken 
as a screening test or because of symptoms?), and the fact that the identifi-
cation of individuals in PALGA (date of bhth, the first four caractel-s of the 
name at bii·th, and gender) is not 100% unique and sametimes combines two 
or more wamen in one identification Code in the registration process. 
iVIain Enraluation issues that have to be addressed are coverage of the wamen 
(most) at risk, the amount of screening outside the targeted age-range and 
interval, the intensity and completeness of follow-up, and the quality of the 
Smear taking and of the cytologie evaluation of smears. 
Sice its in"ception, cervical cancer screening has been mm'c intensive than pre-
scribed in official guidelines. The relatively high prevalenee of pre-invasive 
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neoplasia in young wamen and the occurrence Ofinvasive cancers at young age-
was an incentivetostart screening earlicr in a woman's life. The occmTence 
of interval cancers pusbed clinicians to shmten the screening interval and/or 
to intensify the follow up strategy. These mechanisms, that can result in more 
harm than good, make close monitoring particularly important. 
11 
Conclusions 
In the introduetion ( Chapter 1), se ven crudal questions have been put forward. 
The results of the analyses dealing with these questions have been presented 
an,d discussed in the respèctive Chapters. The_ answers will be summ"arized 
bere. 
1 Is cervical eaueer screening effective in reducing mortality? And if 
so, how large are the beneficia!' effects ( rednetion in incidence and 
mortality)? 
For the Netherlands in the early nineties, mortality reçiuction as ·a result of 
·screening actlvities since the early 1970's is estimated at about one third of 
total cervical cancet' mortality (Chapter 6), thus preveilting around 150 eer-
vical eaueer deaths and 330 cases of invasive cancer- anmially. For the new · 
programme with 7 screenings between the ages 30 and 60, and assuming 75% 
attendance, the mortality rednetion is predicted. at approximately 50%. For 
wamen at tending all 7 screens, thê risk of dying from cervical ca:ncer is red u eed 
by 75%. The main reasou f0r nat attaining 100% in regularly attending wo men 
is the incidence afterage 60, foliowed by false negative test-rcsults, incidence 
under age 30, and fast growing tumors. 
2 How large are the unfavourable health effects of cervical cancer 
screening? Are they outweighed by the beneficia! health effec.ts? 
Befare consiclering cost-cffecti~eness, it must be clear that the net (benefi-
, cial minus unfavourable) health effects are positive. Fora programme in the 
Netherlands with limited screening' evcry 5 years between age 30 and GO, the 
unfavoutable effects can be estimated as follows: per prevented death and 
two pre.vented cases of invasive cervical cancer1 2800 wamen have to attend 
a screening;'140 wamen will have a period of repeat PAP smears 1 70 wamen 
will be referred for colposcopical/histological evaluation, and 30 wamen will 
be treated for preinvasive cervical neoplasia. Using ~entative weighing factors 
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for the beneficia! and unfavourable effects, the quality of life effects represent 
a net unfavourable effect that valnes about 20% of the life years gained (see 
Chapter 10). 
Limited screening here means that no preventive sme(_lrs that are addîtional to 
the official age range and interval schedule are taken, and that of all screened 
wamen only 5% will have borderline smear results (requiring repeat smears). 
When screening is less limited, as in the early nineties, and under a wide range 
of plausible weighing factors, the beneficia! health effects renmin larger than 
the unfavourable ones, but the impact of the unfavourable effects on the net 
health effects may be considerable. 
3 Under what conditions is cervical eaueer screening cost~effective? 
For screening wamen seven times between age 30 and 60 every 5 years in the 
Netherlands, the estimated casts per life-year gained are Dfi 28 000. For the 
optima! policy with 7 screenings per wamen, screening every 7 years from age 
27 to 69, the estimated casts per life-year gained are Dfi 25 000. In a situation 
with limited sCreening (7 smeárs per wo men, no opportunistic screening, a lim-
ited amount offollow-up), the casts per quality of life adjusted life year ( QALY) 
gained, tentativeiy accounting for the unfavourable side-effects, are up to 35% 
higher. These casts per iife-year or per QALY gained are still within the iimits 
of what generally is considered acceptabie in the Dutch health care system .. 
The incremental cost-effectiveness rap.idely becomes more unfavourable with 
every next smear per woman added totheseven sereens policy (Chapter 7), 
. and with an increasing amount of opportunistic screening and more intensive 
fóllow-up of borderline smears (Chapters 3 and 10). 
4 Wbat screening age range and in~ervals sbould be ebasen from tbe 
viewpoint of cost-effectiveness? 
If seven smears are to be offered per woman, optimal screening (in terms of 
casts per life year gained) starts between 25 and 30 years, ends between 65 and 
70 years, with an interval between subsequent sereens of a bout seven years. If 
morethanseven smears are offered, the interval can be shortelled accordingly. 
For any number of screns it is very important to maintain a braad age-range, 
and adapt the screening interval accordingly (Chapter 7). 
5 What follow-up strategy after non-negative smears sbould be eba-
sen from the viewpoint of cost-effectiveness? 
Since the introduetion of screening three decades ago, there has been an impor-
tant trend towards more follow-up after non-negative smears. The differences 
in casts and unfavourable side-effects between follow-up strategiescan be esti-
matod from long term and complete follow-up data from daily practice, but 
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more research. still neecis to he clone. The differ~t-lces in benefi~ial effects are as 
yet unknown because they are very difficult to estimate. Therefore, the ques-
tion on optimal follow-up strategies is unresolved, and ~ priority for further 
research. 
6 Should cervical cancer screening he continued? And what changes 
should he recommended in order to in1prove its efficiency? 
In the Dutch situation, PAP smear cervical eaueer screening could potentially 
prevent 50% of mortality from cervical eaueer at reasanabie casts and with 
acceptable unfavourable side effects. Somet.imes however, physicians and 
. at tending wamen reason and act as if the aim of scre€ning is to minimize the 
risk of interval ca.ncers at all costs. This results in ari inefficient and probably 
harmful practice of screening \vomen under the target starting age, screening 
wo men more frequently than according to the target interval, and following up 
a high proportion of the screeüed wamen. R~striction of these practices is nec-
essary. Furthermore, increasing the coverage of the target population would 
increase effectiveness and imprave the balance between benefits, negative side 
effects, and costs (Chapter 2). 
7 Should new techniques, like automated cytological evaluation of 
cervical smears or HPV-detection in cervical scrapés, be added to 
or replace conventional PAP sn1ear screening? 
Drawbacks of PAP smear screening are the high casts of screening all wamen 
e.g. seven times during their life-time, and the unfavourable side-effects caused 
by follow-up of false-positive test-results and by the detection of non- progres-
sive conditions. The effectiveness in wamen who do attend regularly screening 
cannot be much improved. Thus, in order to be useful, ~ew techniques should 
make cervical cancer screening less costly andfor improve its specificity for pro-
gressive pre-caneerous conditions. The potential effectiveness of automatcd · 
an~ HPV-scrcening may be promising, but the casts and unfavourable effects 
in a routine screen~ng situation have not been well established sa far. Thus, 
although these techniques are interesting and further research is t'ecommended, 
implementation in routine practice at this moment is·not yet warranted. 
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Overview of differences between 
model versions 
A 
Because of newly available data and further analyses, the input parameters of 
the simulation modelchangedover the years. The '1988 version' of the model, 
described by Habbema et al in 1988 !"!, was used in chapters 2, 3 and 5, the 
'1993 version', described by van Ballegooi jen et al in 1993 1121 in chapter. 7, the 
'1996a version' is described in Chapter 6, and '1996b' is used in chapter 9. 
I wil! describe the differences (the main ones are summarized in TableA.2) 
and discuss their impact on the conclusions. 
A.1 The 1993 version of thè model 
compared to the 1988 version 
For the 1993 analysis we had better age,specific invasive cervical eaueer inci-
denCe dq.t.a at our diSposal, bath fortherecent pcriod and for the pre-Sc,reening 
per~od. \Ve used these incidence data in rnadelling the discase course between 
age-specific incidence of pre-invasive disease and age-specific mortality, where 
in the 1988 analysis only inortality and stage-specific survival data werc used 
{oo, 121. luclusion of these additional data led to three closely linked changes in 
model assumptions: 
1 The stage-specific·dinical survival in the 1988 version did not depend on 
age. But in the 1993 version it decreases from age 30 onwards. This was 
a direct consequence of fitting simultaneously ·age..:specific incidence and 
age-specific mortality data. 
2 The incidence of progressive dysplasia, which was fairly constant 0\,er ages 
in the 1988 version of the model, has a distinct peak in age-group 20 to 30 
years in the 1993 version. This change was made to compensate for the 
influence of step 1. on mortality. 
139 
140 Appendix A. DilTerences between model l'ersions 
Table A.l iHodelversions and·conesponding chapters 
Chapter 2, 3 and 5 6 7 9 
Model version 1988 1996a 1993 1996b 
3 For women under age 35, 83% of all new cases of CJN was assumed to be 
regressive in the 1988 model. Th is percentage was decreased to 72% in the 
1993 model,. to compensate for the infiuence of step 1 on detection rates. 
In 'other words, in the 1993 model version, a higher proportion of the onset of 
CIN at young age was progressive, generatihg more invasive cancers at young 
age but with a higher survival. The effect was that screening in young age 
became relatively more effective in preventing incidence from cervical cancer, 
but not in preventing mortality from cervical cancer. 
Moreover, in t.he 1993 version the risk in the women born aftei' 1938 was 
increased with 10%, and the evàluation concerned 1993-2019 insteadof 1988-
2014, thus decreasing the impact of the older cohorts with a high relative 
risk. 
For the optima! policies, the result was a slight decreasein the optima! age to 
start and stop screening. 
A.2 The 1996a version of the model 
compared to the 1993 version 
In the 1996a model used and described in chapter 6, the risk in womén born 
after 1940 was estimated from the Dutch cervical cancer mortality in these 
bhth cohmts only befare screening started. In the 1993 version ofthe model, 
which was used for predictions in Chapter 7, we al ready calibrated the risk in 
women born after 1940 to the mortality from cervical cancer in recent years 
(see FigureA.l}. Tjlis resulted in a higher risk in the young cohmts in the 
1993 model than in the 1996a model. The reason is that in 1993, we already 
anticipated to the condusion from chapter 6 a bout the risk of the women born 
after 1940, When we will use the 1996a model for predictions to support health 
policy decisions, the risk in the youngest cohorts will again be calibrated to · 
mortality from cervical cancer observed in recent years. 
Furthermore, the refined analysis reported in chapter 6 resulted in a 5-year 
survival of clinically diagnosed cancers in middle ages (50-64 years) that is 
around 15% higher than in the 1993 version. This change is an adaption of. 
the age-dependency of survival introduced in the 1993 model: survival in age-
A.3. Tlle 1996b ''ersion of the model'compared to the 1993 version 
Table A.2 1\tfain changCs in successil;e ''ersions of the model 
Model version Main changes 
1993 Clinical survival age~dependent 
1996a Cohort risks fitted to the pre-screening mortality only. Clinical 
survival fitted to pre-screening mottality fincidence ratio only 
1996b Incidence of regfessive lesions incr~ased to fit more recent data on 
detection rat es of histologically confirmed pre-invasive disease 
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group 50+ was decreased in the 1993 analysis, and this deercase has been 
slightly reversed in 1996. We recognized that to test the model agail)st inci-
dence and mortality trends after screening started, it is appropriate to use the 
ratio between mortality and incidence befare screening Started to derive su.r-
vival of clinically diagnosed cancers. In the 1993 analysis used for predictions 
into the future, we derived survival from recent mortality and incidence data. 
Consequently, screening in young age ill' the 1996a model will become slightly 
less cost-effective compared to the 1993 model. 
A.3 The 1996b version of the model 
compared to the 1993 version 
For exploring the (cast-)effectiveness of HPV-screening (model1996b, Chapter 
9), the 1993 model version was used, except for )'egressive GIN. We increased 
the incidence of regressive GIN up to a level where the detection rates (of 
progressive plus negative GIN) corresponded with higher observed levels in the 
early 1990's in the Netherlands. 
In the 1988 and lg93 model versions, these assumptions were basedon detec-
tion rates from the three pilot cervical ca neer screeningprojectsin the Nether-
lands between 1976 and 1984 (ooJ, and from British Columbia from 1949-1969 
[t69J, The use of these data from a p_erlod with low rcferral rates exf>lains why 
the predicted numbers of wamen referred and treated in the 1988 model (see 
Chapters 2 and 3) and in the 1993 model (results not shown) are relatively 
low. The consequence for the results presented in Chapters 2 and 3 is that-
compared to the 199Gb version- the unfavourable effects are underestimated 
for the present situation and the foreseenth future situation, and for the results 
presented in Chaptci- 7 it means that the casts for the management of GIN are 
underestimated. 
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Figure A.l Tlle relathre cen'ical cancer cohort risks assumed in tl1e successhre 
modelversions (see Table J\.1) used in 'tllis thesis, and tlw calibrated risk, lising the 
1996a model, to tlw mortality around 1990 
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AA The predictions concerning negative .side-effects in 
chapter 10 compared to the 1996b and previous model 
versions 
The predicted numbers of wamen with repeat smears and wamen referred and 
treated for pre-invasive neoplasia as presented in Chapter 10.1.4 are not only 
based on recent detection rates, as in the 1996b version, but account for the 
influence of a further intensification of the follow-up practice to be expected 
from the revised follow-up guidelines that are currently being implemented as 
well. These referral and treatment rates are roughly two times higher than 
in the 1996b model and i·oughly sixfold higher than in the 1988 model (see 
Chapters 2 and 3) and in the 1993 model (results not shown). 
Adjusted cost-effectiveness ratios (CERs) to 
campare studies 
I will here describe "how we accOU!lted for differences between other cost-
effectiveness studies and our MISCAN assumptions to calculate adjusted GERs 
(cost-effectiveness r<)tios) in chapter 10. The result~ of the adjustment was 
presented in Table 10.4. The OER in the MISCAN prediction for the Dutch 
cervical eaueer screening situation is: 
In which: 
Costs 
Effects 
(A+B- C-D) 
E 
A :::: # smears x average casts per sffiear including casts for false positive cases 
B = # detected GIN cases x costs per GIN case 
C = # preven.ted invasive cervical cancer cases x the áverage casts per case 
D = # prevent~d ad vaneed eaueer cases ·x the casts per advanced eaueer case 
E = # life years gained 
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Appendix B. Adjusted GERs to campare studies 
This CER was adjusted for differences between the situation as described in 
the respective other studies considered in chapter 10 and the situation in the 
Netherlands as described by us. The differences accounted for are listed in 
Table 10.3 in chapter 10. The adjust.ment was performed as follows: 
A x a(l) + B x b(2 ) * r - C x c x r x e ~ D x d x r x e Adjust.ed CER = ::_:_:_:_::·~_:__:::__:_c_::___:_~~_:_~_:_:_:_::_::__~_:_::_::__ _ _:_ 
Exrxe 
(!) including the costs for follow-up of false-positive screening test result.s, and 
insome studies the costs of detection of pre-invasive disease 
(2) as far as not incltided in the costs per smear. 
In which: 
a, b, c, d are the respective casts used in the other studies relative to the cone-
sponding costs assumed in MISCAN for the Dutch situation. 
For example for Eddy's study a = ~i 
r is the background risk forcervical cmicer used inthe other studies relative 
to the risk assumed in MISCAN for the Dutch situation. 
For example for Eddy's study ,. = 1.8 
e is the relative mortality rednetion 
For example for Eddy's study e = ~: (see text on Eddy's study in Chap-
ter 10) · 
Summary 
In recent years in the Netherlands around 235 women have died annually 
from cet·vical cancer, The CUlTent mortality rate is less than 40% of the level 
around 1960. Mortality was already decreasing befare it could have been 
affected by PAP srnear screening, which started around 1970. The PAP smear 
can detect cervical cancer and its non-invasive precursors before symptoms 
occur. Because randomized cervical cancer screening_ triais have never taken 
place, a direct estimate of the contribution of screening to the deäease in 
mortality is not available. 
The objective of this thesis is to evaluate cervical eaueer screening by assessing 
its various effects and costs. Questions to be addressed concern the rednetion 
in incidence and mortality, the unfavourablc effects and the cost-effectiveness 
of different screening polides (age range and interval combinations). To this 
end, we used acervical eaueer version of MISCAN, a simulation model that was 
designed and programmed to evaluate cancer screening. This cervical eau-
eer screening model. had already been tested against screening data sets from 
British Columbia (Canada) and from Dutch pilot screeningprojectsin 1976-
1985. The potential impact of new developments in cervical eaueer screening, 
such as auto~1ated cytological evaluation and HPV-testing, has been investi-
gated. The ultimate questions are: should ccrvical caoeer screening be con-
ti.nued, and what changes should be recommended in order to iinprove its 
efficiency? 
The relationship between benefits and unfavourable effects was stuclied for 
three efficient cervical cancer screening strategies incorporating 5, 10 and 25 
smears per woman (Chapter 2). It was concluded that wlien the screening 
frequency was increased, the ratio of favourable to unfavourable effects became 
worse. 
Compared to the opportunistic screening in the Netherlands, efficient screen-
ing may yield the same mortality rednetion with only 50% of the smears, the 
costs thus being also around 50% lower (Chapter 3). The reason is that oppor-
tunistic screening smears were taken at relatively young age and with shorter 
intervals and that the resulting coverage of the population at risk was lower. 
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Screening will lead to changes in m~dical practice concerning cen•ical eau-
eer and its precursors, and aécordingly in the casts of this practice. Positive 
screening results will produce. diagnostic and thcrapeutic procedUres for cervi-
cal intraepithelial neoplasia ( CIN) and early invasive cancer. The management 
of CIN wil! on average cost Dfl 3500 per woman ( Chapters 4 and 7). In half of 
the wamen, treatment by conisation or hysterectomy was performed. Effcc-
tive screening will prevent death from cen•ical cancer and therefore also incur 
financial savings. The casts of medica} care of ad vaneed incurable ccrvical 
cancer were estimated at Dfl 30000 per woman (Chaptèr 5). 
A previous analysis of detection rates of pre-clinical discase and pre-screening 
incidence in British Columbia resulted in an estimated average duration of 16 
years for pre-clinical detectable disease, and an estimated sensitivity of the 
PAP smear of 80%. These estimates are crudal in predicting the impact and 
cost-effectiveness of screening. We therefore checked them against trends in 
cervical cancer incidence and mortality in the period 1965-1992, which eneom-
passes some 10 years before screening became widespread and could have had a 
marked impact. To this end, we imbedded the estimates for duration and sen-
sitivity in the MISCAN population cervical cancer screening simulation model. 
This model was adapted to Dutch pre-screening cervical cancer incidence and 
mortality tagether with the screening pattem since its inception around 1970. 
The model-predicted incidence and mortality trends in the Netherlands after 
the start of screening were compared with observed incidence and mortality 
trends ( Chapter 6). The similarity of observed and simulated trends supports 
the estimated natural history, sensitivity and cure rate parameters. 
Using MISCAN, we predicted the life years gained and costs of screening for 
polides with 5 to 10 screenings per woman during her life, also varying the 
age-range and the screening interval. From an effectiveness point of view, a 
-braad age-range is more-important than a short interval. ':Vith seven screen-
ings per wömen, efficient polides are those which screen wamen between 25-30 
and 65-70 every 7 years. If less screenings per woman are planned, the broad 
age-range should be maintained and the intervalmust be increased acco;>rd-
ingly. Given that in the Netherlands 5 years was considered the maximum 
acceptable length for the interval between successive screenings, screening 
women from age 30 to age 60 is viewed as a good policy. Furthermore, this 
policy will prevent opportunistic screening which wil! take place in young age 
groups when programme screening would start at later age. The expected 
mortality rednetion from this policy (with an attendance rate of 75% and no 
opportunistic screening) is 50%, conesponding with around 200 fewer deaths 
from cervical eaueer per year. 
We investigated the potential usefulness oftworecent developments, computer-
aided cytological evaluation and HPV(human papillamavirus )-screening. At a 
Dutch cyto-pathologicallaboratory, a series of enriched (with positive cases) 
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smears initially screened conventionally waS rescreeped with a computer-aided 
methad (PAPNET). A similar series initially screened witl1 the computer aided 
methad was rescreened conventionally (Chapter 8). Results showed a sig-
nificantly lower number of non-negative smears (with borderline and higher 
abnormalities) in rescreening than in initial screening. In camparing con-
ventional to computer aided screening, we corrected for the effects on the 
cytological evaluation that might have reslilted from differences between the 
rescreening situation and the initial routine screeni~1g situation. After correc-
tion, the difference in the number of nón-negative smears between conventional 
and computer aided screening was smal! and nat significant. We coücluded 
that rescreening of enriched ( with positive smears) series of sme~rs, as usually 
performed in the first instanee to investigating a new PAP smear evaluation 
method, was of limited value for investigating the possibilities of these mèthöds 
for routine screening because of astrong rescreen effect. Befare a decision can 
be made about computer aided screening; further testing is neerled in larger 
studies with a close to routine mixture of negative and positive smears. 
'Ve explored the cost-effcctiveness ofHPV-screening, using an extended version 
of the MISCAN cervical cancer disease model which is based on the hypothe-
sis that HPV-infections found in wamen with CIN and invasive cervical eaueer 
generally preeede the detectable neoplasia.(Chapter 9). Two different rnadeis 
were constructed, one extremely fávourable and one extremely unfavourable 
for HPV-screCning, but both in conc<;n·dance with observed IIPV-positive rates 
in wonien with and without cervical neoplasia. According to the favourable 
model, compared with 3-yearly PAP smear screening, 10-ycarly HPV-screening 
was moreeffective in reducing mortality. In addition, casts werelower. Accord-
ing to the unfavourable model, 3-yearly I!PV-screening was less effective than 
3-yearly PAP smear screening and casts were higher. This is true bath for 
HPV-testing alone and in combination with cytology. The crucial uncertainty 
concerns the natura! history and the detectability of HPV-infections befare neo-
plasia is present. Longitudinal data are rcquircd to decrease this uncertainty 
to such an extent that HPV-screening can either be reje~ted or recommended. 
:rvlcanwhile it is possible that an effective, harmless and cheap HPV.:.vaccine will 
be developed in the future. 
The effect measure used up to Chapter 10 in the estimated cost-effectiveness 
ratio's were life years gained. This means that effects on quality of life, and 
therefore the unfavourable effects, were not accounted for. In Chapter 10, we 
ex plored Üw magnitude and potential impact in cost-effectiveness evaluation of 
PAP smear screening of these unfavourable effects, ~hat mainly involve wo men 
being advised to have repeat smears and being referred for colposcopy. Ten-
tative weighing of the effects on quality of life as expressed in quality adjusted 
life years (QALY's) showed that the unfavourable effects in a very restricted 
screening situation are probably acceptable. But in the current· screening sit-
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uation, with a high frequency of smears and very intensive follow up after 
borderline screen results, the unfavourable effects may well have considerable 
negative impact on the total health effects and thus on the eost-effectiven~ss . 
of eenrical eaueer screening. 
In conclüsion, the eüst-effeetiveness of a well-planned and organized cervi-
cal eaueer mass-screening programme in the Netherlands is expected to he 
aceeptablc providing the following eonditions are taken into account: 
- The coverage of screening must be maintained or, everi bet ter, improved. 
- WoJ.llen and physicians must be discouraged to have preventive smears taken 
outside the target age range of 30 to 60 years and with an interval shmter 
than the targeted 5 years. 
The following issues must also be taken under consideration: 
- 'The guidelines for follow-up after borderline results require further evalua-
tion because they might incur toa intensive a follow-up. 
- Computer aided cytology and HP V-screening. are important developments 
but need further research befare aily decision can be made on their role in 
the screeningproeess. 
Samenvatting 
In de afgelopen jaren stierven er in Nederland rond de 235 vromven per jaar 
aan baarmoederhalskanker.· Het huidige sterfte niveau is nog geen 40% van 
dat rond 1960. De sterfte was al aan het dalen voordat vroege opsporing 
·van baarmoederhalskanker, die middels. het nemen van uitstrijkjes bij symp-
toomloze vromven rond 1970 was begonnen, daar een rol in kon spelen. Nien 
verwacht dat het maken van uitstrijkjes sterfte aan baarmoederhalskanker zal 
doen afnemen, omdat met het nitstrijkj~ baarmoederhalskanker en haar niet 
invasie~e voorstadia ontdekt kan worden nog vo~r er symptomen optreden en 
voot·dat de ziekte onbehandelbaar wordt. Echter, omdat gerandamiseerde tri-
als nooit hebben plaatsgevonden is een directe schatting van de bijdrage van 
screening op de daling in de !llOrtaliteit niet mogelijk. 
Het doel van dit proefschrift is vroege opsporing van baarmoederhalskanker 
te evalueren door de verschillende effecten en kosten te schatten. Het gaat 
om de reductie van incidentie en stedte, de ongunstige effecten en de kosten-
effectiviteit van verschillende uitnodigings schema's (combinaties ·van begin-
en eindleeftijd en interval tussen opeenvolgende uitstrijkjes). Om deze te 
schatten gebruikten we een baarmoederhalskanker versie van r..nSCAN, een sim-
ulatiemodel dat is gema.akt om screening op kanker te.evalueren. Dit baarmoe-
derhalskanker model was al in overeenstemming gebracht.met de screenings 
gegevens uit British Columbia (Canada) en uit de Nederlandse proefregio's in 
1976-1985. Er is tevens onderzoek gedaan·naar d_e mogelijkheden van nieuwe 
ontwikkelingen,.zoals geautomatiseerde cytologische beoordeling van uitstrijk-
jes én het testen van schraapsels van de baarmoedermond op humaan papil-
lamavirus (HPV). De uiteindelijke vragen zijn: moet vroege opsporing_van 
baarmoederhalskanker worden \roortgezct, en welke veranderingen moeten er 
komen om het efficiënter te maken. 
De relatie tussen gunstige en ongunstige effecten is·onderzoçht voor drie efficiën-
te screenings schema's: één ri1et 5, ééü met 10 en één met 25 uitnodigingen 
per vrouw (Hoofdstuk 2). De conclusie was dat bij een toenemend aantal 
uitstrijkjes, de ongunstige effecten_ meer toeneme~ dan de gunstige. 
Vergeleken met bpportunistische ('wilde') screening, kan efficiënte screening 
dezelfde sterfte reductie bereiken met half zo veel. uitstrijkjes, waarbij ook de 
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kosten ongeveer 50% lager liggen (Hoofdstuk 3). De reden hiervoor is dat 
opportunistische uitstrijkjes gemiddeld op jongere leeftijd en met een korter 
screenings interval worden gemaakt en dat het bereik van de doel-leeftijdsgroep 
lager is. 
Vroege opsporing zal veranderingen in de medische praktijk ten aanzi~n van 
baarmoederhalskanker tot gevolg hebben. Positieve uitstrijkjes zullen diag-
nostische en therapeutische ingrepen voor cervicale intraepitheliale neoplasie 
( CIN) en vroeg invasievê cervixcarcinomen induceren. De diagnostiek, behan-
deling en nazorg van CIN kost gemiddeld Dft 3500 per geval (Hoofdstukken 4 
en 7). In de helft van de gevallen wordt er een conisatie of een uterusextir-
patie verricht. Aan de andere kant zal effectieve screening sterfte aan baar-
moederhalskanker voorkomen, en daarmee besparingen met zich mee bren-
gen. De medische kosten van vergevorderde baarmoederhalskanker werden op· 
Dfl 30 000 per vrouw geschat (Hoofdstuk 5). 
Een eerdere analyse van detectie cijfers van pre-klinische ziekte bij screening en 
de incidentie voor de aanvang va:n screening in British Colombia, leverde een 
schatting op voor de gemiddelde duur van pre-klinische detecteerbare ziekte 
van 16 jaar, en voor de sensitiviteit van het uitstrijkje van 80%. Deze schat-
tingen zijn cruciaal voor de te verwachten resultaten en kosten-effectiviteit. 
van cervix screening. Daarom hebben we ze getoetst aan de h·end in inci-
dentie en sterfte van baarmoederhalskanker in de periode 1965-1992, waarvan 
de eerste ca. 10 jaren nog nauwelijks door screening beïnvloed zijn. Daartoe 
werden de geschatte duur en sensitiviteit in het MISCAN populatie model voor 
baarmoederhalskanker screening ingebed. Dit model werd aangepast aan de 
Nederlandse incidentie van en sterfte aan baarmoederhalskanker. voor aanvang 
van screening en aan het screenings patroon zoals het sinds 1970 bestond. De 
model voorspellingen voor de· trends in incidentie en s_terfte na aanvang van 
screening werden vergeleken met de waargenomen trends (Hoofdstuk 6). De 
overeenkomst tussen waargenomen en. vo"orspelde trends o.ndersteunt de eerder 
gemaakte schattingen van de parameters die het natuurlijk beloop en de sen-
sitiviteit beschrijven, en de veronderstelde uitstekende behandelbaarbeid van 
pre-invasive stadia. 
Eveneeils gebruik makend van het MISCAN model, deden we voorspellingen 
voor de gewonnen levensjaren en de kosten van screening voor screenings 
schema's met 5 tot 10 uitstrijkjes per vrouw, waarbij de leeftijds range en 
h_et screenings interval werden gevarieerd. Voor de effectiviteit is een breed 
leeftijds bereik belangrijker dan een kort screenings interval. Met zeven uit-
strijkjes per vrouw, is het het meest efficiënt om vrouwen· tussen de 25 à 30 
en 65 à 70 jaar te screenen om de zeven jaar. Als er met minder uitstrijkjes 
wordt gescreend, moet het brede leeftijds bereik worden gehandhaafd, en moet 
het interval overeenkomstig worden verlengd. Gegeven echter het feit dat in 
Nederland 5 jaar als de maximaal haalbare lengte voor het screenings inter-
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val wordt beschouwd, is het screenen van vrouwen tussen de 30 en 60 jaar een 
goed beleid. De verwachte mortaliteits reductie van het screening van vrouwen 
tussen de 30 en60 jaar om de vijfjaar met een deelname-percentage van 75% en 
zonder oppÓrtunistische screening, is 50%, hetgeen overeenkomt met ongeveer 
200 voorkomen sterf-gevallen aan baarmoederhalskanker per jaar. 
We hebben onderzoek gedaan naar het potentiële nut van twee recente ont-
wikkeÜngen, computer ondersteunde cytologische evaluatie van uitstrijkjes en 
screening op humaan papillamavirus (HPV). Door een Nederlands cytologisch 
laboratorium werden een serie uitstrijkjes die oorspronkelijk in de routine prak-
tijk op de conventionele wijze was gescreend, met een computer ondersteunde 
methode (PAPNET) opnieuw gescreend. Tevens werd een serie uitstrijkjes die 
oorspronkelijk in de normale routine met PAPNET was gescreend op de conven-
tionele wijze opnieuw gescreend. Beide series waren in gelijke mate verrijkt 
met positieve uitstrijkjes (Hoofdstuk 8). De resultaten laten zien dat bij het 
opnieuw screenen een significant kleiner aantal uitstrijkjes als niet-negatief 
(borderline of sterk afwijkend) werdeu geclassificeerd dan in de routine prak-
tijk. Door de studie opzet kon conventionele screening met PAPNET screening 
vergeleken worden onafhankelijk van het gevonden n;screen effect. Tussen 
conventionele screening en screening met PAPNET waren de verschillen in aan-
tallen niet-negatieve uitstrijkjes klein en niet significant. We concludeel'den 
dat het opnieuw screenen van verrijkte series van uitstrijkjes, het eerste wat 
gedaan wordt om een nieuwe screenings methode te testen, door het optreden 
van sterke re~creen effecten v~n beperkte waarde is voor het schatten van de 
performance van zo'n nieuwe methode in routine screening. Om voor routine 
screening tot een beslissing te kunnen 'komen zijn ·grotere studies .met een meer 
realistische mix van (veel) negatieve (weinig) positieve uitstrijkjes nodig. 
Voor een explor~tie van. de kosten-effectiviteit van HPV-screening hebben we-
gebruik gemaakt van een versie van het MISCAN ·model waarin het ziekte 
model was uitgebreid met HPV-infecties, onder de hypothese dat HPV-infecties 
die word~n gevonden in vrouwen met CIN en (invasief) cervixcarc.inoom, aan 
de nieuwvorming zijn voorafgegaan (Hoofdstuk 9). We lieten zien dat het 
mogelijk is om twee verschillende modellen te construeren, één uitermate gun-' 
stig voor HPV-screening en één uitermate ongunstig, die beide in overeenstem-
ming zijn met de gemeten HPV-positiviteit in de algemene populatie en in 
vrouwen met cervix neoplasie. Volgens het eerste model is 10-jaarlijkse HPV-
screelling effectiever in het voor~Ûmen van sterfte aan baarmoederhalskanker 
dan 3-jaarlijkse cytologische screening, en bovendien goedkoper. Volgens het 
tweede model is 3-jaarlijkse HPV-screening minder effectief dan 3-jaarlijkse 
cytologie en duurder. De cruciale onzekerheid betreft het natuürlijk beloop 
van HPV-infccties voordat er neoplasie ontstaat en de detecteerbaarlieid van 
HPV-infecties tijdens die periode. Om een uitspraak te kunnen doen over de 
(kosten-)effectiviteit van HPV-screening zijn longitudinale data nodig. Onder-
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tussen is het niet uitgesloten dat er in de toekomst een effectief, ongevaarlijk 
en goedkool? vaccin tegen HPV-infccties komt. 
De effectmaat die tot Hoofdstuk 10 is gebruikt vool' het berekenen van kosten-
effectiviteits ratio's is het aantal gewonnen levensjaren. Dat houdt in dat 
effecten op de kwaliteit van leven, die per saldo negatief zijn, niet in deze 
ratio tot uitdrukking komen. In Hoofdstuk 10 hebben we de mogelijke grootte 
onderzocht van de invloed wanneer wel ,vordt rek<(ning gehouden met negatieve 
effecten. Het gaat bij die negatieve effecten met name om vrouwen die vim-
wege (licht) positieve uitstrijkjes wordt aangeraden op relatief korte termijn 
nogmaals een uitstrijkje te laten maken, en vromven die wegens een afwij-
kend uitstrijkje voor verder onderzoek worden verwezen naar de gynaecoloog. 
Op tentatieve wijze werden effecten op ·de kwaliteit van leven uitgedrukt in 
kwantiteit van leven, zodat voor kwaliteit gecorrigeerde gewonnen levensjaren 
. (gewonnen QALY's) konden worden berekend. De exploratieve berekeningen 
lieten zien dat de ongunstige effecten van screening met een zeer beperkte 
intensiteit waarschijnlijk acceptabel zijn. Maar het werd ook duidelijk dat de 
ongunstige efl'ecten van screening ZC?als die in afgelopen jaren werd toegepast, 
met relatief freqnente uitstrijkjes en intensieve fellow-up ook al bij zeer lichte 
afwijkingen, een aanzienlijke negatieve impact kunnen .hebben op de netto 
gezondheidseffecten, die overblijven na aftrek van deze ~egatieve effecten. 
Cüncludei·end is te verwachtèn dat de kosten-effectiviteits verhouding van een 
goed gepland en georganiseerd bevolkingsonderzoek naar baarmoederhalskan-
ker in Nederland acceptabel zal zijn, mits aan een aantal voorwaarden wordt 
voldaan: 
Het bereik van de screening moet op zijn minst gehandhaafd worden maar 
liever nog verhoogd worden 
Uitstrijkjes bij symptoomloze vrouwen buiten de gestelde leeftijds range 
van 30 tot 60 jaar en met een hogere frequentie dan om de vijf jaar moeten 
tot een minimum beperkt worden. 
Tevens zijn de volgende zaken van belang: 
- De geldende richtlijnen voor vervolgonderzoek na (licht) positieve uitstrijk-
jes moeten opnieuw geëvalueerd worden want induceren m'ogelijk een te 
intensieve follow-up praktijk 
Compnter onderstennde cytologie en HPV-screening zijn belangwekkende 
ontwikkelingen die zeker verder oi1derz_oek behoeven~ Echter, hun nut voor 
bevolkingsonderzoek op baarmoederhalskanker is nog niet aangetoond. 
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